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Vaccinia virus (VACV), the prototypic poxvirus, undergoes a complex life cycle, with multiple stages 
that are not yet fully understood. This work studied two cellular proteins which had previously been 
identified by siRNA screens as playing proviral roles in the replication cycle of VACV: the dual 
specificity mitogen-activated protein kinase kinase 3 (MKK3) and vacuolar protein sorting 52 
(Vps52).  
MKK3 is an upstream regulator in the p38 pathway which, along with MKK6,  phosphorylates and 
therefore activates p38. In HeLa cell cultures, siRNA depletion experiments confirmed that MKK3 
supported VACV replication. MKK3 knockdown reduced production of both early and late-class 
VACV proteins, suggesting that it facilitates viral gene expression. However, this difference did not 
translate to an in vivo model, as comparison between wild type and MKK3 knockout mice infected 
with VACV revealed no significant differences in virus replication or overall disease.  
The Golgi-associated retrograde protein complex (GARP) is composed of four large heteromeric 
proteins: Vps51, Vps52, Vps53 and Vps54, and plays a key role in retrograde transport from 
endosomes to the TGN. The effects of loss of GARP function were investigated using three 
techniques: mouse embryonic fibroblasts (MEFs) containing the hypomorphic Vps54 “wobbler” 
mutation, Vps52-targetting siRNA in HeLa cells and pharmacological inhibition of retrograde 
transport using the drug Retro-2. GARP loss resulted in a marked reduction in VACV spread due to a 
reduction specifically in “double wrapped” extracellular enveloped virion (EEV) production. 
Investigation of the mechanism by which GARP facilitates EEV production revealed a disruption of 
the VACV morphogenesis pathway prior to the double wrapping event, resulting in mislocalisation 
and aggregation of the viral membrane protein B5 within the cytoplasm. The effects of GARP loss 
translated to an in vivo model, as mice infected with VACV and treated with Retro-2 exhibited 
reduced viral replication and overall disease. These results identify GARP as a pro-viral host complex 
required for EEV production, and suggest that cellular retrograde transport pathways are required for 
double-wrapping of VACV virions.   
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Overall, the study illustrates both the potential pitfalls of carrying out genetic screens in a transformed 
cell line and the power of such studies to nevertheless identify novel features of virus biology as well 




Vaccinia virus (VACV) is a complex poxvirus with multiple life cycle stages which are not yet fully 
understood. VACV is most well-known as the vaccine for Smallpox, but also has applications in 
biotechnology and vaccine development for other diseases. This work investigated how specific host 
proteins are used in the VACV replication cycle. Two proteins that had previously been identified in 
large genetic screens as aiding VACV growth were focussed on: the dual specificity mitogen-
activated protein kinase kinase 3 (MKK3) and vaculolar protein sorting 52 (Vps52). 
MKK3 is an enzyme which, when activated by environmental stress, triggers subsequent enzymes 
which are involved in controlling the cellular growth cycle. This chain of events is known as the p38 
pathway. When MKK3 production in cells was inhibited, VACV replication was reduced. MKK3 
inhibition also reduced the production of viral proteins from early and late stages in the VACV life 
cycle, suggesting that it plays role in viral protein synthesis. However, this difference was not seen in 
a whole animal model, infecting genetically normal mice and mice lacking the MKK3 protein with 
VACV showed no significant differences in virus growth or disease symptoms.  
In cells, proteins are packaged for transport at the Golgi apparatus near the centre of the cell, before 
being trafficked to their destination. The retrograde transport pathway transports proteins from the 
periphery of the cell back in to the trans-Golgi network (TGN), for reuse or recycling.  The Golgi-
associated retrograde protein complex (GARP) is a key part of retrograde transport and is made up of 
four large proteins: Vps51, Vps52, Vps53 and Vps54. The effects of GARP loss were investigated 
using three techniques: inhibition of Vps52 protein production, cells containing the wobbler mutation 
which increases the rate at which GARP is degraded, and pharmacological inhibition of retrograde 
transport using the drug Retro-2. GARP loss resulted in a marked reduction in VACV replication and 
spread, due to a reduction specifically in extracellular enveloped virion (EEV) production. EEVs are a 
stage in the VACV life cycle in which a small fraction of intracellular virions are wrapped in an extra 
double-layer membrane, and released before the cell dies for long-range spread of the virus. 
Investigation of how GARP is involved in EEV production revealed a disruption in VACV formation 
before the double-wrapping event, resulting in proteins usually found in the EEV membrane forming 
large, wrongly-trafficked aggregates. The effects of GARP loss translated to an animal-model, as 
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when mice with the wobbler mutation, and therefore reduced levels of GARP, were infected with 
VACV, a reduction was seen in both viral replication and overall disease symptoms. These results 
identify host complex GARP as having a key role in EEV production, and suggests that cellular 
retrograde transport pathways are required for double-wrapping of VACV. 
Overall, the study illustrates both the potential pitfalls of carrying out large genetic screens, and the 
power of such studies to nevertheless identify new features of virus biology as well as potential future 
targets for antiviral treatment.  
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1.1. Vaccinia virus 
In the last two centuries, the impact that infectious diseases have on humanity has lessened 
significantly. For the most part, this is thanks to the advent of vaccines, and the ability to 
comprehensively prevent disease. Therefore, it can be argued that the prototypic orthopoxvirus, 
Vaccinia virus (VACV), as the very first widely used vaccine, is the most important virus in human 
history. While genetically distinct from other orthopoxviruses such as Variola virus (VARV) and 
Cowpox virus (CPXV), VACV carries enough antigenic similarities to provide cross-protection to all 
viruses in this genus (Roberts & Smith, 2008). VACV’s large genome allows it to encode many of its 
own replication and transcription factors, which enables it, unlike most DNA viruses, to replicate in 
viral factories in the cytoplasm of the cell, rather than being dependent on the nucleus (Broyles, 
2003). VACV has a highly complex life cycle, several parts of which are still heavily debated and not 
fully understood, such as the site of extra-membrane wrapping. VACV is considered the prototypic 
poxvirus, and has many applications as a vaccine vector and as a tool to study cellular biology. 
Therefore, further investigation and characterisation of these poorly understood areas may reveal 
novel applications for VACV.  
1.1.1.  History of VACV and first generation vaccines 
Though it was use of VACV that resulted in the final eradication of smallpox, it was CPXV with 
which Edward Jenner began his famous vaccination experiments in the late 19th century. Although 
CPXV and VACV are closely related, they remain genetically distinct (Baxby, 1977). At some point 
during the last century, VACV replaced CPXV as the prevalent source of vaccination for VARV, 
though the time and method of this transition is unknown, as is the original host of VACV (Roberts & 
Smith, 2008). Theories for the origins of VACV include the now extinct horsepox, or an attenuating 
hybridisation of VARV and CPXV, as these viruses do show the possibility of hybridisation under 
experimental conditions (Alcami & Smith, 1996; Bedson & Dumbell, 1964). However, no theory has 
been conclusively confirmed as yet.  
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Smallpox is unique among infectious human diseases in that it is the only pathogen that has been 
successfully removed from nature by man. The widespread use of VACV to induce VARV immunity 
resulted in the last naturally occurring smallpox case being recorded in 1977, the World Health 
Organisation (WHO) declaring official eradication in 1980 (Meyer, 2013). As a vaccine, VACV is 
extremely effective, but not without risk. Vaccines developed and used during the smallpox 
eradication are known as first generation vaccines. First generation vaccines used during the 
eradication, such as the Lister strain, Dryvax and Tian Tan (Midgley et al., 2008) replicate in the 
dermis after subcutaneous injection, resulting in mild fever, local lymphadenopathy and a pustule at 
the site of infection.  This pustule begins as a papule, before becoming vesicular at 5-8 days post 
infection. In a normal infection, the pustule reaches its maximum size at day 10 before scabbing over 
by day 14 post inoculation, and shedding the scab by day 21 (Cono, et al., 2003; Bray, 2003). 
However, as all the first generation vaccines were replication competent viruses, there was a relatively 
high risk of complications, including eczema vaccinatum, post vaccinal encephalitis, generalised 
vaccinia, and progressive vaccinia, all of which had the potential to be fatal (Cono et al., 2003; Meyer, 
2013). Generalised vaccinia can occur at random, regardless of immune status of the vaccinee and 
results in extensive maculopapular lesions, both around the site of inoculation and all over the body, 
due to dissemination of the virus in the blood (Goldstein et al., 1975; Gibson & Langsten, 2004) In 
comparison, progressive vaccinia is associated with immunodeficiency and the significant expansion 
of the pustule, both across the dermis and into deeper tissues, is often compounded by bacterial 
superinfection, resulting in osteomyelitis and necrosis (Goldstein et al., 1975; Bray & Wright, 2003). 
Eczema vaccinatum occurs in cases of atopic dermatitis, in both primary vaccines and through 
secondary contact, with over half of cases seen in children under 5 (Vora et al., 2008). Post vaccinal 
encephalitis and encephalomyelitis are the rarest, but most severe of the potential VACV 
complications, and have no link with immunodeficiency. Symptoms, including convulsions, paralysis 
and coma manifest within two weeks post inoculation, and have a 30% mortality rate (Goldstein et al., 
1975). For progressive and generalised vaccinia, and eczema vaccinatum, treatment can be 
administered using Vaccinia immunoglobulin (VIG) from recently, successfully vaccinated 
individuals, or oral or topical application of the anti-poxvirus drug ST-146 (Bray, 2003; Lederman et 
al., 2012). Despite a relatively high rate of complications, the overall rate of fatal complications from 
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VACV inoculation was thought to be less than one per million vaccinations during the eradication 
(Bray, 2003). 
In addition to these complications, first generation vaccines were often passaged in ovine or bovine 
skin, or in chicken eggs, resulting in contaminations and wide variations in virulence, immune 
protection and genetic sequences (Medaglia et al., 2015) Genetic examination of first generation 
vaccine strains has shown that not only were these vaccines not clonal, there was more genetic 
diversity within the vaccine strain Dryvax, than between the major and minor strains of VARV (Qin 
et al., 2011). Therefore, improved and genetically homogenous VACV strains were developed for use 
in vaccination. 
1.1.2. Post-eradication Vaccinia vaccines 
In the years since the eradication of smallpox, several attenuated 2nd and 3rd generation vaccines have 
been developed  in order to reduce side effects and bacterial contamination, such as Modified Vaccine 
Ankara (MVA), New York Vaccinia (NYVAC) and Lister clone 16 medium pock size clone 8 
(LC16m8). While these vaccines have been used in clinical settings, their efficacy has never been 
tested in an endemic situation (Meyer, 2013). These attenuated vaccines are produced by extensive 
passaging of fully pathogenic VACV strains, such as MVA, a non-replicating, avirulent VACV strain 
developed in Germany in 1975. The original VACV Ankara strain was passaged 575 times in primary 
chick embryo fibroblasts until it became highly attenuated in mammalian cells (Mayr, 2003). Six 
major deletions, totalling 24kb have been identified, in the MVA genome compared to the fully 
virulent Western Reserve strain (WR). However, these major deletions are not sufficient to cause the 
level of attenuation seen in MVA, suggesting the avirulence stems from additional or co-operative 
mutations. (Altenburger et al., 1989; Meisinger-Henschel et al., 2010). Several of the major deletions 
affect genes involved in host range, the late stages of morphogenesis, and several immunomodulatory 
proteins usually found in orthopoxvirues such as receptors for interferon-γ (IFN-γ), IFN-α/β, and 
certain chemokines (Blanchard, et al.,1998; Altenburger, et al., 1989; Moss, 1996). Consequently, 
MVA has been used without complications in over 150,000 vaccinations, even in cases of 
immunodeficiency (Mayr, 2003), and has been shown to induce humoral and cellular immunity 
comparable to fully-virulent strains in mice, as well as protecting against monkeypox in non-human 
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primates (Earl et al., 2004; McCurdy et al., 2004). Another highly attenuated strain, LC16m8 was 
developed at the same time in Japan, this time from the Lister strain through several intermediates 
(Hasizume, 1975). A frame-shift from a single deletion mutation results in no B5R gene, and therefore 
a decreased ability for the virus to attain long-range spread. However, since the B5 protein is the 
major target for immune responses against extracellular enveloped virions (EEVs), it is possible that 
an immune response generated against LC16m8 is not as potent as those from wild type strains, and 
therefore may not be the ideal vaccine candidate (Johnson et al., 2011). Though it is possible for 
LC16m8 to revert back to more virulent forms, it has been used in over 100,000 successful, 
complication-free vaccinations and has been shown to be 100 fold more effective than MVA 
(Kidokoro, et al., 2005). A more recent 3rd generation vaccine, defective vaccinia Lister (dVV-L) has 
been derived from Lister and Elstree strains, as a vector rather than a vaccine. dVV-L is infectious, 
but contains a replication block at late gene expression due to the deletion of the gene for uracil DNA 
glycoslylase, D4R, which is essential for vaccinia replication (Holzer & Falkner, 1997). Unlike 
LC16m8, dVV-L cannot regain its full pathogenic status, and is shown to induce similar levels of 
humoral and cellular immune responses to MVA (Ober et al., 2002).  
1.1.3. Vaccinia post-eradication 
Despite the eradication of VARV in the 1970s, VACV still remains important in biological research, 
not only as an insight into other poxviruses such as VARV, but also as a tool to investigate cellular 
mechanisms, such as actin polymerisation (Frischknecht et al., 1999), and immune evasion (Smith, 
1999). Due to its large, easy to manipulate genome, VACV can be used as a vector for the delivery of 
other vaccine epitopes, such as MVA expressing influenza proteins haemagluttinin, neuraminidase 
and Matrix-protein 1 in order to stimulate humoral and cellular immunity (Breathnach et al., 2004; 
Mullin et al., 2016). Several other infectious diseases such as Mycobacterium tuberculosis and West 
Nile fever have also been successfully protected against under experimental conditions using a VACV 
vector (Zhu et al., 1997; Volz et al., 2016). As well as protection against microbial disease, VACV is 
currently under investigation as a potential oncolytic virotheraputic, as it has the potential to infect a 
broad range of cancerous cell types. An early paper on the topic showed that deletion of the Vaccinia 
growth factor (VGF) gene and thymidine kinase (TK) gene produces an attenuated virus that 
replicates specifically in tumour cells in vivo, and highlighted VACV as a key potential oncolytic 
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(McCart et al., 2001). Since then, several strains of VACV have shown anti-tumour activity, including 
the WR strain which, when containing targeted gene deletions is able to inhibit the growth of certain 
tumours, in human patients (Zeh et al., 2015).  
1.1.4. Life cycle and morphogenesis  
The life cycle of VACV is complex and progresses through several different stages and morphologies, 
with the virion consisting of a conserved DNA protein core surrounded by varying numbers of lipid 
membranes. The number and structure of the membranes present is dependent on the life cycle stage. 
Replication begins with the entry of an uncoated viral core into the cytoplasm of a host cell, where it 
is transported on microtubules further into the cytoplasm (Carter et al., 2003). Unlike the majority of 
DNA viruses, VACV replicates exclusively in the cytoplasm, and never enters the nucleus. Instead, 
VACV creates viral factories in peri-nuclear areas of the cytoplasm (Minnigan & Moyer, 1985). 
These factories begin to appear approximately two hours post infection, as dense accumulations of 
filaments and granules, and are the site of the viral DNA replication, transcription, and the initial 
stages of morphogenesis. Between 10 and 24 hours post infection the number and size of these 
factories rapidly increases, until the cell is filled by virion replication (Dales & Siminovitch 1961). 
Vaccinia virus virions are formed from initial membrane crescents which associate with viroplasm to 
form immature virions (IVs) which then develop further to intracellular mature virions (IMVs), 
intracellular enveloped virions (IEVs), cell-associated enveloped virions (CEVs) and extracellular 
enveloped virions (EEVs). The existence of different virion forms results in different methods of cells 
entry and cell exit.  
1.1.4.1 Entry 
Vaccinia exhibits more than one method of entry, due to the structural and antigenic differences in 
mature virions (MVs) and EEVs. For both MVs and EEVs, initial adsorption is required to begin the 
entry process and although both forms of virion adsorb at the same rate, IMVs are internalised at a 
faster rate than EEVs (Payne & Norrby, 1978; Vanderplasschen & Smith, 1997).  
Two methods of MV entry have been observed: macropinocytosis, and entry via the fluid phase 
endocytic pathway. Direct fusion is initiated by the binding of MV proteins such as D8 and A27 to 
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glycosaminoglycans (GAGs) on the cellular surface, including chondroitin sulphate and heparin 
sulphate respectively (Chung et al.,1997; Hsaio et al., 1999). Once adsorbed, a large, multi-protein 
complex known as the entry fusion complex (EFC) is required for fusion with the plasma membrane 
and entry into the cytoplasm. The complex consists of several MV proteins including A16, A21, A28, 
G2, G9, H2 J5, L1 and L5, and although its exact role is as yet unknown, loss of any of the proteins 
results in the same phenotype and an inability to enter cells (Senkevich et al., 2005). On the cellular 
side, vaccinia virus penetration factor (VPEF) is required for entry, along with actin signalling 
cascade signalling cascade which includes Ras homolog gene family, member A (RhoA), Cell 
division control protein 42 (Cdc42) and small GTPase Ras-related C3 botulinum toxin substrate 1 
(Rac1). This cascade results in the formation of filopodia to ensure the largest possible surface area of 
the plasma membrane is in contact with the virion (Vanderplasschen et al., 1998; Locker et al., 2000; 
Huang et al., 2008). Fusion then occurs consisting of direct continuity of the viral and plasma 
membranes, and the ejection of the naked viral core and the lateral bodies into the cell cytoplasm, 
ready for early transcription and DNA replication to begin (Armstrong et al., 1973; Carter et al., 
2005). This model of entry is consistent with the hypothesis that the IMV/MV has only one 
membrane, and indeed the Carter et al. study in 2005 proved this conclusively using tilt series 
analysis. 
Direct fusion of the virus with the membrane appears to be the preferred entry mechanism for IMVs 
early on in infection, while entry via macropinocytosis predominates at later stages (Armstrong et al, 
1973). This fluid-phase endocytic entry involves virally induced, rapid blebbing on the cell surface, 
followed by the low pH- and dynamin-dependent engulfment of the MV into an endosome. Once 
internalised, the MV then fuses with the endosomal membrane for release into the cytoplasm (Mercer 
& Helenius, 2008; Huang et al., 2008).  
EEV entry is more complex than MV, as it has an extra membrane which must be removed before 
entry can occur. GAGs on the cell surface interact with EEV proteins B5 and A34 to induce 
membrane rupture, in a process called ligand-dependent non-fusogenic dissolution. The EEV 
membrane does not fuse with the plasma membrane, but instead drapes over the virion core while it 
fuses, most likely to protect it from immune system attack. (Law et al., 2006; Roberts et al., 2009). It 
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is also thought that EEVs can enter via endocytosis. Ichihashi, et al., (1996) put forward the 
hypothesis that low-pH dependent endocytosis encloses EEVs in endosomes where the outer 
membrane is disrupted to allow the MV core to fuse with the endosomal membrane for release into 
the cytoplasm. 
1.1.4.2 Genome replication and the transcription cascade 
The VACV genome encodes over 200 open reading frames (ORFs), which must be selectively 
expressed at the correct point in replication. To achieve this regulation, VACV exerts control at a 
transcriptional level, expressing its genome in a cascade mechanism, in which genes are classified as 
early, intermediate and late, and transcription of each class is initiated by the gene products of the 
previous class (Broyles, 2003; Keck et al., 1990).  
Once the virions are uncoated, early transcription begins with early mRNA being seen within 12 
minutes of cell infection, before DNA replication. This is possible as VACV contains all the 
components required for early transcription, already-synthesised in the viral core (Kates & McAuslan, 
1967; Munyon et al., 1967). Further research showed that this early transcription machinery consisted 
primarily of Vaccinia early transcription factor (VETF), RNA polymerase associated protein (RAP94) 
and the viral RNA polymerase (RPO), as well as capping and methylating enzymes, poly(A) 
polymerase, and ATPases; all of which are transcribed from late genes and packaged into virion cores 
before dissemination (Broyles, 2003; Gershon & Moss, 1990; Ahn & Moss, 1992; Munyon et 
al.1967). The presence of a virally encoded, DNA dependent RNA polymerase is unusual, as usually 
invading viruses seek to hijack the cellular RNA polymerase for their own use. During early 
transcription, the VACV RPO is recruited to the site of early promoters by VETF, in order to initiate 
transcription. (Broyles, et al., 1988). VETF is composed of two independently produced subunits 
transcribed by late genes: an 82kDa polypeptide encoded by the A8L gene (Hu et al., 1997), and the 
slightly smaller 70kDa gene product of D6R (Broyles and Fesler, 1990; Gershon and Moss, 1990). 
The 70kDa subunit contains an ATP binding site, which has been shown to be the main source of the 
ATPase activity that drives early transcription, thus showing that VETF is required for the continued 
progress of RPO, as well as transcription initiation (Broyles and Fesler, 1990). The remaining 
component of early transcription machinery, RAP94, is a transcription specificity factor and ensures 
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that only early genes are transcribed during early transcription, by controlling the association of RPO 
and VETF by the formation of a link between the two (Yang and Moss, 2009). RAP94 is also 
essential for early transcription termination, through its interaction with the Vaccinia early 
transcription termination factor (VTF) and the ATPase nucleoside triphosphate phosphohydrolase-1 
(NPH1) at the UUUUUNU termination motif (Piacente et al., 2008) 
The VACV genome begins to replicate after early transcription, at around 2h post infection, as the 
DNA replication machinery is translated from early viral mRNAs. DNA replication, RNA 
transcription and translation all occur inside viral factories located close to the cell nucleus, which are 
also later the site of IMV morphogenesis (Kastafanas & Moss, 2007). The VACV genome consists of 
one continuous polynucleotide chain with incompletely paired, AT-rich hairpins at each end. DNA 
replication is initiated near these terminal hairpins, and initially forms concatermeric intermediates 
before the new genome is completed (Pogo et al., 1984; Moss, 2013). As with transcription, VACV 
encodes much of its own DNA replication machinery, minimising its dependence on cellular factors. 
This includes the VACV polymerase Pol, encoded by the E9L gene, which previous evidence has 
shown to be homologous to several eukaryotic DNA polymerases (Wang et al.,1989). Multiple other 
viral proteins are required for successful DNA replication in addition to Pol, including nucleotide 
hydrolysis catalyst D5 which forms a complex with processivity factors A20 and D4, all of which are 
essential for genome replication (Ishii & Moss,2001). Once genome replication is complete and the 
intermediate concatemers are resolved, the resulting DNA nucleoids are packaged into viral 
membrane crescents before the membranes close off to become spherical intermediate virions (IVs) 
(Moss, 2013), a process discussed in more detail later on in this section.  
Of the VACV genome, 115 genes are considered early genes, comprising approximately half of the 
entire genome (Yang et al., 2010). Several of these genes code for the necessary machinery for 
intermediate transcription and the continuation of the cascade. Vaccinia intermediate transcription 
factors (VITF) are synthesised de novo, but as they are products of early genes they do not require 
DNA replication for their formation.  Where early transcription requires only one specific 
transcription factor, the transcription of intermediate genes requires several: VITF-1, VITF-2, VITF-3, 
as well as capping enzyme VITF-A and the RPO. However, while VITF-1 is the 30kDa gene product 
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of viral gene E4L (Rosales et al., 1994a), the 68kDa VITF-2 is a cellular factor, as it can be isolated 
from the nuclei of uninfected cells (Rosales, et al., 1994b). Further investigation revealed VITF-2 to 
be a heterodimer of cellular factors cytoplasmic activation/proliferation-associated protein p137, and 
Ras-GTPase-activating protein SH3 domain-binding protein G3BP (Katsafanas & Moss, 2004) A 
third transcription factor of 100kDa, originally designated as VITF-3, is composed of 35kDa and 
45kDa subunits encoded by viral genes A8R and A23R respectively (Sanz & Moss, 1999). All three 
factors are required to form a complex with RPO for the transcription of intermediate genes. However, 
as RPO is required for all stages of transcription, VITF-3 also provides stage specificity, so that only 
intermediate genes are transcribed at this time (Sanz & Moss, 1999).  
The final stage of the transcription cascade consists of the synthesis of late genes, a process initiated 
by products of intermediate transcription. DNA replication is also required, as late genes can only be 
transcribed from progeny, not parental DNA (Keck & Moss, 1990). Again, RPO is required, along 
with several newly synthesised trans-activating transcription factors: Vaccinia late transcription 
factor-1 (VLTF-1), VLTF-2, VLTF-3 and VLTF-X. VLTF-1, VLTF-2 and VLTF-3 are all viral 
genes, encoded by G8R, A1L and A2L respectively (Wright et al., 1991; Wright & Coroneos, 1993; 
Hubbs & Wright, 1996). In comparison, the transcription factor originally designated as VLTF-X has 
now been shown to be a cellular heterodimer. Wright et al., 2001 showed that VLTF-X activity co-
purified with cellular single stranded nucleic acid binding proteins: Putative RNA-binding protein 3 
(RBM3) and Heterogeneous ribonucleoprotein particle (hnRNP) A2/B1. These factors are initially 
expressed at approximately 4.5 hours post infection, then accumulate to a peak between 12 and 24 
hours post infection (Wright et al., 1991), forming a complex for late transcription with extensive 
protein-protein interactions (Dellis et al., 2004). Once late transcription is initiated, the viral gene 
product G2R aids elongation, before interacting with the DNA dependent ATPase and DNA helicase 
A18 for transcription termination and mRNA release (Black and Condit, 1995; Condit et al., 1996). 
Many of the products of late genes are involved in early transcription and DNA replication, and are 
packaged into progeny virions for the immediate initiation of viral replication in new cells.  
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1.1.4.3 The formation of immature virion crescents and intracellular mature virions 
The formation of the initial precursors through to mature virions occurs in viral factories very early on 
in infection, with the first membranes recorded at 3-3.5 hours post infection. This occurs almost 
immediately after DNA replication, as the majority of progeny DNA is produced between 2.5-3 hours 
post infection (Dales & Mosbach, 1968). The first stage of virion morphogenesis is the formation of 
membrane crescents which, despite displaying similarities to cellular membranes in terms of their 
structural and chemical make-up, are unique from any host membranes (Dales & Mosbach, 1968). 
The single lipid bilayer crescents surround electron-dense viroplasm filaments, in order to become 
spherical IVs containing a nucleoid (Morgan, 1976; Heuser, 2005). The successful association of 
viroplasm and membranes to become IVs is regulated by a highly conserved, seven-protein complex, 
consisting of core components A30 and G7, and F10, as well as A15, D2, D3 and J1. All seven 
proteins are required for the correct functioning of the complex, as the same phenotype is seen if any 
one of the proteins is repressed: no association between membranes and viroplasm (Szajner et al., 
2004). The curvature and rigidity of the membrane crescents, and subsequently the IV membrane, is 
regulated by the association of 65kDa structural protein trimer D13. D13 forms a honeycomb-like 
lattice of hexagons and pentagons on the convex surface of the membrane crescents, and the outside 
of IVs in order to maintain their shape (Heuser, 2005; Szajner et al., 2005). As D13 itself doesn’t 
display a transmembrane domain, it is able to stabilise the membrane via binding to the N-terminal of 
IV membrane protein A17 (Bisht, et al., 2009).  
Proteolytic cleavage of  core proteins such as the processing of P4a and P4b to major IMV proteins 4a 
and 4b; and intramolecular disulphide bond formation occurs in the IV core in order to convert the IV 
through a series of brief transitional intermediate forms into the brick-shaped IMV (Szajner et al., 
2004; Senkevich et al., 2002; Cepeda & Esteban, 2014). A range of virion core proteins are essential 
for this process, including A19 and A6, as loss of either factor arrests VACV morphogenesis at the IV 
stage, and prevents IMV formation (Meng et al., 2007; Satheshkumar et al., 2013). Other proteins, 
such as the scaffold protein D13 are no longer required once transition from IV to IMV begins. 
Proteolysis of A17 by viral protease I7 results in the disassembly of the D13 lattice, so that by the 
time IMV formation is completed, no D13 is detected on the IMV surface (Bisht, et al., 2009). The 
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source of the IMV membrane is complex and highly debated. Analysis of purified IMVs has not 
shown any cellular membrane proteins, or evidence of signal peptides that would indicate trafficking 
through cellular secretory pathways. However, several IMV membrane proteins have been seen to 
localise by the rough endoplasmic reticulum (ER) and the ER-Golgi intermediate compartment, 
suggesting a role for these organelles in membrane formation (reviewed in depth in Moss, 2015). The 
number and exact structure of membranes enclosing IMVs was also controversial, and debated for 
decades, but it has now been conclusively shown that IMVs have only a single, 5nm thick lipid 
bilayer, covered by an 8nm thick protein coat, and have no continuity with cellular membranes 
(Hollinshead et al., 1999; Heuser, 2005).  
1.1.4.4 Intracellular and extracellular enveloped virions 
IMVs are by far the most abundant form of VACV, and the vast majority remain as such in the cell 
until lysis occurs, when they are released for short-range dissemination. However, a small percentage 
Figure 1.1 VACV replication and morphogenesis. Adapted from Smith et al., 2002. Initial stages of 
replication occur in juxta-nuclear viral factories. Viral membranes initially form crescents, which 
surround electron-dense viroplasm to form immature virions (IVs). IVs are then formed into brick 
shaped intracellular mature virions (IMVs). IMVs leave the viral factory, and the majority of remain 
in the cell until lysis. A small percentage of IMVs are transported on microtubules (MTs) to a 
wrapping station thought to be located near the trans-Golgi network (TGN). Here they are wrapped in 
a double layer membrane to become intracellular enveloped virions (IEVs), then are transported on 
MTs to the cell surface. At the cell surface, the outer IEV membrane fuses with the plasma membrane 
to form cell-associated enveloped virions (CEVs) which are pushed away from the cell on actin tails. 
CEVs can also be released as extracellular enveloped virions (EEVs). Virions are coloured green here 
to represent an enhanced green fluorescent protein (EGFP)-tagged VACV strain, which allows 
fluorescence to be measured as a representative of viral growth.  
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of IMVs are wrapped in an extra double layer membrane to become IEVs, before being transported to 
the cell surface where they are released as CEVs and EEVs for long range dissemination (Appleyard 
et al, 1971; Payne, 1980). Microtubules are used to transport IMVs to the wrapping station, regulated 
by the viral A27 protein (Sanderson et al., 2000), and once IEV formation is complete, microtubules 
are used again to transport the wrapped virions to the cell surface for release, this time mediated by 
the A36 and F12 IEV proteins (Herrero-Martinez et al., 2005; Johnston et al., 2009). The proportion 
of IMVs that become IEVs varies according to the strain of VACV in question. VACV-Western 
Reserve (WR) wraps only 1% of it progeny to become IEVs, while infection with the International 
Health Department-J (IHD-J) strain results in 25-30% IEVs, and elongated plaques known as 
‘comets’, due to the high levels of EEV release (Payne, 1980).  
Much like the IMV membrane, the source of the IEV membrane has been a topic of much debate. 
Cases have been made for both the intermediate compartment, between the endoplasmic reticulum 
(ER) and the Golgi network (Sodeik et al., 1993; Van Eijl et al., 2002) and the Golgi and trans-Golgi 
network (TGN) (Ichihashi et al., 1971; Hiller & Weber, 1985; Schmelz et al., 1994) as the origin of 
the extra IEV double membrane. However, it has more recently been shown that IEV membranes can 
be labelled with fluid phase marker horseradish peroxidase (HRP), indicating an endosomal origin 
(Van Eijl et al., 2002). None of these hypotheses have yet been conclusively proved, and the wide 
range in opinions most likely stems from highly increased traffic through the ER, Golgi and TGN 
during VACV infection, making pinpointing a specific origin extremely difficult (Van Eijl et al., 
2002). As EEVs are responsible for long distance dissemination, and are essential for a fully 
infectious virus, the production of IEVs and EEVs is an attractive target for pharmaceutical 
intervention. One of the earliest anti-VACV drugs to target this stage of the infection cycle was N1-
isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine (IMCBH). Treatment of cells with this 
compound inhibits EEV double membrane formation, without affecting the IMV stage, and helped to 
prove the existence of the IEV double membrane (Payne & Kristenson, 1979). Although IMCBH is a 
useful method of inhibiting IEV production in vitro, further research has shown that it is ineffective 
both in vivo and against other poxviruses, ruling it out as a viable anti-poxvirus drug for anything but 
laboratory use (Payne & Kristenson, 1979; Schmutz et al., 1991). A more recently characterised anti-
poxvirus drug, 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-di oxo-4,6-ethenocycloprop 
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[f]isoindol-2(1 H)-yl)-benzamide (ST-246), was first discovered during a high-throughput screening 
for small molecule compounds with anti-VACV activity (Yang et al., 2005). Again, this drug does not 
affect IMV production but is able to significantly inhibit viral spread and multi-cycle growth by 
targeting the IEV/EEV membrane protein F13 in order to prevent wrapping. However, as it targets a 
key viral protein, ST-246 is susceptible to survival mutations and resistance to the drug can occur 
(Yang et al., 2005; Duraffour et al., 2015) 
The presence of an additional stage in the poxvirus life cycle was initially observed as an antigenic 
difference between intracellular and extracellular virus from lysed cells infected with rabbitpox, and 
Figure 1.2 Location of VACV IEV/EEV membrane proteins. Taken from Smith et al.,2002.IEV 
and EEV membrane proteins are shown, along with their orientation. Of the seven proteins 
associated with the IEV membrane, not all are localised to both layers of the double membrane. A36 
and F12 are present on the outer membrane of the IEV, and are not seen on EEVs or CEVs. B5, 
A56, A34 and A33 face outwards on the EEV/CEV membrane, while F13 faces inwards between the 
membrane and capsid. 
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further investigation using electron microscopy also showed a morphological difference with the 
presence of an extra membrane wrapping the extracellular virions (Appleyard et al., 1971). Further 
investigation by Payne, (1980) demonstrated that immunisation with whole IMV or whole EEV 
conferred protection against both intra- and extracellular virus, while immunisation with purified EEV 
envelopes alone only protected against EEV, not IMV. This confirmed not only that an antigenic 
difference in IMV and EEV membranes is conserved in VACV, but also that the EEV membrane 
contains of a number of proteins that are not seen in the IMV. To date, a total of seven proteins have 
been identified as being specific components of the IEV and/or EEV: A33 (Roper et al., 1996), A34 
(Duncan & Smith, 1992), A36 (Parkinson & Smith, 1994), A56 (Payne & Norrby, 1976), B5 
(Engelstad et al., 1992), F12 (Zhang et al., 2000), and F13 (Hirt et al., 1986). The functions and 
structures of these proteins will be discussed in the following sections 
 B5 
One of the most studied IEV/EEV proteins, B5 is a 45kDa, glycosylated protein transcribed from a 
late promoter, that also has some early activity, as production reaches a peak at 6-7 hours post 
infection (hpi), but is also seen in low level amounts early on in infection (Engelstad et al., 1992). B5 
deletion mutants exhibit a very strong EEV inhibition phenotype of tiny plaques and loss of comet 
formation, due to a 90% reduction in EEV levels, almost completely inhibited IMV wrapping, and 
lack of IEV migration within the cell. IMV production is unaffected. (Engelstad & Smtih, 1993; 
Wolffe et al., 1993).  
B5 has a complex structure, including four short consensus repeats (SCRs) in its extracellular domain, 
which play key parts in its EEV release activity. All four SCRs are required to ensure that B5 is 
correctly formed, and the deletion of any one SCR results in a loss of intracellular actin tail formation 
which ultimately leads to a small plaque phenotype (Mathew et al., 1998). Wrapping of IMVs to form 
EEVs, and IEV transport within the cell were not affected by SCR loss, which indicated that that other 
areas of the B5 protein were required for overall IEV/EEV production, and the 90% reduction in EEV 
levels seen in the B5 negative mutants described above (Herrera et al., 1998; Engelstad & Smith, 
1993). The transmembrane domain has been implicated in the signalling required for ER to Golgi 
transport, while the cytoplasmic tail has been suggested to control the speed and timing of this 
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movement, as well as the accumulation of the protein in the Golgi before wrapping occurs (Ward & 
Moss, 2000; Mathew et al., 2001). The cytoplasmic tail is also required for the transport of B5 (and 
therefore the IEV) from the Golgi to the plasma membrane after wrapping has occurred, as deletion of 
the cytoplasmic tail reduces B5 expression on the cell surface (Mathew et al., 2001). B5 is one of the 
few VACV IEV proteins that is able to maintain its standard distribution pattern in the cell even when 
expressed alone, in the absence of virions and other IEV proteins (Lorenzo et al., 2000). Intense 
juxtanulcear staining, around the Golgi region is seen in both full infections and when B5 is expressed 
alone. Only the punctate peripheral staining indicating the presence of IEVs are not seen. This 
indicates that the targeting of the B5 to the Golgi is down to its own cytoplasmic and transmembrane 
domains and is not dependent on any other IEV protein, despite associations with A33 and A34 
described below (Katz et al., 1997; Lorenzo et al., 2000). 
A33 
The 25kDa A33R gene product is classed as a type II membrane protein, and is localised in the outer 
envelope of the IEV, as well as the Golgi complex and its surrounding area, and the plasma membrane 
(Roper et al., 1996; Lorenzo et al., 2000). Loss of A33 results in a small plaque phenotype usually 
characteristic of inefficient or reduced EEV production. However, these plaques exhibit a comet-like 
shape, usually seen in the replication of IHD-J. Comets are seen in IHD-J plaques due to the high 
EEV levels seen in this strain, suggesting an increase in EEV in A33 null mutants (Roper et al., 1998). 
Despite this increase, fully wrapped IEVs are almost completely absent inside the cells, and the only 
evidence of IEV production is in partially wrapped IEVs, suggesting that the EEVs released by A33 
mutant virus are not fully formed (Roper et al., 1998). Indeed, only 1 in 12.9 EEV genomes created 
by A33 mutant viruses are able to form a plaque, compared to 1 in 1.6 genomes in a GFP-labelled 
wild type (WT) virus, confirming a severe loss of infectivity caused by A33 deletion (Chan & Ward, 
2010). In addition, actin tails that would usually push CEVs away from the host cell, for cell-to-cell 
spread, are not seen in A33 mutant viruses, indicating that A33 is required for actin microvilli 
production, though this lack of actin tail formation may be linked to the loss of fully wrapped IEVs 
(Roper et al., 1998). 
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A33 also directly interacts with several other envelope proteins: A34, A36 and B5. A33 and A36 
interact via their cytoplasmic domains, and the deletion of either interaction site results in both less 
A36 localising to IEVs, suggesting that A33 plays a role in A36 recruitment (Ward et al., 2003). A33 
may play a large role as a recruiter of other IEV proteins, as neither B5 nor A34 are correctly 
glycosylated or targeted into IEVs in the absence of A33, though B5 is still targeted to the general 
Golgi area (Lorenzo et al., 2000; Perdiguero & Blasco, 2006; Breiman et al., 2013).  
A34 
Like A33, A34 is another type II integral membrane protein, and is encoded by the 23kDa A34R gene 
at late stages of infection (Duncan & Smtih 1992). Infection with A34 deletion viruses show a similar 
phenotype to A33 mutants in that they can only form small plaques, despite an increase in EEV 
presence. This combination of seemingly contrasting phenotypes shows that A34 is involved not in 
IEV production, but in EEV infectivity (McIntosh & Smith, 1996). Membrane disruption of the EEVs 
formed during an A34 mutant infection results in normal, fully infectious IMVs, and confirms that the 
EEVs do not express a fully competent outer membrane. This is most likely due to the role that A34 
plays in regulating the direct recruitment of A36, B5 and the indirect recruitment of A33, into the 
enveloped virions (McIntosh & Smith, 1996; Perdiguero et al., 2008). A34 is also involved in the 
production of actin-containing microvilli required for cell-to-cell spread of CEVs, as infection with 
A34 mutant virus results in a loss of actin tail formation and thickened, inefficient microvilli (Wolffe 
et al., 1997). A34 is particularly key in VACV infection, as a single point mutation changing its 
Lysine to Glutamine at position 151 has been linked to the difference in EEV release seen in VACV-
WR and VACV-IHD-J strains. This is most likely due to the role of A34 in actin tail formation, as 
VACV-WR exhibits more EVs retained at the cell surface than IHD-J (Blasco et al., 1993). 
 A34 typically exhibits a similar distribution pattern to A33, in that it can be visualised in a 
juxtanuclear, larger-than-Golgi area, and small membrane structures in the cell periphery, potentially 
due to the strong associations between the two proteins. However, when expressed alone, without the 
intact virion or other IEV proteins, A33 exhibits similar staining to a full infection just with less 
intense labelling, while A34 is retained close to the nucleus in an area that does not correspond with 
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Golgi staining (Lorenzo et al., 2000), confirming that A34 is more reliant on other EV proteins for 
correct targeting than A33 (Perdiguero & Blasco, 2006;) 
A36 
The third protein required for IEV production is the 45kDa A36R gene product, which exhibits type 
1b topology, and is integral to the IEV membrane via attachment at the N-terminal (Parkinson & 
Smith, 1994; Van Eijl et al., 2000). Like the previously described proteins, loss of A36 results in the 
classic small plaque phenotype with an absence of actin tails. However, unlike the majority of the EV 
proteins, A36 is found only on the outer of the IEV double membranes and is not seen on EEVs.  
(Parkinson & Smith, 1994; Van Eijl et al., 2000). The presence of A36 is only required on IEV outer 
membranes as it is responsible for interacting with the actin cytoskeleton.  Specifically, A36 
phosphorylates tyrosine residues at positions 112 and 132, and inducing actin nucleation for the 
formation of actin tails and EEV release. Therefore, A36 remains at the cell surface during IEV 
egress, present only directly underneath tethered CEVs, in order to create actin tails.  If A36 
undergoes a mutation at the specific tyrosine 112 and 132 residues, EEV production is reduced as 
virions remain attached to the plasma membrane due to tight, viral protein-protein interactions (Van 
Eijl et al., 2000; Horsington et al., 2013). A36 is also involved in the transport of IEVs to the cell 
surface, although it does not directly interact with kinesin as IEVs with an A36 deletion mutation are 
still able to move on microtubules. However, movement of these mutated virions is slower, with 
shorter periods of uninterrupted movement, and they are far more dispersed within the cell than the 
wild type IEVs (Herrero Martinez et al., 2005; Johnston et al., 2009). 
F12 
The most recently characterised EV protein is the 65kDa, late gene product F12 which, like A36, is 
only found on the outer IEV membrane and is not seen to be associated with EEVs (Van Eijl et al., 
2002). As with A36 protein, F12 is required for the production of normal-sized plaques. (Zhang et al., 
2000), indicating that like A36, F12 is key for the production of actin tails. However, while A36 is an 
integral membrane protein, F12 is only membrane associated and has no transmembrane domain, and 
so is easily left behind when the IEV is released from the cell (Van Eijl et al., 2002; Johnston et al., 
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2009). F12 interacts with the IEV membrane via binding with A36 using motifs at amino acid 
residues 351-458 and 91-111. As this interaction with A36 is the only way that F12 associates with 
the IEV, it is essential for the prevention of the small plaque phenotype and actin tail production 
(Zhang et al., 2000; Johnston et al., 2009). Actin tail formation is highly dependent on F12 as this 
protein is responsible for the movement of IEVs on microtubules (MT). F12 shares a structural 
similarity to kinesin light chains (KLCs), a key part of the microtubule transport machinery which 
form a bridge between kinesin heavy chains and cargo, in this case IEVs, to allow movement along 
MTs (Morgan et al., 2010). The F12 motifs required for interaction with A36 overlap the 
tetracopeptide-like repeats that confer the KLC similarity, and both A36 and F12 are essential for MT 
movement (Johnston et al., 2009; Morgan et al., 2010).  
F12 also shares similarities in action with B5, both are transported to the cell periphery even after IEV 
formation is arrested and IMVs are retained in the viral factories. Once at the periphery, they are seen 
to colocalise in endosomes labelled with fluid phase marker horseradish peroxidase (HRP) (Van Eijl 
et al., 2002).  
F13 
The unglycosylated, palmitoylated F13, which was previously known as p37 due to its molecular 
weight is the most abundant protein in the EEV membrane, composing 5-7% of the total EEV protein 
levels (Hirt et al., 1986; Hiller et al., 1981). Once again, F13 loss results in a small plaque phenotype 
(Vliegen et al., 2012). F13 is a late protein, and is not produced until 6 hpi. Soon after synthesis, it 
associates with the cytosolic face of the TGN in transitional vesicles before becoming incorporated 
into the IEV membranes (Hiller & Weber, 1985; Schmutz et al., 1995; Baek et al., 1997). Once 
integrated into virion, F13 is located on the inner side of the IEV membrane, as well as between the 
membrane and the IMV. Consequently, F13 is found on the cytosolic rather than the extracellular side 
of the plasma membrane after EEV exit (Schmutz et al., 1995).  
While the other five IEV proteins are glycosylated, F13 is palmitoylated to allow association with the 
IEV membrane (Husain & Moss, 2003). Although unique in this manner, F13 also shares several 
similarities with B5, with which it has been seen to associate (Payne, 1992; Husain & Moss, 2002). 
 31 
For example, like B5, F13 is still correctly targeted to the Golgi area when expressed in the absence of 
virions and other IEV proteins (Lorenzo et al., 2000). Another unique feature of F13 is its 
phospholipase activity. F13 contains a partially conserved sequence between amino acid residues 313 
and 329 known as the (H)KD domain, which is essential for phospholipase action and is shared with 
lipases such as phospholipase D (PLD) (Sung et al., 1997; Baek et al., 1997). Though F13 doesn’t 
express the conserved histidine in this motif, it is still able to exert PLD-like enzymatic activity and 
produce lipids such as diaglycerol, choline phosphate and lysophosphatidylcholine (Baek et al., 1997; 
Husain & Moss, 2002).  Both A36 and B5 are able to interact with PLD, and inhibition of 
phospholipase activity with butanol-1, or mutation of the (H)KD domain results in accumulation of 
F13 in the Golgi, and prevention of normal plaque and comet formation, indicating that the HKD-like 
domain is essential for F13 function (Sung et al., 1997; Husain & Moss, 2002). Vesicle budding from 
the Golgi membrane requires the presence of human PLD, so it may be that it is the presence of F13 
in IEVs at the TGN that triggers the trafficking of IEVs to the surface (Sung et al., 1997).  
A56 
Originally identified as the VACV haemaglutinin due to its irreversible interactions with red blood 
cells, A56 was the first protein to be classified as an IEV protein (Payne & Norrby, 1976). Unlike the 
other 5 IEV proteins however, A56 is the only one that plays no direct role in EEV and CEV release 
and dissemination. Instead, it complexes with another viral protein, K2 and is expressed on the cell 
surface in order to prevent superinfection (Wagenaar & Moss, 2009). The A56/K2 complex binds to 
the entry/fusion complex (EFC), on the approaching virion, thereby preventing it from interacting 
with the cellular glycosaminoglyans that would otherwise allow entry. The repellent action of the 
A56/K2 complex is such that if transfected and expressed on the surface of an uninfected cell, it can 
prevent initial infection with VACV (Wagenaar & Moss, 2009).  
In another EEV independent role, A56 is also thought to exhibit complement regulation activity, 
through interaction with the viral complement control protein (VCP). VCP is essential for an in vivo 
infection, and requires interaction with A56 via disulphide bond formation at the A56 N-terminal for 
its expression at the cell surface, where it is able to interfere with the complement immune cascade at 
several different stages (DeHaven et al., 2010).  
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1.1.4.5 Release  
As VACV exhibits two different infectious forms, IMV and IEV, with different structures and 
membrane antigens, it follows that there is more than one method of cell egress seen in VACV 
infection. Although they are the most abundant form of viral progeny, IMV release is a poorly 
researched area of VACV exit. The vast majority of IMVs accumulate in the cell and are not released 
until lysis occurs, for short range dissemination. However, while EEVs and CEVs are predominantly 
released during earlier stages of infection (Tsutsui, 1983), several studies have suggested that IMV 
release, via budding, is the most common form of viral release in the later stages of infection (Tsutsui, 
1983; Ulaeto et al., 1996; Meiser et al., 2003). These studies suggested that IEV production plateaus 
relatively early in infection, and the majority of IMVs are formed after this point (Ulaeto et al., 1996). 
As IMV synthesis increases, the unwrapped virions accumulate in the cell periphery, and cytoplasmic 
packets are formed on the plasma membrane. Filaments extend from these packets, and release IMVs 
from their ends (Tsutsui, 1983). However, IMVs never directly fuse with the plasma membrane on 
exit as EEVs do. Instead, it is suggested that the unwrapped mature virions make use of B5 remaining 
on the cell surface from EEV release for their own egress (Tsutsui, 1983; Meiser et al., 2003).  
However, since these studies were performed, there has no further evidence to support this theory. 
Little is known about IMV budding in comparison to the most well-characterised form of virion exit – 
the actin-based motility and fusion of EEVs and CEVs. CEVs are involved in direct, cell-cell 
transmission, while EEVs are required to spread through the extracellular matrix, and the bloodstream 
in vivo, for more long-range spread. The proportions of EV released as CEV compared to EEV differs 
according to the infecting viral strain. VACV-WR for example, retains a higher percentage of virions 
attached to the plasma membrane as CEVs compared to VACV IHD-J which exhibits less actin tails 
and more EEVs, creating the characteristic “comet” shaped plaque formation (Blasco & Moss, 1992). 
This is most likely due to the IHD-J single point mutation in the actin-tail forming A34 protein, as 
mentioned previously (Blasco et al., 1993). 
 The first step in the formation of the actin tails that push CEVs towards adjacent cells is the 
disruption of actin stress fibres by VACV infection. Cortical actin is instead formed into intracellular 
microvilli, each of which measure between 6.4 -9.6µm long and exhibits an IEV associating with the 
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tip (Cudmore et al., 1995). Formation of the actin tails requires a complex signalling pathway which 
includes not only IEV proteins such as A34 and A36, but also the involvement of cellular factors. 
Phosphorylation of A36 recruits actin nucleation factors such as Nck, WASP, Grb2 and the Arp2/3 
complex to the virion in order to begin actin tail formation from G-actin (Cudmore et al., 1996; 
Scaplehorn et al., 2002). The microfilament extends in a tapering shape by addition of actin 
monomers to free ends in the vicinity of the virion, as nucleation is stimulated only by the association 
with the CEV (Cudmore et al., 1996). Eventually, the CEV inside the filament fuses with the plasma 
membrane at the tip of the tail, and emerges for insertion into another cell (Payne & Kristensson, 
1979). EEV release also occurs through fusion of its outer membrane with the plasma membrane, 
although this is rarely seen in progress and so is thought to occur rapidly (Payne & Kristenson, 1979). 
The rate at which a virus spreads can be predicted by its replication kinetics. However, even taking 
into account the ability of EEVs to promote long range spread, it has been shown that VACV is able 
to infect new, distant cells at a rate four-fold higher than expected. (Doceul et al. 2010). This is due to 
a phenomenon known as ‘trampolining’. Should a virion come into contact with a cell that is already 
infected, it would be pointless for the virus to attempt to enter. Invading virions are alerted to an 
already-established VACV infection in a cell by the presence of the A56/K2 complex on the cell 
surface, which, as discussed earlier prevents further entry (Wagenaar & Moss, 2009). However, this 
complex binds the EFC, which is found on the IMV surface and is therefore not exposed on 
EEVs/CEVs, indicating that another method for the prevention of super-infection must exist. While 
the IEV/EEV proteins A33 and A36 are responsible for the production of actin tails to expel progeny 
enveloped virions from the cell before lysis (Roper et al., 1998; Horsington et al., 2013), Doceul et 
al., showed in their 2010 study that these proteins can also induce the formation of actin tails under 






A 2014 high throughput screen (Beard et al.) identified a component of the p38 mitogen activated 
protein (MAP) kinase pathway as a pro-viral factor in a successful VACV infection. This cellular 
protein, MAP kinase kinase 3 (MKK3) is involved in activation of the p38 pathway, in order to 
subsequently activate various cellular processes. This activation, along with the other MAP kinase 
pathways, will be discussed in the following sections.  
1.2.1. Mitogen activated protein kinases 
All cells must be able to adapt to changes in their environment.  Extracellular stimuli, such as UV 
radiation, osmotic stress, and toxins all demand a response from the cell, ranging from apoptosis to 
conformational changes that allow survival. These responses are mediated by a number of complex, 
overlapping kinase pathways which culminate in the activation of transcription factors by MAPKs, 
and the subsequent expression of stimuli-appropriate genes. MAPKs are the terminal components of 
what is usually a 3-kinase cascade, and are activated by dual phosphorylation of a Thr-Xaa-Tyr motif, 
by upstream MAPK kinases. (Jonak & Hirt, 1994). These MAPK Kinases (MAPKK/MAP2Ks) are in 
turn activated by dual phosphorylation of Ser and Thr residues in a similar activation loop by MAPK 
kinase kinases (MAPKKK/MAP3Ks). There are four known MAPK cascade families: the 
extracellular signal regulated protein kinases (ERK1), the c-Jun NH2 terminal kinases (JNK) family, 
the p38 isoforms, and the ERK5/Big MAPK 1 (BMK1) cascade (Raman & Cobb, 2003; Wang & 
Tournier, 2006). Although each family contains at least two very specific MAP2Ks, and three more 
promiscuous, often inter-family MAP3Ks, certain stimuli result in the activation of extremely specific 
regulatory responses and genes, due to the presence of several controlling mechanisms, such as 
scaffold proteins, crosstalk with other signalling pathways and differential use of MAP2K and 
MAP3Ks (Raman & Cobb, 2003; Shaul & Seger, 2006).  
1.2.1.1 ERK1/ERK2 
The first MAPK cascade to be characterised was the ERK pathway. Initially thought to be triggered 
by growth factor signalling, further investigation showed it to be involved in a wide range of cellular 
processes, including cell proliferation, differentiation, survival and apoptosis (Seger & Krebs, 1995; 
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Shaul & Seger, 2006). The ERK cascade consists of 3 core levels – MAPK, MAP2K and MAP3K - 
but can extend to further tiers, including MAP4Ks and MAPK-activated protein kinase (MAPKAPK) 
(Shaul & Seger, 2006).  In the ERK cascade, growth factors activate GTP- binding protein Ras, which 
in turn activates MAP3Ks, including the protein kinase rapidly accelerated fibrosarcoma (RAF). RAF 
then activates mitogen-activated  protein/ERK kinase kinase 1 (MEK1) by dual phosphorylation of 
Ser217 and Ser221, which is then ready to phosphorylate the next tier of the cascade (Alessi et al, 
1994). The MEKs, the MAP2Ks of the ERK cascade, are extremely specific to ERK1 and 2, and 
activate their substrates by dual phosphorylation at Thr188 and Tyr190 (Seger et al., 1992). At the 
final stage in the cascade, ERK1 and 2 phosphorylate their substrates at a Pro-Xaa-Ser/Thr-Pro motif, 
where Xaa is any neutral or basic amino acid (Gonzalez et al., 1991). 
Figure 1.3 MAPK signalling cascades. Taken from Sabio & Davis, 2014. MAP kinase pathways 
consist of three core components, initiated by a signal from an external stimulus. A MAP3K activates 
a MAP2K by dual phosphorylation which then activates a MAPK by the same method. There are four 
classical families of mammalian MAP kinases. The core ERK pathway is initiated by MAP3Ks, 
RAFs, and Tpl2.. These kinases activate MKK1 and MKK2, which in turn phosphorylate ERK1 and 
ERK2 for the activations of multiple subtrates The p38 and JNK pathways share several promiscuous 
MAP3Ks, including MEKKs, MLKs and TAK1. In the p38 pathway, these MAP3Ks activate MKK3 
and MKK6, which in turn activate the 4 isoforms of p38. In the JNK pathway, these MAP3Ks activate 
the MAP2Ks MKK4 and MKK7, followed by activation of JNK1-3.. Finally, the core ERK5 pathway 
is initiated by the MAP3Ks MEKK2 and MEKK3, which phosphorylate MKK5, which in turn 
activates ERK5. All the pathways then go on to activate multiple transcription and translation factors. 
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1.2.1.2 JNK 
The MAPK JNK is present in three isoforms in mammals; JNK1 and JNK2 are ubiquitous throughout 
the body, while JNK3 is found only in the brain, heart and testes. The most well studied substrates of 
JNK are the transcription factor component and proto-oncogene c-Jun, and activating transcription 
factor 2(ATF2) (Davies, 2000; Vlahopoulos & Zoumpourlis, 2004).  Although JNK is not essential 
for cell growth and proliferation, one of its key roles is the mediation of stress-induced apoptosis, 
most notably due to cytokine induced reactive oxygen species (ROS). Cytokines such as interleukin 
(IL)-1 and tumour necrosis factor (TNF)-α induce ROS, which activate the JNK cascade, resulting in 
the expression of c-Jun. TNF-family proteins can also differentially activate the JNK pathway in order 
to induce further cytokine response, via TNF-receptor associated factor (TRAF) signalling. (Lo et al., 
1994; Davies, 2000; Vlahopolous & Zoumpourlis, 2004). The JNK pathway contains a number of 
MAP3Ks, including MEKK 1-4, and mixed lineage protein (MLK)1-3, though it is not yet fully 
understood which are relevant to which stimuli. At the second tier of the cascade, there are only two 
MAP2Ks that can activate JNK: MKK4 and MKK7, though several isoforms of these kinases exist for 
specific stimulation. Both kinases activate JNK by dual phosphorylation on Thr180 and Tyr182 and 
are required for full and optimal JNK activation, though MKK4 preferentially activates Tyr, and 
MKK7 is preferential to the Thr residue (Davies, 2000; Tournier et al., 2001). This preference of the 
MAP2Ks for different activating residues shows another mechanism of maintaining specificity in the 
signalling cascade, particularly since MKK4 and MKK7 are non-redundant, and are activated by 
different external stimuli (Tournier et al., 1999). For example, MKK4 activation by MEKK1 is 
essential for JNK response to heatshock and treatment with protein synthesis inhibitor anisomycin. 
Both MKK4 and MKK7 are required for optimal activation during UV radiation-induced stress; and 
only MKK7 is required for the cascade to respond to TNF-α and IL-1 stimulus (Yang et al., 1997; 
Tournier et al., 2001). 
1.2.1.3 ERK5/BMK1 
Of the MAPK cascades, the ERK5/BMK1 pathway is the least well characterised. ERK5 was 
originally identified along with its specific MAP2K, MEK5, and is found in a wide range of 
mammalian tissues, particularly the heart and skeletal muscle (Zhou et al., 1995). ERK5 is heavily 
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involved in cardiovascular development, as well as cell proliferation, neuronal cell survival and 
tumour malignancy (Wang & Tournier, 2006). MEK5 is currently the only known activator of ERK5, 
phosphorylating the MAPK at Tyr221 and Thr219. However, several MAP3Ks are known to activate 
MEK5, including MEKK1, MEKK2 and MEKK3 (Mody et al., 2003; Wang & Tournier, 2006). In 
addition to its role in the ERK5 cascade, MEKK1 is also a key activator in the JNK1 cascade, while 
JNK MAP3K MLK-3 is also involved in the p38 pathway, demonstrating the promiscuity of 
MAP3Ks. (Enslen et al., 1998; Davies, 2000).  
1.2.2. MKK3 and the p38 pathway 
p38, the fourth MAPK pathway was first identified through the activation and phosphorylation of a 
38kDa MAPK in response to lipopolysaccharide (LPS) stimulation, and was determined to be unique 
to other MAPK families by specific amino acid sequences surrounding the phosphorylation sites (Han 
et al., 1993; Han et al., 1994). The p38 cascade can be activated by a range of stimuli, including UV 
radiation, heat shock, osmotic shock, growth factors, and certain families of cytokines. These stimuli 
activate small Rho GTPases, which in turn phosphorylate the non-specific MAP3Ks of the cascade, 
including MLK1 and MEKK1(Raingeaud et al.,1996; Zarubin & Han, 2005). In comparison, the 
second tier of the cascade is far more specific, and the two major MAP2Ks, MKK3 and MKK6 
activate only p38. However, a third p38 activating MAP2K, MKK4 is also involved in activating the 
JNK pathway (Derijard et al., 1995; Han et al., 1996; Moriguchi et al., 1996; Raingeaud et al.,1996). 
Once phosphorylated and activated by MAP2Ks, p38 activates its own substrates, including heat 
shock protein 27, transcription factor ATF1, and the first discovered MAPK substrate, MAPK-
activated protein kinase (MAPKAPK). Activation of p38 has been linked to a wide range of biological 
processes, such as inflammation, particularly in autoimmune diseases, apoptosis, cell cycle 
progression, tumour suppression and cell differentiation (Rouse et al., 1994; Zarubin & Han, 2005). 
The activators and roles of p38 are extremely diverse, and dependent on a variety of conditions, such 
as the nature of the stimuli and cell type. For example, in foetal neurons, p38 activity is inhibited by 
up to 90% by insulin treatment, whereas insulin significantly stimulates p38-dependent glucose 
transport in adipocytes (Heidenreich & Kummer, 1996; Sweeney et al., 1999). 
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There are four p38 isoforms: p38α, p38β, p38γ and p38δ. All isoforms are activated in the same 
manner, instigated by a similar range of stimuli, but their localisation and response to activation varies 
(Raingeaud et al.,1996; Jiang et al., 1997). For example, although p38α, p38β and p38δ are all able to 
successfully activate ATF2, the β isoform shows most activity towards the transcription factor, and 
p38δ the least. In comparison p38γ doesn’t activate ATF2 at all, but is able to activate a unique 7kDa 
skeletal muscle protein that the other isoforms cannot (Jiang et al.,1996; Li et al., 1996; Jiang et al., 
1997). The isoforms are also differently regulated by MAP2Ks. MKK6 is able to interact with, and 
activate all isoforms; MKK3 phosphorylates p38α, p38γ and p38δ, and MKK4, which is not a strong 
p38 activator, interacts with p38α, and weakly with p38δ and p38γ (Enslen et al.,1998; Enslen et al., 
2000).  Despite this differential regulation, MKK3 and MKK6 exhibit extremely similar in vivo 
knockout phenotypes, and loss of one of the two MAP2Ks does not entirely inhibit p38 
phosphorylation. This, along with their ability to selectively activate p38 indicates a level of 
redundancy between the two proteins, and suggests that they are able to compensate for each other to 
a certain extent (Raingeaud et al., 1996; Brancho at al., 2003; Ma et al.,2007).  
All p38 isoforms are activated in the same manner by MAP2Ks, through dual phosphorylation of 
Thr180 and Tyr182 in the p38 activation loop (Raingeaud et al., 1994; Enslen et al., 2000). Before 
this can occur however, the MAP2K must bind to the MAPK at a docking site, which contains 
hydrophobic residues in an ØA-Xaa-ØB motif, where ØA and ØB represent any combination of Leu, 
Ile or Val, and Xaa is any amino acid (Chang et al., 2002; Weston et al., 2003). This docking site is 
also the same domain to which MAPK substrates bind. The MAPK docking domain interacts with a 
docking groove in the C-terminal of the MAP2K or MAPK substrate, causing a conformational 
change in the proteins, which allows phosphorylation and therefore activation to occur. It is thought 
that different MAP2Ks cause differing conformational changes in p38, thereby inserting another level 
of specificity (Chang et al., 2002; Weston et al., 2003). 
1.2.3. p38 in infection and inflammation 
One of the key roles of the p38 pathway is its involvement in inflammation during infection. 
Differential activation of p38 by MKK3 or MKK6 gives rise to the production of different cytokines 
and other inflammatory effects. Both TNF-α  and transforming growth factor (TGF)-β, two essential 
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inflammatory mediators, activate varying p38 isoforms via MKK3, giving MKK3 a critical role in 
downstream cytokine production. (Wysk et al.,1999; Wang et al. 2002). Loss of MKK3 expression 
results in a significant reduction in not only TNF-α induced cytokines such as IL-1 and IL-6, but also 
a wide range of other cytokines, including IL-5, IL-12(p70), IL-17, eotaxin and 
granulocyte/macrophage colony stimulating factor (GM-CSF), a reduction that is seen both intra- and 
extracellularly (Wysk et al., 1999; Srivastava et al., 2015). Type 1 interferons, such as IFN-α are able 
to activate downstream p38 by rapidly engaging both MKK3 and MKK6 after IFN receptor binding. 
The expression of interferon stimulated genes (ISGs) are then directly influenced by p38, as the 
MAPK phosphorylates the ISG mediator, signal transducer and activator of transcription (STAT1).  
Consequently, MKK3, MKK6 and p38 are required for inducing innate inflammation, and cytokine 
storms (Li et al., 2005; Börgeling et al., 2014). Conversely, p38 can also be involved in the anti-
inflammatory response, as it is required for the expression of the anti-inflammatory cytokine IL-10, 
which inhibits IL-6 and TNF-α, thereby causing p38 to regulate its own activity (Hammaker et al., 
2014).  
The pathogenesis of several diseases has been linked to the p38 pathway, including influenza A. 
During influenza A infection, p38 is thought to be responsible, either partially or fully, for the 
expression of 94% of virus-induced genes, and demonstrates a role the adaptive immune response in 
addition to the innate immune response. Activation of p38 in T-cells not only increases IFN-γ 
expression in CD4+ and CD8+ T-cells, but also selectively targets CD8+ cells for apoptosis during 
influenza infection (Conze et al., 2000; Börgeling et al., 2014). As this is a counterintuitive measure 
during infection, a protective environment is produced in the lungs in which IL-6 regulates T-cell 
death, and inhibits p38 activity. Since p38 is responsible for initial TNF-α stimulated production of 
IL-6, this demonstrates another way in which p38 is able to regulate its own activity (Wysk et al., 
1999; Conze et al., 2000).  
p38 has been implicated in the pathology of the number of diseases in addition to influenza, by 
increasing inflammation-associated damage and inducing apoptosis. For example, p38 is thought to be 
responsible for injury and apoptosis on neurons during HIV infection, leading to HIV-associated 
neurocognitive disorders, by activating monocytes that release neurotoxins (Medders & Kaul, 2011). 
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In dengue virus infection, p38, ERK and JNK are all activated in endothelial cells, but p38 
specifically leads to increased expression of TNF-α, IL-8 and RANTES, as well as contributing to 
vascular leakage (Fu et al., 2014). 
The key roles of MKK3, MKK6 and p38 in inflammation and disease make this cascade an attractive 
target for therapeutic mediation, and indeed, several p38 inhibitors already exist, including p38 
MAPK specific pyridinyl imidazoles SB202190 and SB203580, and berberine, a plant-derived 
isoquinoline alkaloid (Engelman et al., 1998; Shin et al., 2015). However, clinical trials so far have 
been unsuccessful due to low levels of efficiency in vivo and adverse side effects (Choi et al., 2016).  
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1.3. Vps52 
The 2014 high throughput screen for cellular factors involved in VACV infection (Beard et al.) also 
identified a tethering factor complex, the Golgi associated retrograde pathway (GARP) complex. 
GARP is involved in retrograde transport of cargo from the cell periphery back to the Golgi body. 
This complex, along with general vesicle transport , will be discussed in the following sections.  
1.3.1. Retrograde Transport 
1.3.1.1 Vesicle transport 
A eukaryotic cell requires the constant movement of cargo throughout the cell for continued existence. 
Anterograde transport describes the transfer of molecules through the ER and Golgi to the cell 
surface. However, in order for balance and transport homeostasis to be maintained within the cell, 
retrograde, or recycling transport of cargo back to, for example, the Golgi area is also required. It is 
this form of retrograde transport which will be focused on here. Both anterograde and retrograde 
transport utilise the same general mechanism, as outlined in the vesicular transport hypothesis. 
Specific proteins in a donor compartment are sorted and selected before budding from said 
compartment in a vesicle. Vesicles are then targeted to a specific acceptor compartment, where the 
vesicular and acceptor membranes fuse and the cargo is delivered (Bonifacino & Glick, 2004). Each 
stage of these pathways involves multiple and specific regulators and facilitators (reviewed in Faini et 
al., 2013).  
Transport is initiated by recruitment of vesicle coat proteins to the donor compartment. These coat 
proteins are responsible for selecting and sorting the cargo to be transported, as well as initiating the 
budding formation of the endosome. There are three main types of vesicles: Coat protein complex 
(COP)I-coated, COPII-coated and clathrin-coated. The coat proteins form a scaffold on the outside of 
the donor membrane surface and induce membrane curvature, which subsequently become budding 
vesicles (McMahon & Mills, 2004). COPI-coated vesicles are found predominantly in Golgi to ER 
transport, as well as transport within the Golgi stack, whereas COPII-coated are involved in transfer 
from the ER to the Golgi. In contrast, clathrin coated vesicles are the main form of transport carriers 
in the endocytic and recycling pathways, from the plasma membrane to the lysosome or TGN 
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(McMahon & Mills, 2004). Once budded, vesicles are targeted by the presence of SNAP (Soluble N-
ethylamide factor attachment protein) receptors (SNAREs) on both the vesicle (v-SNARE), and 
acceptor (t-SNARE) membranes (Südhof & Rothman, 2009). SNARES are promiscuous and can 
interact with multiple other SNARES. In addition, these targeting proteins are recycled, and so the 
same SNARES are found on both anterograde, and retrograde vesicles. Therefore, additional factors 
are required to ensure specific vesicle targeting. Tethering factors, such as the exocyst and the Golgi 
associated retrograde pathway (GARP) complex, are protein complexes which mediate the initial 
contact between a vesicle and its acceptor compartment, before v- and t-SNAREs form complexes 
known as SNAREpins, which bring the membranes together and initiate fusion (Südhof & Rothman, 
2009; Chia & Gleeson, 2011). Tethering factors are a large and varied family, consisting of multiple 
subclasses, each of which deals with a different vesicle transport route. One of the first tethering 
factors discovered was p115, a type of tethering factor now known as a golgin, which facilitates 
vesicular transport between Golgi cisternae (Waters et al., 1992; Yu & Hughson, 2010). Golgins are 
members of the long coiled-coil tethering factor family, one of the two main classes of tethering 
factors. In the other class are the heteromeric multi-subunit tethering complexes (MTCs), and include 
Figure 1.4 Vesicle transport from donor to acceptor compartments. Adapted from Bonifacino & 
Glick, 2004. Coat proteins are recruited to the donor compartment and recruit and sort cargo. Coat 
complexes then polymerise into a scaffold and induce membrane curvature, concentrating cargo and 
forming the bud. Eventually the link between the bud and the donor compartment is severed, either by 
accessory proteins or the coat proteins themselves. As the vesicle nears the donor compartment, it is 
uncoated, and coat proteins are recycled back to the donor compartment for further budding. Tethering 
factors and Rab proteins initiate contact between the vesicle and the acceptor compartment, and bring 
the v-SNAREs on the vesicle in contact with the t-SNAREs on the acceptor compartment. This allows 
the SNAREs to form a trans-SNARE complex, promoting fusion of the vesicle and compartment 
membranes, and subsequent delivery of the cargo. 
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such tethering factors as the HOPS complex. The HOPS (homotypic fusion and vacuole protein 
sorting)/class C Vps (vacuolar protein sorting) complex, and its variant the class C core 
vacuole/endosome tethering (CORVET) complex tether vesicles between early endosomes and 
lysosomes, and are both composed of four vacuolar protein sorting proteins; Vps11, Vps16, Vps18 
and Vps33, as well as two additional subunits which differ between the two complexes.  (Yu & 
Hughson, 2010).  Like HOPS and CORVERT, the aforementioned GARP complex is composed of 
four Vps proteins, Vps51, Vps52, Vps53 and Vps54. However, GARP is a member of the CATCHR 
(complex associated with tethering containing helical rods) subclass, and is responsible for tethering 
vesicles from endosomes back to the TGN, a route of transport known as the retrograde pathway 
(Bonifacino & Hierro, 2011). 
Trafficking is also co-ordinated by Rab GTPases, which reversibly interact with membranes by the 
ability to ‘switch’ between GDP and GTP binding. In the GTP-bound ‘on’ state Rab GTPases act as 
recruiters for transport components such as tethering factor and sorting adaptors, thereby mediating 
vesicle docking and fusion (Stenmark, 2009). 
1.3.1.2 The retrograde transport pathway 
As previously described, retrograde transport is required to recycle vesicles and cargo back from 
endosomes to the Golgi, in order to maintain homeostasis in the cell. Retrograde transport consists of 
multiple pathways from the early endosomal to Golgi compartments: via the late endosome, via the 
recycling endosome, or directly to the TGN (Johannes & Popoff, 2008). Distinct SNAREs, GTPases 
and tethering factors direct the action of retrograde transport, many of which have not been observed 
in anterograde trafficking. One such example is a retrograde SNARE complex required for early 
endosome and late endosome to TGN transport. This SNARE complex is composed of endosomal t-
SNAREs Syntaxin 6, Syntaxin 16 and Vti1a and the v-SNARE vesicle associated membrane protein 4 
(VAMP4), and interacts with Rab GTPase Rab6a. (Mallard et al., 2002). In addition to Rab6, several 
more GTPases, including Rab9 are involved in endosome to TGN transport; as Rab9 localises to late 
endosomes for membrane fusion (Lombardi et al., 1993; Carroll et al., 2001).  
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An increasing number of proteins are seen to be trafficked back to the Golgi, both endogenous and 
exogenous. One such endogenous protein is the mannose-6-phosphate receptor (MPR). MPRs 
chaperone mannose-6-phosphate-modified hydrolases from the TGN to lysosomes, but then must be 
recycled back to the TGN via the late endosome for further chaperoning, and so can be used as a 
marker for retrograde transport function (Mallard et al., 1998; Pérez-Victoria et al.,2008). The B-
subunit of Shigella dysenteriae and haemorrhagic Escherichia coli toxin Shiga toxin (STxB) also uses 
retrograde transport, though it uses a separate retrograde pathway to MPR (Mallard et al., 1998). 
STxB enters cells via clathrin mediated endocytosis, and hijacks early and recycling endosomes, 
where it accumulates before being rapidly transferred to the TGN and on to the Golgi (Mallard et al., 
1998).  
Despite travelling by separate pathways, both MPR and STxB are dependent on the retromer complex 
for transport (McKenzie et al., 2013). Retromer is a coat complex localised to recycling endosomes, 
and is comprised of two distinct subcomplexes: one containing sorting nexins (SNX)1/2 and SNX 5/6 
and one containing Vps26, Vps29 and Vps35 (Carlton et al., 2004). Cation independent-MPR (CI-
MPR) is thought to bind Vps35, while Vps26 is required for STxB transport (McKenzie et al., 2013). 
The fact that retromer straddles two completely distinct retrograde transport pathways identifies it as a 
central component in endosome to TGN trafficking.  
1.3.2. The GARP complex 
The GARP complex is a member of the quatrefoil family of tethering factors, and is involved in 
endosome, particularly early and late endosome, to TGN retrograde transport (Conibear et al., 2003; 
Bonifacino & Hierro, 2011). GARP was initially discovered in the yeast Saccharomyces cerevisiae as 
a trimer of three large proteins: Vps52p, Vps53p and Vps54p which localised to the TGN and were 
involved in carboxy peptidase Y (CPY) trafficking, a pathway analogous to MPR recycling (Conibear 
& Stevens, 2000). Further investigation showed that mutation of any of the three Vps proteins resulted 
in the same slow growth phenotype, destabilisation of late Golgi membrane proteins, and mis-
trafficking of CPY pathway components, confirming their role in retrograde transport (Conibear & 
Stevens, 2000). Additionally, none of the three GARP components are known to exist as monomers, 
and all three are required for complex stability (Conibear & Stevens, 2000).  
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In order to further classify the GARP trimer, its interactions with other transport components were 
investigated in S. cerevisiae. Subsequently, the active form of the Rab6 S. cerevisiae homologue, 
Ypt6p, was seen to recruit the GARP complex to the Golgi for protein recycling, by binding to 
Vps52p (Siniossoglou & Pelham, 2001; Siniossoglou & Pelham 2002). This interaction then triggered 
the recruitment of late Golgi SNARE Tlg1p, for recycling from early endosomal membranes to the 
Golgi (Siniossoglou & Pelham, 2001). However, none of the three known GARP components directly 
bound to Tlg1p, prompting further research into GARP associated proteins and the discovery of a 
fourth protein in the complex, Vps51p. It is Vps51p that binds the SNARE Tlg1p via its N-terminal 
(Siniossoglou & Pelham, 2002; Conibear et al., 2003). Although VPS51p was initially highlighted in 
the original screen for components of vesicular transport machinery, it did not appear to have the 
identical mutant phenotype or role as Vps52p, VPs53p and Vps54p and so was not originally 
considered part of the complex (Conibear & Stevens, 2000). Indeed, Vps51p is not essential for 
GARP formation, or targeting to the Golgi membrane, and its mutation results in a milder slow-
growth phenotype than Vps52p, Vps53p or Vps54p mutation (Siniossoglou & Pelham, 2002; 
Conibear et al., 2003).  
In 2005, the human homologue of GARP was first characterised by Liewen et al., but again, it was 
thought to consist of only human Vps52, Vps53 and Vps54. Vps51, originally known as Another new 
gene 2 (Ang2), was not identified as the fourth component until several years later, when it was 
identified on a yeast 2-hybrid screen of GARP interactors, and was seen to bind Vps52, Vps53 and 
Vps54, in a complex of 1:1:1:1 stoichiometry (Pérez-Victoria et al., 2010a).   
In humans, GARP localises predominantly with the TGN and Golgi, but also exhibits a dispersed 
vesicular distribution (Liewen et al., 2005). The dispersal seen in location is caused by recruitment of 
GARP to endosomes involved in the retrograde pathway before vesicle budding, so that when the 
transport vesicle does bud and travels to the acceptor compartment, it is already ready to dock without 
needing to recruit extra factors (Quenneville et al., 2006). The most well-studied cargo that human 
GARP facilitates is CI-MPR, which is recycled back to the TGN after chaperoning mannose-6-
phosphate-modified hydrolases such as cathepsin D (CatD) to lysosomes for degradation (Pérez-
Victoria et al., 2008). Rab9 and TIP47 (Tail interacting protein of 47kDa) are required for CI-MPR 
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retrieval from late endosomes, but cannot complete the cycle without GARP action. GARP loss 
results in reduced levels of CatD, due to a precursor being mis-sorted into lysosomes rather than the 
fully formed protein (Pérez-Victoria et al., 2008). GARP depletion shows similar effects to retromer 
loss, as it blocks STxB transport to the TGN, and results in reduced and more diffuse staining of TGN 
marker TGN46 (Mallard et al., 1998; Pérez-Victoria et al.,2008). In addition to its role in tethering 
retrograde transport intermediates, GARP is also able to interact with individual SNAREs, particularly 
t-SNARES syntaxin 6, syntaxin 16, Vti1a and v-SNARE VAMP4 in order to promote assembly of 
retrograde trafficking SNARE complex (Pérez-Victoria and Bonifacino, 2009). 
The GARP complex is relatively large, and three of the four components, Vps52, Vps53 and Vps54 
range from 700-1700 amino acid residues in size (Bonifacino & Hierro, 2011) The fourth component, 
Vps51 is far smaller, at 125-320 residues, but still exhibits the conserved amphipathic coiled-coil 
domain found at the C-terminus of all four components; which is responsible for complex assembly 
and stabilisation (Siniossoglou & Pelham 2002; Quenneville et al., 2006; Bonifacino & Hierro, 2011). 
As GARP is a heteromeric complex, each of the four components play distinct roles in the tethering 
action. The complex is assembled by the interaction of coiled-coil domains at the C-terminals of each 
component. Therefore, the N-terminal domains, which extend from the centre of the complex, are 
responsible for complex function (Conibear et al., 2003; Siniossoglou & Pelham 2002). Vps51 links 
GARP to syntaxin 6, the mammalian homologue of Tlg1p, and sytaxin 10 via binding between the 
conserved syntaxin HabC motif and a short α-helix containing a di-tyrosine motif in the N-terminal of 
Vps51 (Pérez-Victoria et al., 2010b; Abascal-Palacio et al., 2016).  This interaction with syntaxin 6 
contributes to the formation of the retrograde SNARE complex for endosome to TGN trafficking. 
However, as Vps51 also interacts with syntaxin 10 in the same manner, this suggests that GARP 
engages in a second SNARE interaction at the TGN, as simultaneous binding is not possible (Abascal-
Palacio et al., 2016). Vps52 colocalises with the GTPase Rab6 for vesicle delivery to the late Golgi, 
and has also been seen to interact with syntaxin 10 (Liewen et al., 2005). Vps53 and Vps52 are both 
able to recruit syntaxin 16 and Vti1a, while Vps53 and Vps54 interact with the v-SNARE VAMP4 for 
SNARE complex assembly (Pérez-Victoria et al., 2009; Luo et al., 2011). Vps53 also binds to 
retrograde transport intermediates for tethering function (Pérez-Victoria et al., 2009). Vps54 however, 
is perhaps the most important member of the complex, as it is not only solely responsible for GARP 
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recruitment to the early endosomal compartment, but also for localisation to the TGN, and is essential 
for both the beginning and end of this retrograde transport pathway (Quenneville et al., 2006).  
While GARP plays a clear and direct role in eukaryotic retrograde transport from early and late 
endosomes back to the TGN, it has also been indicated as indirectly affecting a number of other 
processes, emphasising the impact that retrograde transport has on multiple cellular mechanisms. For 
example, as a complex, GARP affects gene regulation in Caenorhabditis elegans as GARP depletion 
compromises the miRNA pathway, possibly due to loss of a membrane related miRNA process 
(Vasquez-Rifo et al., 2013).  
Mutations in specific components of the GARP complex have been reported to have effects in a wide 
range of species. The UNH-1 mutation in the Vps51 homolog UNHINGED in the plant group 
Arabidopsis confers a deformed leaf phenotype, as GARP may be responsible for recycling of 
proteins essential for leaf development (Pahari et al., 2014). The spontaneous hypomorphic wobbler 
mutation in Vps54 results in destabilisation of the entire GARP complex, and motor neurone disease 
similar to amyotrophic lateral sclerosis (ALS) in humans, as well as infertility in mice (Duchen et al., 
1968; Schmitt-John et al., 2005), suggesting that GARP plays a key role in neuronal development and 
maintenance.  This is further supported by the discovery that heterozygous mutations in Vps53 have 
been identified as the cause of progressive cerebello-cerebral atrophy type 2, which causes 
progressive microcephally, spasticity and epilepsy in humans (Feinstein et al., 2014).  
Vps52 is the only component of the complex which has, so far been implicated in a GARP-
independent role. Interestingly, a mutation in Vps52 during embryonic development, tw5 , which 
results in severe gastrulation defects and embryonic death at 6.5 days into development (E6.5) in 
mice, occurs while Vps52 is not complexed in GARP, or indeed even expressed in the same 
embryonic tissues as Vps53 and Vps54 (Sugimoto et al., 2012). This implies that Vps52 is the only 
GARP component so far to have a role outside of the complex, especially as the homozygous 
mutation results in much earlier embryonic lethality than that of homozygous Vps54 mutations at E11 
days (Karlsson et al., 2013). 
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1.3.3. Retrograde transport and infection 
As an important cellular pathway to traffic cargo into the heart of the cell, endosome-Golgi retrograde 
transport pathways (EGRTP) is an ideal target for hijack by invading pathogens, and has been 
implicated in the pathogenicity of multiple bacterial and viral infections and intoxications. Several 
toxins, particularly bacterial toxins featuring the A/B subunit conformation, such as STx, cholera 
toxin (CTx), and Pseudomonas toxin (PEx) all utilise the retrograde transport pathway to reach the 
ER, where they shut down host protein production (Spooner et al., 2006; Mukhopadhyay & Linstedt, 
2013). The plant toxin ricin also exploits EGRTP in a similar fashion to reach the ER. (Wesche, 
2002). Cellular factors involved in the mechanisms of transport differ from toxin to toxin, despite the 
common destination. For example, STx and PEx rely on a Rab6 dependent pathway to reach the ER, 
but neither ricin nor CTx interact with Rab6 at all (Spooner et al., 2006; Morikawa et al., 2009), again 
highlighting the complexity of EGRTP.  
In addition to bacterial toxins, there are several species of bacteria which directly affect the 
mechanisms of retrograde transport, without secreting endotoxins. Rather than hitching a ride on the 
retrograde pathway, Legionella pneumophila, the causative agent of Legionnaire’s disease, 
translocates its RidL protein, which binds to the retromer component Vps29. This interaction diverts 
the retromer complex to the Legionella-containing vacuole, disrupting retrograde transport, and 
promoting bacterial growth (Finsel et al., 2013). In a similar mechanism, the Q fever pathogen 
Coxiella burnetii also subverts EGRTP by recruitment of retromer in order to promote bacterial 
growth (McDonough et al., 2013; Personnic et al., 2016). 
Use of EGRTP is not limited to bacteria and toxins. Several viruses have been shown to interact with 
retromer to promote their own growth. Retromer is exploited in the retrograde trafficking of the key 
envelope glycoprotein (Env) of human immunodeficiency virus (HIV)-1. However, rather than entry, 
Env uses EGRTP for facilitating virion morphogenesis. Env is initially trafficked by the anterograde 
transport pathway to the peripheral site of virion formation. If Env is not incorporated into a novel 
virion, it is transported back to the Golgi in a retromer-dependent manner. Loss of retromer therefore 
results in excess levels of Env incorporated into virions (Groppelli et al., 2014).  
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Although a conclusive linking of VACV with specific components of EGRTP had not been seen at the 
time of this investigation, a substantial amount of evidence existed to suggest that successful VACV 
growth involves the retrograde transport system. During IEV fusion with the plasma membrane and 
EEV egress, some B5 from the IEV outer membrane remains on the cell surface. Evidence collected 
by Ward & Moss (2000) and Husain and Moss (2005) indicates that this B5 may be recycled back 
from the cell surface to the Golgi network via the retrograde transport pathway, as the cytoplasmic tail 
domain contains a tyrosine residue at position 310, and two leucine residues at 315 and 316, a motif 
which has been implicated in several proteins as a regulator for endocytosis (Marks et al., 1996). 
These motifs may be involved in signalling for inclusion in clathrin coated vesicles for retrieval from 
the plasma membrane back to the Golgi network, as deletion of any of the residues results in reduced 
rates of retrograde transportation, as seen by the rate of antibody uptake, and far higher levels of 
staining on the cell surface than the Golgi area (Ward & Moss, 2000). Additionally, expression of 
EH21, a known inhibitor of endocytic function resulted in a significant reduction in B5 uptake from 
the surface, a significant increase in the surface staining of B5, F13 and A36, and a reduction of EEV 
in the extracellular media (Husain & Moss, 2005). F13 also shows evidence of being recycled from 
the cell surface back to the TGN. F13 has been seen to colocalise with both endocytic marker FM64 
in punctate structures in the cell periphery, and clathrin-coated pit marker Texas-red conjugated 
transferrin (TR-tfn). Late endosome marker LAMP2 and F13 were also seen to associate (Husain & 
Moss, 2003) Taken together, these imply retrieval of F13 from the cell surface in late endosomes via 
clathrin-mediated recycling, a hypothesis confirmed by the blocking of F13 retrieval by endocytosis 
inhibitors such as EH21 (Husain & Moss, 2003; Husain & Moss 2005). This recycling of individual 
IEV proteins, including B5, F13 and A36 may occur in order to maximise IEV formation at the viral 
wrapping station, if EV proteins have limited production, or to decrease the visibility of infected cells 
to immune responders (Ward & Moss, 2000; Husain and Moss, 2005), though neither has been 
conclusively proved as yet.  
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1.4. Aims and Objectives 
The aim of this thesis is to investigate the roles of two proteins: MKK3 and Vps52 in the replication 
and spread of VACV. By using several methods of inhibiting gene expression, such as siRNA 
transfection, mutation and pharmaceutical inhibition, we can determine the roles of these proteins in 
the VACV replication cycle, and examine the effects of their loss. By attaining greater understanding 
of the complex VACV life cycle and how it interacts with the host cell, new methods of anti-poxviral 
treatment, or biomedical applications may be revealed. The aims of this project are as follows: 
1. To inhibit expression of MKK3 both in vitro and in vivo, and examine the effects of this loss 
on VACV replication. Furthermore, identify which stage of the VACV replication cycle 
MKK3 influences (Chapter 3) 
2. To inhibit expression of Vps52 and the GARP complex by siRNA transfection and mutation, 
and examine the effects of this loss on VACV replication. Furthermore, identify which stage 
of the VACV replication cycle Vps52 and GARP influence (Chapter 4 & 5). 
3. To detail the cellular components of the EGRTP that are required for VACV morphogenesis, 
specifically the effects of retromer loss, and Retro-2 treatment (Chapter 5). 
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2 Materials and Methods 
2.1. Cell lines and viruses 
2.1.1.  Cell lines 
Dulbecco’s modified Eagle’s medium (DMEM) (Life Technologies), containing 50µg/ml 
streptomycin, 50µg/ml penicillin (pen/strep) (Sigma) and 10% foetal bovine serum (FBS) (Life 
Technologies) was used to grow the following cell lines: rabbit kidney epithelial cells (RK-13), 
African green monkey kidney epithelial cells (BS-C-1 and Vero), and human cervix carcinoma 
epithelial cells (HeLa). All cell lines were passaged regularly to maintain viability. Cells were washed 
in phosphate buffered saline (PBS) and lifted off the flask using 0.5% Trypsin EDTA (Life 
Technologies) before transfer to a fresh tissue culture flask.  Wild type (WT) mouse embryonic 
fibroblasts (MEFs) and mutant (MU) Wobbler (Wob) MEFswere kindly provided by Professor 
Thomas Schmitt-John (Aarhus University, Denmark) and were grown in pyruvate-free DMEM (Life 
Technologies), containing 50µg/ml penicillin, 50µg/ml streptomycin (Sigma), and 20% FBS (Life 
Technologies). Wob MEFs contain a leucine to glutamine substitution at position 967 in Vps54, which 
decreases the half –life of both Vps54 and the entire GARP complex (Schmitt-John et al., 2005; 
Pérez-Victoria et al., 2010a) MEFs were received as primary cells and were immortalised through 
their crisis stage by repeated 1:1 passages every 72 hours until cells became permissible for growth in 
tissue culture flasks. Once immortalised, MEF cells were passaged regularly for maintenance as 
described above. All cells were grown at 37oC, 5% CO2 and 95% humidity.  
2.1.2.  Viruses 
Vaccinia virus Western Reserve (VACV-WR) and VACV-A5-enhanced green fluorescent protein 
(VACV-A5-EGFP) were provided by Professor Geoffrey L Smith (University of Cambridge). Viruses 
used in all experiments were sucrose cushion-purified VACV-WR and VACV-A5-EGFP.  
2.1.3.  Preparation of viral stocks 
RK-13 cells were grown to confluency in ten 175cm2 tissue culture flasks and infected with VACV-
WR at a multiplicity of infection (MOI) of 0.1 in DMEM containing 2.5% FBS and pen/strep and 
incubated for 48h at 37oC and 5% CO2. Once the majority of the cells showed a cytopathic effect, 
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cells were scraped down in the media, centrifuged at 3000g for 10min and the supernatant discarded. 
Cells were re-suspended in 10ml 10mM Tris-HCl, pH 9, and incubated on ice for 15min before being 
dounce homogenised on ice for 25 strokes. The dounced pellet was then centrifuged at 2000g for 
5min and the supernatant layered on top of 18ml 36% sucrose in 10mM Tris-HCl (pH 9). Tubes were 
filled to capacity on top of the viral supernatant with additional 10mM Tris-HCl (pH 9), and 
centrifuged in an ultra-centrifuge (XL-90, Beckman) rotor SW28 for 80min at 13500rpm. Finally, the 
supernatant was discarded and the pellet re-suspended in 1ml Tris-HCl (pH9), and stored at -70oC. 
2.2. siRNA transfection 
HeLa cells (1.5x105 cells per well for a 6 well plate and 4x103 cells per well for a 96 well plate) were 
incubated at 37oC, 5% CO2 for 24h to approximately 75% confluency. siRNA (Table 1) was prepared 
from 20µM stocks stored at -70oC to dilutions of 5µM for a 6 well plate transfection and 250nM for a 
96 well plate, in 1x siRNA buffer (Thermo Scientific).  
For a 6 well plate transfection, 5µM siRNA stocks were further diluted to a concentration of 0.25µM 
in serum free, antibiotic free DMEM. Transfection reagent Dharmafect 1 (Dharmacon) was diluted in 
serum free, antibiotic free DMEM to a final concentration of 1%. For the mock transfected negative 
control, siRNA was replaced with 1x siRNA buffer. Dharmafect and siRNA were incubated 
separately for 5min at room temperature (RT), mixed at a 1:1 ratio and incubated for a further 20min 
at RT.  After incubation, media was removed from the previously prepared HeLa cells and 400µl 
siRNA Dharmafect mix was added to each well, along with 1600µl 5% FBS, antibiotic free DMEM. 
Plates were incubated at 37oC, 5% CO2 for 48h. 
For a 96 well plate transfection, Dharmafect 1 was diluted in serum-free, antibiotic-free DMEM to a 
final concentration of 0.15% and incubated at RT for 5min. siRNA and Dharmafect 1 were combined 
in a 1:1 ratio and incubated at RT for 20min. Media was removed from the prepared HeLa cells in the 
96 well plate and replaced with 80µl DMEM supplemented with 5% FBS only, and 20µl appropriate 
siRNA/Dharmafect 1 mix. The siRNA/Dharmafect 1 mix was replaced with 20µl siRNA buffer for 
the mock transfected control. Cells were incubated for 48h at 37oC, 5% CO2. 
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GAACAAUCACCUCCAGUUA;   CAAUCAAGCUUCAAAUAUG; 
GGAAACCAGUGCUAAGAAU;     CAGCAUGAAUCCCGAAUAU 
PLK1 
(SMARTpool) 
CAACCAAAGUCGAAUAUGA;  CAAGAAGAAUGAAUACAGU;  
GAAGAUGUCCAUGGAAAUA;  CAACACGCCUCAUCCUCUA 
MKK3 
(SMARTpool) 
GGUGGAGGCUGAUGACUUG;  CCGCAGAGCGUAUGAGCUA 




CGAAAGAGGCAGUAAGGAA;  GAUCACACCCACAAUGAAA 





GCUAGAACACCAAGGAAUU;  UAAAGUGACAAUAGUGAGA 
UGAGAUCGAUAUUGUUCUU;  CCACCUAUCCUGAUGUUAA 
Vps35 
(SMARTpool) 
GAACAUAUUGCUACCAGUA;  GAAAGAGCAUGAGUUGUUA 




2.3. Western blotting 
2.3.1.  Protein collection and protein concentration calculation 
Adherent cells were washed twice with ice-cold PBS, then lysed in protein lysate buffer (50 mM Tris-
Cl pH 7.5, 100 mM NaCl, 1% (w/v) NP40) and 1:7 protease inhibitor (Complete tablets, Roche) on 
ice for 30min before storage at -70oC. After thawing, lysates were centrifuged at 16,100 g for 5 min 
and the pellet discarded. A BCA (Bicinchoninic acid) Protein Assay Kit (Thermo Scientific Pierce) 
was used to calculate protein concentrations according manufacturer’s instructions, in a 96 well plate. 
The plate was the incubated for 30min at 37oC and the absorbance was determined on a FluoStar 
Optima plate reader at 562nm. 
2.3.2.  Sodium dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blotting 
Protein samples were mixed in a 1:1 ratio with 2x Laemmli sample buffer (Biorad) with added β-
mercaptoethanol at a final concentration of 355mM. Samples were then boiled at 98oC for 5mins 
before being separated, along with a SeeBlue plus 2 prestained standard ladder (Invitrogen), by SDS-
PAGE on either a 10% or 15% polyacrylamide resolving gel. The resolving gels were layered with 
5% stacking gels, and electrophoresis was performed in TRIS running buffer (final concentrations: 
192mM glycine, 25mM tris base, 3mM SDS, pH adjusted to 8.3) at 90-120v for 2-3h. Either a semi-
dry or a wet blotting technique was used to transfer samples onto nitrocellulose (Maniatis) or PVDF 
membranes (Merck Millipore). Nitrocellulose membranes were equilibrated in transfer buffer (Final 
concentrations: 39mM glycine, 48mM trisbase, 1.3mM SDS, 20% (v/v) methanol). PVDF membranes 
were first activated by submersion in methanol, then distilled water, and finally briefly equilibrated in 
transfer buffer. Semi-dry blot gels were blotted at 15V for 30min while wet blot gels were blotted at 
100v for 1h. Following protein transfer, membranes were blocked in Odyssey blocking buffer (Li-
Cor), diluted 1:1 in PBS, for 1h at RT. Membranes were then incubated with primary antibodies at 
4oC overnight, then fluorescent secondary antibodies for 1h at RT. Blots were scanned in a Li-Cor 
Odyssey scanner and quantified using Image Studio Lite version 3.1. 
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Table 2.2 Antibodies used for western blotting 





Mouse monoclonal 1:1000 Abcam 3700S 
Anti-Actin (loading 
control) 
Rabbit polyclonal 1:1000 Cell signalling 4967 
Anti-MKK3 Rabbit polyclonal 1:1000 Cell Signalling 5674 
Anti-p38 Rabbit polyclonal 1:500 Cell Signalling 9212 
Anti-Phosphorylated 
p38 
Mouse monoclonal 1:500 Cell Signalling 9216 
Anti-Vps51 (Anti-
C11orf2) 
Rabbit polyclonal 1:500 GeneTex GTX105644 




Anti-Vps53 Rabbit polyclonal 1:500 Novus 
Biologicals 
NBP1-76901 
Anti-Vps54 Rabbit polyclonal 1:500 Aviva Systems 
Biology 
OAAB09222 
Anti-E3 Mouse monoclonal 1:500 BEI Resources NR-4547 
Anti-D8 Mouse monoclonal 1:1000 
Gift from Professor Geoffrey 
Smith, University of 
Cambridge 
Anti-Vps26 Rabbit polyclonal 1:1000 Abcam ab23892 
Anti-Vps35 Mouse monoclonal 1:500 Abcam ab57632 
Secondary Antibodies 
Li-Cor Anti-mouse 
IgG (DyLight 680 
conjugate) 
Goat polyclonal 1:15000 Cell Signalling 5470 
Li-Cor Anti-mouse 
IgG (DyLight 800 4X 
PEG conjugate) 
Goat polyclonal 1:15000 Cell Signalling 5151 
Li-Cor Anti-rabbit 
IgG (DyLight 680 
conjugate) 
Goat polyclonal 1:15000 Cell Signalling 5366 
Li-Cor Anti-rabbit 
IgG (DyLight 800 4X 
PEG conjugate) 
Goat polyclonal 1:15000 Cell Signalling 5151 
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2.4. Growth curves 
2.4.1.  Fluorescent growth curves 
Cells were infected with VACV-A5-EGFP at a multiplicity of infection (MOI) of 0.05 for multistep 
growth curves and MOI of 5 for single step growth curves. Viral stocks were diluted in complete 
DMEM containing 2.5% FBS. For Wob MEF cells, pyruvate-negative DMEM, containing 2.5% FBS 
and pen/strep antibiotics was used to dilute the viral stocks. Cells were incubated with viral inoculum 
for 1hr at 37oC, 5% CO2. Inoculum was removed, cells were washed with medium and incubated with 
2.5% DMEM. This was considered the 0 hours post infection (hpi) time point. Fluorescence of EGFP 
was measured as an indicator of viral growth, using a Synergy HT Multi-Mode Microplate 123 
Reader (BioTek), with excitation set to 485nm, and emission at 528nm.  For a multi-step growth 
curve, fluorescence was measured at 0, 12, 24, 36 and 48hpi, and at 0, 4, 8, 12 and 24hpi for a single 
step growth curve.  
2.4.2.  Plaque assay growth curve 
Cells were infected as described above for either a single- or a multi-step growth curve. For multistep 
growth curves, cells were scraped down into the media and viral titres present determined by plaque 
assay on confluent BS-C-1 cells. Viral samples were frozen and thawed three times and sonicated at 
level 2 in a Misonix 3000 sonicator. Samples were serially diluted in complete DMEM containing 
2.5% FBS and pen/strep. For titrations involving wobbler MEF cells, complete DMEM was 
substituted for pyruvate negative DMEM. BS-C-1 cells were inoculated with 1ml per well of viral 
dilutions for 1h at 37oC and 5% CO2, then removed and replaced with a 1:1 solution of 2xDMEM 
containing 5% FBS and pen/strep and 1.5% carboxymethylcellulose (CMC) (Sigma), before 
incubation for 72h at 37oC and 5% CO2. After 72h, the DMEM/CMC overlay was replaced with 0.1% 
crystal violet (Sigma-Aldrich) solution made up in 15% methanol for 1hr to allow plaque counting. 
In a single-step growth curve, supernatants were removed from wells at each time point and 
centrifuged to remove cell debris. Anti-L1 antibody (BEI Resources, 1:500 dilution) was then added 
to the supernatants at a ratio of 1:500, and incubated for 1hr at 37oC to inactivate IMVs. Viral titres in 
the supernatants were determined immediately by plaque assay. Cell monolayers were scraped down 
into the medium and titre also determined by plaque assay, as previously described.  
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2.4.3.  Staining and counting cells 
Cells from siRNA transfections and fluorescent growth curves were fixed in 96 well plates by 
addition of 100µl formalin for 30min. Formalin was then discarded and replaced with 50µl of 25µg/ml 
Hoechst 33342 solution diluted in ice cold, serum- and antibiotic-free DMEM. Plates were incubated 
for 30min in the dark at RT. Images were taken in 2 channels using a Zeiss Cell Observer microscope 
and the Zen 2012 (Carl Zeiss Microscopy) program. Cells were then counted using Image J software 
and a macro written by Dr Charlotte Bell (The Roslin Institute). Fluorescence per cell was calculated 
using the data from single- and multi- step fluorescent growth curves.  
Cell death was also determined using CellTiter Blue Cell Viability Assay (Promega). 20µl reagent 
was added to each well of a growth curve plate and incubated for 1-4h at 37oC. Fluorescence was then 
determined on a Synergy HT Multi-Mode Microplate 123 Reader (BioTek) at 590nm. 
2.5. MKK3 In vivo experiments 
2.5.1.  In vivo VACV infection time course in MKK3 knockout and wild type mice 
Wild type (WT) and MKK3 knockout C57Bl6 ;129S1-Map2k3tm1Flv/J (MKK3-/-) mice were kindly 
donated by Dr J. Kenneth Baillie, and bred by Dr Sara Clohisey (The Roslin Institute), after having 
originally been obtained from The Jackson Laboratory. Mice were infected intranasally with 4x105 
pfu VACV-WR in a PBS vehicle. Control mice were inoculated with PBS only. Clinical scores and 
weights were recorded daily. Mice were scored on the severity of clinical symptoms on a 0-3 scale 
according to severity, where 0 indicated no symptoms, and 3 indicated severe signs. Clinical signs 
included: reduced spontaneous activity, ruffled fur, and hunched posture as well as weight loss. Any 
mice falling below 75% of the starting body weight or scoring higher than 3 for clinical symptoms 
were euthanized. All mice were euthanized day 7 post infection, and their lungs, liver, brain and 
spleen collected for tissue analysis. Lungs were also collected for staining and fixing for histological 
examination. The experiment was covered by appropriate Home Office personal and project licences 
and approved by the local ethics committee. All live animal work, post mortem examinations and 
histopathology were carried out by Dr. Pip Beard, under the Home Office Project Licence 
PPL60/3777, in accordance with the Animal (Scientific Procedures) Act, 1986. 
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2.5.2.  Viral titration from mouse tissues 
Mouse tissues were lysed before titration by adding 1ml DMEM with 2.5% FBS and pen/strep 
antibiotics to safe-lock Eppendorf tubes (Eppendorf) along with one 5mm stainless steel bead 
(Qiagen). Mouse organ samples were then layered on top of the DMEM. Tubes were lysed at 
28,000Hz for 2min in a Qiagen tissue lyser. Sample blocks were rotated and lysed again at 28,000Hz 
for a further 2 minutes to ensure thorough lysis. Supernatants were collected and centrifuged for 5min 
at 3000rpm in a tabletop centrifuge. The resulting pellets were discarded, and the viral titres in the 
remaining supernatants were assessed by plaque assay as previously described. 
2.5.3.  Histopathology of mouse tissues 
Lungs collected from the mice in section 2.5.1 were inflated and immersed in 10% neutral buffered 
formalin (Sigma-Aldrich UK) until fixed, then processed using routine methods, and embedded in 
paraffin blocks. 5µm thin sections were cut and stained with haemotoxylin and eosin for histological 
examination. The sections were then assessed blind by a veterinary pathologist (Dr Pip Beard), before 
being unblinded and groups analysed.  
2.5.4.  Cytokine array of mouse tissues 
An R&D Systems Proteome Profiler Array Kit – Mouse Cytokine Array Panel A was used to examine 
the levels of cytokines in mouse tissues. Triton-X 100 was added to 400µl previously homogenised 
mouse lung tissue to a final concentration of 1%. Samples were freeze-thawed and centrifuged at 
10,000g for 30min for immediate assay. The manufacturer’s protocol was followed, with the 
exception that bound cytokines were detected using LiCor Odyssey. Array membranes were incubated 
for 30min at RT in IRDye 800 Strepavidin antibody (LiCor catalogue #926-32230) diluted at a ratio 
of 1:200 in array buffer 6. Membranes were washed 3 times in 1x wash buffer for 10min and then 




Table 2.3 Antibodies for immunofluorescence 
Antibody Specifications Dilution Supplier Catalogue 
number 
Primary antibodies 
Anti-TGN46 Sheep polyclonal 1:500 AbD Serotec AHP500 
Anti-LC3B Rabbit polyclonal 1:200 Cell Signalling 3868 
Anti-Giantin Rabbit polyclonal 1:250 Biolegend 924302 
Anti-B5  Mouse monoclonal 1:500 BEI Resources NR-556 
Anti-B5  Rabbit polyclonal 1:500 BEI Resources NR-629 








Alexa Fluor 488 
conjugate 






Alexa Fluor 568 
conjugate 
 






Alexa Fluor 568 
conjugate 
 




 Alexa Fluor 594 
Anti-Sheep IgG (H 
/ L) 
 
Donkey polyclonal 1:500 Life Technologies A11016 
 
2.6.1.  Immunofluorescence 
Cells were seeded onto 20mm x 20mm coverslips (SLS) in six well plates at a density of 1.5x105 cells 
for HeLa cells, and 2x105 cells per well for MEF cells. If VACV infection was being examined, cells 
were infected at an MOI of 5 for 8h. Cells were fixed with 2ml of formalin for 30min, washed with 
PBS, then permeabilsed in 0.2% Triton-X100 for 5min at RT, and washed 3 times in PBS. Primary 
antibody was diluted in PBS + 2% FBS, and was incubated on cells in a humidity chamber for 1h at 
RT. Coverslips were washed three times in PBS + 2% FBS before addition of secondary antibody, 
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also diluted in PBS+ 2% FBS, and fluorescently labelled phalloidin (Alexa Fluor 633, Molecular 
Probes). Cells were incubated with secondary antibody for a further 1h at RT, then washed three times 
in PBS and once in distilled water. ProLong Gold mounting media containing DAPI (4-,6-diamidino-
2-phenylindole) (Cell Signalling) was used to mount the coverslips on slides, which were then 
allowed to dry at 4oC overnight. Slides were then examined on a Zeiss 710 confocal microscope.  
2.6.2.  IMARIS image analysis 
Two- dimensional Z –stacks were taken on a Zeiss 710 confocal microscope. These Z-stacks were 
then rendered into three-dimensional (3D) images, and analysis was performed with IMARIS image 
analysis software (IMARIS, version 8.2; Bitplane AG, Switzerland). Z-stacks were rendered into three 
dimensions and the IMARISCell module was used to segments the nucleus, cell, and B5 labelled 
vesicles. Images of vesicles were exported to spots and filtered for association with EGFP 
representing VACV cores, or AlexaFluor 488 representing VACV F13. These vesicles were then 
quantified in order to analyse number of B5-labelled vesicles, their diameter, and the percentage of B5 
–labelled vesicles associating with other labelling of interest.  
2.7. Retro-2-based assays 
2.7.1.  Shiga toxin survival assay 
Vero cells were seeded into a 96 well plate at a density of 1x105 cells per well and incubated at 37oC 
and 5% CO2 for 24h to confluency. Retro-2 (Sigma, or kindly donated by Dr Daniel Gillet at French 
Atomic Energy Commission (CEA) Saclay) was re-suspended in dimethyl sulphoxide (DMSO), then 
diluted to a range of concentrations in FBS-free, antibiotic-free DMEM. Appropriate dilutions were 
added to each well and cells incubated for 2h at 37oC, 5% CO2. Shiga toxin 2 (STx-2) (lot #111108V2 
Toxin Technology, Inc) was serially diluted from the stock concentration of 500µg/ml in serum- free 
and antibiotic-free DMEM, to a range of concentrations and added to appropriate wells. Cells were 
then incubated for 48h, in the continued presence of STx-2 and Retro-2. At 48h post intoxication, cell 
viability was determined using CellTiter Blue, as described in 2.4.3.  
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2.7.2.  Retro-2 growth curve assays 
HeLa cells were seeded into a 96 well plate at a density of 5x104 cells per well and incubated at 37oC 
and 5% CO2 for 24h to confluency. Retro-2 and the related compounds – Retro-1, VP184 or Retro-2.1 
(kindly donated by Dr Daniel Gillet at CEA Saclay) were re-suspended in DMSO to a range of 
concentrations in FBS-free, antibiotic-free DMEM and the appropriate dilution was added to each 
well. Plates were incubated for 2h at 37oC, 5% CO2. Cells were then infected with VACV-A5-EGFP 
at an MOI of 0.05 for a multi-cycle based growth curve as described in section 2.4.1 and 2.4.2, or an 
MOI 5 for a single cycle growth curve, as described in 2.4.2. The drugs remained present for the 
duration of the assays. 
2.7.3.  In vivo VACV infection time course in Retro-2 treated mice 
Retro-2 was re-suspended in DMSO at a concentration 66.6mg/ml (210mM). Groups of 6 female 
BALB/c mice (aged 6-8 weeks) were injected intraperitoneally with 270µl PBS containing 30µl (10% 
v/v) DMSO alone as a negative control, or 30µl Retro-2 solution. Mice were also intranasally 
inoculated with VACV-WR at a concentration of 1x104 pfu diluted in 20µl PBS, or sham infected 
with just the PBS vehicle, while lightly anaesthetised with isofluorane.  Mice were injected with the 
Retro-2 or control solution at either days -1 and 1 post infection, or days 1 and 2 post infection. Mice 
were observed daily and scored for clinical signs of disease (ruffled fur, hunched posture, reduced 
activity), and measured daily for weight loss. Any mice falling below 75% of the starting body weight 
were euthanized. All animal experiments were carried out under a UK Home Office Licence and 
assessed by the local Animals Ethics and Welfare Committee. After the experiment’s conclusion, 7 
days post infection, all mice were euthanized and lungs were taken and titred for virus according to 
the protocol in section 2.4.2. All live animal work and post mortem examinations were carried out by 
Dr Pip Beard, under the Home Office Project Licence PPL 70/8483, in accordance with the Animal 
(Scientific Procedures) Act, 1986. 
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3 The cellular MAPK Kinase protein MKK3 is not required for 
VACV growth in vitro or in vivo 
3.1. Introduction 
A 2014 high throughput loss of function screen of cellular factors influencing VACV replication 
(Beard et al., 2014.) identified p38 activator MKK3 as a pro-viral factor in a successful VACV 
infection. This  chapter focuses on examining the role of MKK3 in VACV growth and replication, by 
siRNA knockdown of the MKK3 gene in vitro, and through the use of MKK3 knockout mice. 
The extracellular environment is constantly changing, and cells must be able to react appropriately to 
stimuli such as UV radiation, inflammation, heat shock and osmotic stress. MAP kinase pathways 
trigger and mediate responses to these stimuli, and the subsequent expression of required genes. 
Currently, there are four known MAPK families: ERK, JNK, p38 and ERK5/BMK1 (Raman & Cobb, 
2003; Wang & Tournier, 2006). Although the specific kinase cascades vary from family to family, all 
the MAPK families have a conserved core cascade consisting of three layers. In this core, MAP3Ks 
activate MAP2Ks by dual phosphorylation of Ser and Thr residues, and these MAP2Ks then go on to 
activate the final layer, MAPKs, by dual phosphorylation of specific Thr and Tyr residues (Raman & 
Cobb, 2003). In most cases, MAP3Ks exhibit a certain level of promiscuity and can activate 
downstream components in more than one cascade, such as MEKK1, which is involved in both the 
JNK and the ERK5 pathway (Davis, 2000; Wang & Tournier, 2006). In comparison, MAP2Ks are far 
more specific, and in general, only activate the MAPK from one family. However, exceptions do 
exist, such as MKK4, which phosphorylates both JNK and p38, though while it is an essential 
component of the JNK cascade, it is not a strong activator of the p38 pathway (Derijard et al., 1995; 
Yang et al., 1997). 
The p38 MAPK pathway was first identified through its response to LPS stimulation, and is now 
known to be activated by a wide range of stimuli, including UV radiation, heat shock, osmotic 
changes, growth factors and certain families of cytokines (Han et al., 1993; Zarubin & Han, 2005). 
Multiple MAP3Ks are involved in the p38 cascade, including MLK1, MEKK1 and TGF-β-activated 
kinase (TAK)1. Several of these MAP3Ks are also part of the JNK cascade, meaning that activating 
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these kinases can result in either specific, or simultaneous p38 and JNK activation, depending on the 
nature of the stimuli (Zarubin & Han, 2005). At the MAP2K stage of the cascade, only 3 kinases are 
able to phosphorylate p38 at the Thr180 and Tyr182 residues: MKK3, MKK4 and MKK6 (Raingeaud 
et al., 1995; Derijard et al., 1995; Han et al., 1996; Moriguch et al., 1996; Raingeaud et al.,1996). Of 
the two MAP2Ks specific to the p38 cascade, MKK3, (also known as MAP2K3), is activated by dual 
phosphorylation of Ser189 and Thr193 residues, and MKK6 by dual phosphorylation of Ser151 and 
Thr157 (Han et al., 1996). Although the majority of p38 activation involves MKK3, 4 or 6, there 
exists an MKK-independent method of p38 phosphorylation, mediated by transforming growth factor 
β-activated protein kinase (TAK)- binding protein 1 (TAB1). When p38 is expressed with TAB1, it 
induces auto-phosphorylation of p38 at a level of activation similar to MKK6 (Ge et al., 2002). Once 
the cascade is completed and p38 activated, it triggers a range of biological processes, including 
inflammation and cytokine production, apoptosis, cell cycle progression and tumour suppression 
(Zarubin & Han, 2005).  
As the cascade is fairly simple, and culminates in only one MAPK, multiple mechanisms of regulation 
exist in order to ensure that the correct final substrate is activated. One such method of ensuring 
specificity is the presence of multiple isoforms of both p38. p38 exists in four different isoforms p38α, 
p38β, p38γ and p38δ, and the isoform activated depends both on the stimuli present and the MAP2K 
involved (Enslen et al., 2000). MKK6 can phosphorylate all four of the p38 isoforms, while MKK3 
activates p38α, p38γ and p38δ, and MKK4 is able to only significantly activate the p38α isoform, 
though it can also weakly activate p38γ and p38δ (Enslen  et al., 1998; Enslen et al., 2000; Remy et 
al., 2010). Specificity of end product production is also obtained by differential activation of 
MAP2Ks and subsequent p38 isoforms according to the nature of the triggering stimuli. For example, 
MKK3 is the dominant activator of p38δ by UV radiation, osmotic shock and TNF-α (Remy et al., 
2010). With regards to other isoforms, many forms of environmental stress except TNF-α binding 
activate p38β, while p38α is responsive to a wide range of stresses and cytokines, but not growth 
factors (Remy et al., 2010). 
 Optimal activation of p38 in the presence of TNF-α or TGF-β activity requires MKK3 (Wang et al., 
2002; Branch et al., 2003). Although MKK6 is non-essential for TNF-α-induced p38 activation, 
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MKK3 and MKK6 double knockout mice display lower levels of TNF-α-induced p38 stimulation 
compared to MKK3 single knockout animals. This, along with the similarity of the MKK3 and MKK6 
in vivo knockout phenotypes, and the fact that loss of one MAP2K does not entirely remove p38 
phosphorylation, shows that the two kinases are somewhat redundant, and are able to compensate for 
each other in the event of expression inhibition (Raingeaud et al., 1996; Brancho at al., 2003; Ma et 
al., 2007).  
As previously mentioned, p38 is activated by stimulation by the key inflammatory mediators TNF-α 
and TGF-β, meaning that p38, and specifically MKK3 play an important role in the inflammatory 
response and cytokine production. TGF-β selectively activates the p38α and δ isoforms via MKK3 in 
order to mediate the formation of extracellular matrixes (Wang et al., 2002). TNF-α also acts via 
MKK3, stimulating p38 in order to induce the production of cytokines including IL-1 and IL-6, but 
also a wide range of other cytokines, including IL-5, IL-12(p70), IL-17, eotaxin and GM-CSF (Wysk 
et al., 1999; Srivastiava et al., 2015). Interferons have been linked to p38 in both the innate and the 
adaptive immune responses. Both MKK3 and MKK6 are recruited by type 1 interferons during the 
innate immune response for rapid p38 activation and production of ISGs (Li et al., 2005), while IFN-γ 
expression by CD4+ and CD8+ T-cells is up-regulated following p38 activation (Conze et al., 2000). 
The pathology of several viruses are thought to involve p38 in some form, including development of 
neuronal injury in HIV-1, interferon release and T cell regulation in influenza A virus, and vascular 
leakage in Dengue virus (Conze et al., 2000; Medders & Kaul, 2011; Börgeling et al., 2014; Fu et al., 
2014). 
Previous research has shown that VACV is able to interact with not only the p38 pathway but several 
of the MAPK cascades in a variety of ways. VACV releases a protein, Vaccinia growth factor (VGF) 
which has sequence homology to the mammalian epidermal growth factor (EGF). The main role of 
VGF is to modulate host defences and evade the inflammatory response. It also activates the ERK1/2 
pathway at early stages of infection (Magalhães et al.,2001; Andrade et al., 2004). This activation is 
then sustained for the duration of VACV replication cycle, and is required for optimal viral DNA 
replication, as well as anti-apoptotic signals which prevent cell death while the virus replicates 
(Andrade et al., 2004).  
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The early VACV protein E3 antagonises protein kinase R (PKR) activity, and subsequently PKR-
dependent activation of p38. One of the substrates of p38 in the context of an infection is NF-κB, a 
transcription factor that mediates cytokine expression. E3 therefore suppresses p38 and NF-κB in 
order to inhibit the expression of a wide array of anti-viral cytokines, including multiple members of 
the IFN, IL, TNF and TGF families (Myskiw et al., 2009). Conversely, the VACV protein A52 
interacts with TRAF6 in order to activate the p38 pathway and NF-κB activation, resulting in 
upregulation of the anti-inflammatory cytokine IL-10 production. The interaction of A52 with TRAF6 
induces non-classical p38 activation, stimulating TRAF6 oligomerisation and subsequent 
phosphorylation of MAP3K TAK1. TAK1 is then able to phosphorylate p38 via TAB1, independently 
of MKK3 or MKK6 (Ge et al., 2002; Maloney et al.,2005; Stack et al., 2013). Simultaneously, A52 
also inhibits p38-induced NF-κB through differential regulation, and interaction with the interleukin 
receptor associated kinase 2 (IRAK2), inhibiting the production of cytokines IL-8 and RANTES 
(Maloney et al., 2005).  
These opposing interactions of p38 with VACV exhibits the important role that differential regulation 
plays in p38 activation and activity. The activation of the p38 pathway by VACV proteins E3 and A52 
occurs through non-classical mechanisms: E3 via RIG-I-like receptor signalling (Zhang et al., 2009), 
and A52 via TAK1, TAB1 and IRAK2 (Maloney et al.,2005; Stack et al., 2013). Neither of these 
mechanisms have shown signs of classical p38 activation involving the major p38 activators MKK3 
or MKK6. However, a high throughput loss of function screen of cellular factors influencing VACV 
replication highlighted MKK3 as having a pro-viral role in VACV growth (Beard et al., 2014). This 
was the first study to examine the effects of the p38 pathway on VACV growth, rather than the effects 
of VACV on the p38 cascade and related cellular mechanisms. Therefore, this chapter focuses on 
examining the role of MKK3 in VACV growth and replication, by siRNA knockdown of the MKK3 




1. To investigate the effect of knockdown of the MKK3 protein by MKK3-targeting siRNA 
on VACV replication. 
2. To examine the in vivo effects of MKK3 loss. 




3.3.  Results 
3.3.1.  Transfection of HeLa cells with MKK3-targeting siRNA inhibits protein expression 
In order to investigate the impact of MKK3-loss on VACV spread and replication, MKK3 was 
knocked down by transfection of specific MKK3-targeting siRNA. A previous study has identified 
MKK3 as a strong pro-viral host factor, and showed that MKK3 loss resulted in a significant 
reduction in VACV-induced fluorescence (Beard et al., 2014). Initial experiments in this chapter set 
out to replicate this finding. In order to investigate the impact of MKK3-loss on VACV spread and 
replication in vitro, MKK3 expression was inhibited (“knocked down”) by transfection of specific 
MKK3 targeting siRNA. HeLa cells were transfected with either a non-targeting control siRNA 
directed at the HSV-1 protein VP16 (NT), or a SMARTpool of four individual siRNAs targeting 
different sequences within the MKK3 gene. A SMARTpool was used rather than one single siRNA to 
enhance the specificity and magnitude of the siRNA knockdown, and reduce the chances of off-target 
effects obscuring the true outcome of MKK3 knockdown on VACV growth. At 48h post transfection, 
cells were collected and MKK3 expression was examined using western blotting. Transfection of cells 
with the MKK3-targeting siRNA SMARTpool resulted in a 55% significant reduction in protein 
expression compared to MKK3 levels in the non-targeting control (Figure 3.1A,B) 
Figure 3.1 MKK3 expression is reduced by siRNA knockdown. (A) HeLa cells were transfected 
with either a non-targeting siRNA (NT), or a SMARTpool composed of 4 siRNAs targeting MKK3. 
After 48h, cells were collected and proteins separated by SDS-PAGE, then probed using anti-MKK3 
(green) and anti-actin (red) antibodies and visualised using fluorescent secondary antibodies and direct 
infra-red fluorescence (Li-Cor) on an Odyssey scanner. (B) Levels of MKK3 compared to actin were 
quantified in MKK3 knockdown cells and the NT control in Image Studio Lite. Data represents means 
and SEMs of 2 biological repeats. ***,p<0.001. 
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3.3.2.  MKK3 knockdown reduces VACV growth as measured by fluorescence 
Once the siRNA was shown to successfully reduce MKK3 levels, MKK3 knockdown cells were 
infected with VACV in order to determine the effect of MKK3 depletion on VACV replication and 
spread. Here, replication refers to the production of infectious virions, including replication of the 
viral genome, protein production and morphogenesis of IMVs over the course of one replication 
cycle. ‘Spread’ refers to the maturation of IMVs to IEVs, their transport to the cell surface, egress as 
CEVs or EEVs, and their ability to travel to and infect other cells. Collectively, spread and replication 
will here be referred to as growth. Firstly, a multi-cycle growth curve was used to examine the growth 
(incorporating replication and spread) of the virus. In a multi-cycle growth curve, cells are infected at 
a low MOI, and measurements are taken up to 48h post infection (hpi). Not all cells are infected on 
inoculation, enabling multiple replication cycles to occur. In these initial studies, a strain of VACV 
containing the fluorescent protein enhanced green fluorescent protein (EGFP) attached to the A5 
capsid protein was used (VACV-A5-EGFP). The EGFP tag allowed fluorescence intensity to be 
measured as a proxy of viral growth (Carter et al., 2003).  HeLa cells were transfected with either an 
NT siRNA as a negative control, or siRNA targeting the known pro-VACV host factor Rab1A as a 
positive control. Rab1A is a small GTPase localised to the ER-Golgi membrane, and has been shown 
to play a key role in VACV growth (Pechenick-Jowers et al., 2015; Liu et al., 2016), making it an 
ideal positive control for VACV growth curves. A third cohort of HeLa cells were transfected with the 
siRNA SMARTpool targeting MKK3. After 48h of transfection, cells were infected with VACV-A5-
EGFP at an MOI of 0.05, and fluorescence was measured at 12h intervals up to 48hpi. The 
fluorescence levels in all 3 samples remained around 1600 units for the first 36hpi (Figure 3.2A). 
However, after this time point, the NT siRNA-transfected cells began to exhibit an increase in 
fluorescence, with levels eventually increasing by 40% compared to background levels present at 
0hpi. In comparison, the cells transfected with the Rab1A positive control siRNA exhibited an 
increase in viral fluorescence of just 2% compared to the 0hpi background levels over the course of 
the growth curve, confirming the inhibitory effect that Rab1A loss has on VACV fluoresence. Loss of 
MKK3 only resulted in only a 20% increase in fluorescence over the course of the experiment, a 
significant reduction compared to the negative control. Therefore, the results shown here are in 
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agreement with those seen in the previously published Beard et al study, that MKK3 is a proviral host 
protein. 
 Viral replication was also measured via fluorescence over the course of a single step growth curve, in 
order to examine the effect of MKK3 knockdown on viral replication. HeLa cells were siRNA 
transfected as described above. After 48h, cells were then infected with VACV-A5-EGFP at an MOI 
of 5. This high MOI ensures that all cells are infected at the 0h time point, and allows intracellular 
virion replication to be examined by EGFP fluorescence over the course of one 24h replication cycle. 
Fluorescence readings were taken every 4h, up till 12hpi, then a final reading was taken at 24h. While 
NT siRNA was used as a negative control, the serine/threonine protein kinase polo-like kinase (PLK)-
1 was used as a positive control rather than Rab1A, as Rab1A affects VACV spread, rather than 
replication (Pechenick-Jowers et al., 2015). PLK-1 is a host cell protein essential for mitosis and cell 
survival, and inhibition of PLK-1 expression is lethal (Lu et al., 2008). Therefore, transfection of 
siRNA targeting PLK-1 results in cell death, and subsequently prevents EGFP expression. In cells 
treated with the NT siRNA, fluorescence signal initially decreased but began to increase again at 
Figure 3.2 MKK3 knockdown inhibits VACV growth in both multi- and single-step growth 
curves, as measured by fluorescence. (A) HeLa cells were transfected with either a SMARTpool 
targeting MKK3, NT siRNA as a negative control, or siRNA targeting known cytotoxic gene Rab1A 
as a positive control. After 48h, transfected cells were infected with VACV-A5-EGFP at an MOI of 
0.05, and fluorescence was measured every 12h for 48h. Results show the means and SEMs of five 
technical repeats and are representative of 2 biological repeats. Statistical analysis was performed 
using a one-way analysis of variance (ANOVA) with multiple comparisons at the 48 hpi time point. 
***, p<0.001.  (B) HeLa cells were transfected with a SMARTpool targeting MKK3. NT siRNA was 
used a negative control, while siRNA targeting PLK-1 was used as a positive control. After 48h, 
transfected cells were infected with VACV-A5-EGFP at an MOI of 5, and fluorescence was 
measured at 0, 4, 8, 12 and 24h post infection. Results show the means and SEMs of five technical 
repeats and are representative of 2 biological repeats. Statistical analysis was performed using a one-
way analysis of variance (ANOVA) with multiple comparisons at the 48 hpi tie point. ***, p<0.001 
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12hpi and reached levels clearly above background at 24hpi (Figure 3.2B), consistent with the 
expected VACV replication kinetics. PLK-1 loss resulted in a significant reduction in viral replication 
compared to the NT negative control at 24hpi, confirming the efficacy of siRNA transfections (Figure 
3.2B). Depletion of MKK3 gave an intermediate phenotype in which the cells clearly supported 
detectable levels of viral EGFP expression, but to significantly lower levels than the NT control cells. 
Taken together, these results suggest that MKK3 knockdown significantly inhibits both the replication 
and spread of VACV, when measured via levels of fluorescence 
3.3.3.  MKK3 knockdown does not influence production of infectious virions 
In order to directly assess the effects of MKK3 loss on the formation of infectious virions, the multi-
cycle and single-cycle growth curves were repeated, however virus growth was assessed using a 
plaque assay rather than measuring A5-linked fluorescence. HeLa cells were transfected with either 
siRNA targeting the NT negative control, the Rab1A positive control, or the SMARTpool targeting 
MKK3. After 48h, cells were infected with VACV-WR at low MOI of 0.05, and then were collected, 
and virus titrated at 12h intervals until 48hpi. Although a reduction of approximately 0.5 log10 in viral 
titre was seen at 48hpi in the positive control compared to the negative control (Figure 3.3), this result 
did not reach significance, due to high levels of inter-experiment variance. At 48hpi, there was no 
difference in viral titre seen between MKK3 knockdown cells and the NT control, and this result was 
seen consistently across all repeats. Accordingly, in order to examine the effect of MKK3 loss on 
specific stages of the VACV life cycle, a single-step, titrated growth curve was also performed. At 
each time point, the supernatant of infected samples was collected separately from the cell monolayers 
Figure 3.3 Loss of MKK3 does not 
affect viral titre. HeLa cells were 
transfected with either a SMARTpool 
targeting MKK3, NT siRNA, or siRNA 
targeting known proviral host factor 
Rab1A. After 48h, transfected cells 
were infected with VACV-WR at an 
MOI of 0.05. Cells were collected and 
titrated for plaque assay at 12h intervals 
post infection, up to 48hpi. Data is a 
collation of 3 biological repeats. 
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in order to measure both extracellular (EEV) and intracellular (IMV, IEV and CEV) production. As 
described in Materials and Methods, the supernatant was treated with an antibody targeting the early 
VACV IMV protein L1, thereby neutralising any IMVs present, and ensuring that only the levels of 
EEVs were examined in the supernatant fraction. The cellular fraction was also collected and titred 
separately, in order to measure the levels of cell-associated virus (CAV) present, thereby allowing the 
effects of host protein loss on individual parts of the life cycle to be determined. HeLa cells were 
transfected with siRNA as described above, and at 48h post transfection, cells were infected with 
VACV-WR at a high MOI of 5. Supernatant and cells were collected and titred separately at intervals 
up to 24hpi. At the final time point, Rab1A knockdown had significantly reduced EEV titre in the 
extracellular fraction compared to the NT negative control (Figure 3.4A). The EEV present in the 
supernatant of Rab1A knockdown cells increased from 1x104 pfu/ml to 5x104, whereas the cells 
treated with the NT siRNA control increased from 1x104 pfu/ml to 2x105 pfu/ml, four fold higher than 
the positive control. This result was consistent with previously published data, as Rab1A is known to 
affect the wrapping stage of the VACV life cycle, and its depletion detrimentally affects the levels of 
EEV released (Pechenick-Jowers et al., 2015). However, no difference in viral titre in the supernatant 
was seen when comparing the samples transfected with siRNA targeting MKK3 and the negative 
control. In the cellular fraction, loss of Rab1A had no effect on viral titre compared to the negative 
Figure 3.4 Effects of MKK3 loss are not evident in a viral titre in a single replication cycle (A 
and B) HeLa cells were transfected with either a SMARTpool targeting MKK3, NT siRNA or siRNA 
targeting Rab1A. After 48 h, transfected cells were infected with VACV-WR at an MOI of 5. At 0, 4, 
8, 12 and 24 h post infection, supernatant (A) was removed, neutralised for IMVs using anti-L1 
antibody and titrated. Cell monolayers (B) were also collected and titrated. Data represents the means 
and SEMs of 2 biological repeats. ***, p<0.001 
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control, a result which was again in agreement with previous data, as Rab1A does not affect the 
formation of IMVs, only EEVs (Pechenick-Jowers et al., 2015). In addition, no difference in IMV 
titre was seen in the MKK3 knockdown cells compared to the NT control, in fact the NT-, MKK3- 
and Rab1A- knockdown cells all demonstrated very similar titres of IMV production at all time points 
over the course of the experiment (Figure 3.4). Taken together, these results suggest that knockdown 
of MKK3 has no effect on viral growth when growth is measured directly by titre. However, cell 
culture does not always accurately reflect the effects of gene knockdown in vivo. Therefore, the effect 
of MKK3 loss in vivo was examined. 
3.3.4.  MKK3 loss does not affect VACV infection in vivo 
A murine model of VACV disease was used in order to further investigate the relationship between 
MKK3 and VACV.  Pharmaceutical inhibition of MAPK p38 has previously been shown to have 
protective effects during in vivo infection with a number of other viruses, such as influenza A virus 
and dengue virus (Börgeling et al.,2014; Fu et al., 2014). Mice containing an MKK3 null mutation 
were already available at the Roslin Institute for an influenza project, and were kindly donated by Dr 
Kenneth Baillie. All mouse work was performed by Dr Pip Beard. Wild type (WT) and MKK3 
knockout mice (MKK3-/-) were either given an intranasal inoculation of 1x104 pfu VACV-WR, or 
mock infected with the PBS vehicle. Body weights and clinical symptoms were then recorded daily 
over the course of a 7d infection. Clinical symptoms included ruffled fur, weight loss, hunched 
posture and reduced activity, and were scored on a 0-3 scale according to severity, where 0 indicated 
no symptoms, and 3 indicated severe signs. Uninfected mice, both WT and MKK3-/- maintained their 
body weight over the course of the infection (Figure 3.5A), while infected mice, of both phenotypes 
exhibited weight loss of up 25% of their starting weight by 7days post infection (dpi). There was no 
difference between the weight loss seen in infected, WT mice and in infected MKK3-/- mice. A similar 
trend was seen in the scoring of clinical symptoms recorded during the infection (Figure 3.5B). 
Uninfected mice of both phenotypes showed no clinical signs as expected, and though clinical 
symptoms appeared a day earlier in MKK3-/- mice than in the WT animals, by the end of the 
experiment, both groups exhibited the same levels of symptoms.  These results show that loss of 
MKK3 does not greatly influence the severity of VACV disease in mice.  
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At the conclusion of the experiment, lungs, liver, brains and spleen were collected from infected mice, 
and lysed and titred for virus. In all four organs examined: brain. lung, liver and spleen, there were no 
significant differences in viral titre between the WT and MKK3-/-  mice (Figure 3.5C). Although the 
brains, lungs and livers of several individuals exhibited viral titres below the limits of detection, equal 
numbers of these ‘titre-negative’ mice were seen in both phenotypes in each organ, therefore resulting 
in no overall difference in viral titre.  Interestingly, the individuals seen to have undetectable viral 
titres in one organ did not necessarily have undetectable levels of virus in other organs. Overall, these 
show that MKK3 loss has no effect on viral titre in a variety of organs in vivo.  
Figure 3.5 MKK3 loss does not affect viral growth or disease in a murine model of VACV in 
vivo. WT C57BL/6 mice and C57BL/6 with an MKK3 null mutation (MKK3-/- ) were originally 
obtained from The Jackson Laboratory, and donated to this project by Dr Kenneth Baillie. Animals 
were randomly sorted into groups of 6, and one group of 5. Group 1 were WT mice, mock infected 
with PBS. Group 2 were mock infected, MKK3-/- knockouts. Group 3 were WT mice were inoculated 
intranasally (i.n.) with 1x104 PFU of purified VACV-WR on day 0. Group 4 were MKK3-/- knockout 
mice infected on day 0 as described (group of 5). All mice were examined daily for weight loss (A), 
and clinical symptoms (B). At 7dpi, the experiment was terminated and viral loads were assessed (C). 
Lungs, livers, brains and spleens were collected from all infected mice and processed for viral titration 
using plaque assay. Mean titre and SEM are also shown. Dashed line on scatter plots represents the 




In order to further investigate the course of VACV infection in an MKK3 knockout mouse, 
histological analysis was performed on the lung, liver brain and spleen tissue of infected mice. All 
sections for histology were examined by Dr Pip Beard, a trained veterinary pathologist. The tissue 
sections were fixed in neutral buffered formalin and stained according to standard haematoxylin and 
eosin protocols, before being examined blinded (Figure 3.6). After examination, slides were unblinded 
and each group analysed. In the lung tissue, neither WT nor MKK3-/-, mock infected mice exhibited 
any significant lesions, as expected. 4 of the 6 infected WT mice, and 2 of the 5 infected MKK3-/- 
mice exhibited moderate levels of pathology characterised by multifocal, subacute, fibrinonecrotic 
bronchopneumonia with rare intracytoplasmic eosinophilic inclusions in the lung tissue. The 
remaining 2 infected WT mice and 3 MKK3-/- mice displayed milder changes characterised by mild to 
moderate perivascular inflammation (neutrophils, lymphocytes and macrophages). Overall, there was 
Figure 3.6. MKK3 loss does not affect VACV-induced tissue pathology. Lung tissue was collected 
at necropsy from the WT (a and b) and MKK3-/- (C and d) mice used in Figure 3.5. Tissue sections 
were fixed in neutral buffered formalin and stained according to standard haematoxylin and eosin 
protocols. Slides were examined blind, by light microscopy, for signs of disease. Slides were later 
unblinded and each group analysed. All histopathology carried out by Dr Pip Beard. 
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no histopathological evidence present that suggested that MKK3 loss affected disease in vivo, as the 
pathological changes identified and severity of lesions did not correlate with genotype. In addition, no 
significant pathology was identified in the liver, spleen or brains of any mice involved in the 
experiment (data not shown).  
3.3.5.  MKK3-dependent cytokine expression is not essential for VACV clearance in vivo  
As loss of MKK3 had no effect on the overall course of VACV infection in the mouse model, we 
examined the in vivo effects of MKK3 loss on cytokine levels in mouse tissue to determine if MKK3 
gene deletion resulted in any changes in immune response during infection. In order to do this, a 
cytokine array was performed on tissues collected from the mouse experiment described in 3.3.4. 
Previous studies have shown that MKK3-dependent p38 activation is essential for the expression of a 
wide range of cytokines, including multiple members of the IL, and IFN families, eotaxin, GM-CSF, 
macrophage inflammatory protein (MIP-1), and TNF-a (Wysk et al., 1999; Lia et al., 2005; 
Srivastiava et al., 2015). The clearance of a VACV infection is also dependent on a number of 
cytokines, several of which overlap with those dependent on MKK3 activation for expression; 
including type I and type II interferons, IL-1b, IL-10, IL-12p40 and TNF-a (Haga & Bowie, 2005; 
Ryan et al., 2009). The cytokine array aimed to examine the cytokine response to VACV infection, 
and determine if MKK3 loss results in any changes in immune response to VACV infection, that 
could be too subtle to be seen using body weight, clinical signs, or histopathology. Lung tissues from 
infected WT and MKK3-/- mice were pooled and analysed using a mouse cytokine array panel, 
consisting of immobilised capture antibodies for 40 different cytokines in duplicate on a nitrocellulose 
membrane. Clarified tissue was incubated with the membranes to allow binding, and fluorescent 
detection reagents were used to produce a signal proportionate to the amount of cytokine present. A 
PBS negative control was also used, which exhibited a relative fluorescent level of 0, and a reference 
spot provided by the kit was used as a positive control, which gave a relative level of 100.  Only 10 
cytokines showed a significant difference in expression between WT and MKK3-/- lung tissue lysates: 
I-309, eoxtaxin, IL-1b, IP-10 (CXCL10), MCP-5 (CCL12), MIG (CXCL9), MIP-1a (CCL3), MIP-1b 
(CCL4), TIMP-1 and TREM-1. The level of significance varied from p< 0.05 to p<0.001 (Figure 3.7). 
All the significant changes identified showed a decrease in cytokine/chemokine expression in the 
MKK3-/- compared to the WT samples, with the exception of TREM-1, which exhibited a higher level 
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of expression in the MKK3-/- samples. Of the 10 differentially expressed cytokines, IL-1b, eotaxin, 
MIP-1a, MIP-1b, exhibit a direct dependence on MKK3-induced p38 activation for their expression 
(Srivastiava et al., 2015). IP-10, TIMP-1 and TREM-1 are dependent on general p38 signalling 
(Tibbles  et al., 2002; Tong et al., 2004; Murakami et al., 2007)  while I-309, MIG and MCP-5 have 
only been loosely linked to p38 (Wang et al., 2006; Kanda et al., 2007; Huang et al., 2010).  The 
reduction of expression levels of these cytokines and chemokines indicates that the p38 pathway is 
affected by MKK3 loss, but that this loss is not significant enough to impact viral growth. In 
conclusion, loss of MKK3 in vivo results in an inhibition in the cytokine response to infection, but this 
inhibition is not sufficient to alter the course of VACV disease as a whole. When considered together, 
the results of the cytokine array, in vivo experiment and direct measurement of viral growth indicate 
that MKK3 loss, whether by siRNA knockdown, or genetic mutation, is not sufficient to inhibit 





Figure 3.7 (facing page) MKK3 is not essential for an overall effective cytokine response. Levels of 
cytokines present the mice used in Fig3.5 were analysed using an R&D systems mouse cytokine array 
panel, according to the protocol provided in the kit. Cytokine levels were visualised using fluorescent 
secondary antibodies and a LiCor Odyssey. Data shows means and SEMs of 2 technical repeats. 





3.3.6.  MKK3 knockdown does not reduce total or phosphorylated p38 levels 
Despite the results demonstrating that alteration of MKK3 expression levels does not affect 
production of infectious virions in vitro or in vivo, or alter disease course in mice, there still remains 
the apparent reduction in VACV growth in MKK3 knockdown cells when measured via fluorescence 
of EGFP tagged to the A5 capsid protein.  The final section of this work concentrated on determining 
the reason for the apparent reduction in A5 production (Figure 3.2). Initially, levels of p38 and 
phosphorylated p38 (Pp38) were examined in control and MKK3 knockdown cells. MKK3 is one of 
the three MAP2Ks responsible for activating the MAPK p38, along with MKK6, and to a lesser 
extent, MKK4 (Raingeaud et al., 1994; Derijard et al., 1995; Han et al., 1996; Moriguch et al., 1996; 
Raingeaud et al.,1996). Therefore, MKK3 knockdown may not be sufficient to impact overall Pp38 
levels. HeLa cells were transfected with either the NT negative control siRNA, or an siRNA 
SMARTpool targeting MKK3.  After a 48h transfection, cells were either infected with VACV-WR at 
an MOI of 5, or mock infected. At 0, 1 and 2hpi, cells were collected and examined for levels of p38 
and Pp38 by Western blotting. With some fluctuations, levels of p38 in the Western blot appeared 
consistent across the 2h in uninfected and infected cells, and in both  NT control and MKK3 
knockdown conditions (Figure 3.8A). Pp38 levels in both infected, WT and MKK3 knockdown cells 
also appeared relatively consistent, though again fluctuations were seen (Figure 3.8C & D). In 
uninfected MKK3 knockdown cells, Pp38 appeared to decrease over the course of the experiment, 
though no consistent trend was seen in NT-transfected cells. Overall, these results suggest that 
knockdown of MKK3 does not consistently affect the expression of p38, or its activation, compared to 
NT cells. However, these results represent only one biological repeat and therefore further repeats 





Figure 3.8 MKK3 knockdown does not reduce total or phosphorylated p38 levels. HeLa cells 
were transfected with either a non-targeting siRNA (NT), or a SMARTpool composed of 4 siRNAs 
targeting MKK3. After 48h, cells were infected with VACV-WR at MOI 5, or mock infected as an 
uninfected control. At 0, 1 and 2h post infection, cells lysed and proteins separated by SDS-PAGE, 
then probed using anti-p38 (A) or anti-phosphorylated p38 (C) and anti-actin antibodies, and 
visualised using fluorescent secondary antibodies and direct infra-red fluorescence (Li-Cor) on an 
Odyssey scanner. Image Studio Lite was used to quantify the total p38 (B) and phosphorylated p38 
(D) blots. The actin loading control bands were used to normalise the quantification of p38 and Pp38. 
Data represents one biological repeat. 
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3.3.7.  MKK3 loss affects production of VACV proteins 
As levels of p38 nor Pp38 were not consistently affected in the MKK3 deficient cells compared to the 
control cells, levels of viral proteins were examined in the knockdown cells in order to further 
investigate the role that MKK3 apparently plays in the generation of fluorescence during VACV 
infection. Ultimately, a fluorescent growth curve, using the VACV-A5-EGFP strain does not directly 
measure viral production. Instead, production of the tagged A5 protein is being measured (Carter et 
al., 2003). Therefore, we considered the possibility that MKK3 loss was affecting viral protein 
production rather than whole virion replication. The early IMV protein E3, and the late protein D8 
were selected to investigate the levels of viral protein over the course of one replication cycle to see if 
A5 production was specifically affected, or if a there was a more global effect on viral protein 
production. Early proteins such as E3 are transcribed immediately upon virion uncoating and viral 
mRNA may be produced as early as 12 minutes post infection (Kates & McAuslan, 1967; Munyon et 
al., 1967; Wright et al., 2001). In contrast D8 is a late protein, and so is not transcribed until late in the 
replication cycle after DNA replication has occurred (Keck & Moss, 1990) astranscription factors for 
late proteins are typically activated at approximately 4.5hpi.  
HeLa cells were transfected with either the NT control siRNA, or the siRNA SMARTpool targeting 
MKK3. After 48h transfection, cells were infected with VACV-WR at a high MOI of 5. At 2h 
intervals, up to 8h post infection, cells were collected and the levels of E3 and D8 were examined by 
Western blotting (Figure 3.9A). MKK3 levels were also included, to test that the siRNA knockdown 
had worked. Actin was used as a loading control. Visualisation of the SDS-PAGE gel showed a clear 
reduction in MKK3 expression in the cells transfected with MKK3-targeting siRNA compared to the 
NT control (Figure 3.9A). Quantification of these bands relative to the actin loading control confirmed 
an average reduction in MKK3 expression of 50% throughout the infection (Figure 3.9B), consistent 
with the 55% reduction seen in Figure 3.1 
Levels of the early VACV capsid protein E3 increased over the course of the full 8h infection in both 
control and MKK3 knockdown cell types as expected. However, the MKK3-deficient cells showed a 
reduction in E3 expression compared to the NT negative control transfected cells (Figure 3.9A). This 
was confirmed by quantification of the bands visualised in the western blot (Figure 3.9) which showed 
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that E3 expression in MKK3 knockdown cells was inhibited by approximately 50% by MKK3 
depletion compared to the NT control at 4, 6 and 8hpi. Levels of D8 expression were far lower overall 
(Figure 3.9A).  Minimal levels of protein were detected in NT and MKK3 knockdown cells from 0-
6h, possibly from input virus. Quantification showed that D8 was not expressed in control cells until 
Figure 3.9. MKK3 loss affects production of VACV proteins. HeLa cells were transfected with 
either a non-targeting siRNA (NT), or a SMARTpool composed of 4 siRNAs targeting MKK3. After 
48h cells were infected with VACV-WR at MOI 5, or mock infected as an uninfected. At 0, 2, 4, 6 
and 8h post infection, cells were were lysed and proteins separated by SDS-PAGE, and then probed 
using antibodies raised against MKK3, early VACV protein E3, or late VACV protein D8. Anti-actin 
antibodies were used as a loading control (A). Bands were visualised using fluorescent secondary 
antibodies and direct infra-red fluorescence (Li-Cor) on an Odyssey scanner, and were normalised 
according to the actin loading control. Image Studio Lite was used to quantify the levels of MKK3 
(B), E3 (C) and D8 (D). Data represents one biological repeat. 
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8hpi (Figure 3.9D). At 8hpi, MKK3 loss resulted in an approximate two-fold reduction in D8 
expression compared to the NT-transfected control cells. Together, these reductions in both early and 
late protein production in MKK3 knockdown cells indicate that MKK3 loss impairs viral protein 




The main focus of this chapter was to examine the effect of MKK3 loss on VACV growth through 
siRNA transfection in vitro, and genetic mutation in vivo, and to subsequently characterise this 
interaction. A potential pro-VACV role for MKK3 was first highlighted during a high-throughput 
siRNA-based screen for host factors involved in VACV infection, in which MKK3 appeared as a 
positive hit (Beard et al., 2014). MKK3 is a MAP2K which, along with MKK6 and to a lesser extent, 
MKK4, initiate dual phosphorylation, and activation of the MAPK p38 in order to then activate genes 
involved in a wide range of cellular mechanisms, including apoptosis, cell differentiation and immune 
response (Raingeaud et al., 1994; Derijard et al., 1995; Han et al., 1996; Moriguch et al., 1996; 
Raingeaud et al.,1996).  
For the in vitro investigations, a SMARTpool of four siRNAs was used to knockdown MKK3, 
resulting in approximately a 55% reduction in gene expression. Initially, these knockdown cells were 
used to investigate the effect of MKK3 loss on VACV growth and replication, using a strain of VACV 
containing EGFP bound to the VACV A5 capsid protein. This virus allows EGFP fluorescence to be 
used as a surrogate measure of viral growth (Carter et al., 2003). Viral replication and spread, i.e. the 
completion of several sequential life cycles, was measured using a multicycle growth curve. Viral 
replication was measured using a single-cycle growth curve. The observed reduction in MKK3 
expression significantly reduced EGFP fluorescence when compared to the non-targeting siRNA 
control. However, when viral load was measured directly by titre, rather than indirectly by 
fluorescence, no significant difference was seen either in multi-cycle growth or the EEV and IMV 
fractions of a single replication cycle.  This result was also translated to the in vivo investigations. WT 
and MKK3-/-  C57BL/6 mice infected with VACV-WR and observed over the course of 7 days showed 
no differences in clinical symptoms, weight loss or disease progression. In addition, no difference in 
viral load or histopathology was identified.The levels of 40 key cytokines in the lungs of the mice 
from the in vivo time course were examined, and although 10 cytokines which have previously been 
implicated as interacting with MKK3 were significantly reduced in the MKK3-/- animals, the overall 
all change in cytokine response was not sufficient to alter the course of disease. 
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The final experiments in this programme of work concentrated on the discrepancy between the two 
methods of assessing viral growth – the levels of VACV-A5-EGFP fluorescence in MKK3 
knockdown cells was reduced compared to the negative control, however viral titres were unchanged. 
When the levels of p38 and phosphorylated p38 were examined in infected and uninfected cells, no 
differences were seen in total p38 levels in MKK3 deficient cells compared to negative control cells. 
Phosphorylated p38 appeared to decrease over the course of the experiment in both infected and 
uninfected cells. Finally, levels of VACV IMV proteins were examined over an 8h infection. Levels 
of both the early protein selected, E3, and the late IMV protein D8 were reduced in MKK3 
knockdown cells, suggesting MKK3 promotes viral protein production. 
While the Beard et al. siRNA screen identified MKK3 in particular as a pro-viral host factor, the p38 
pathway has previously been linked to VACV infection. However, previous work has not examined 
the effect of p38 on VACV growth, but instead focused on the effects of VACV on the p38 pathway. 
Early VACV IMV protein E3 inhibits PKR-dependent p38 activation in order to suppress NF-κB and 
the production of inflammatory cytokines (Myskiw et al., 2009). Another VACV protein, A52 
deliberately activates p38 via TRAF6 and TAK1 in order to upregulate NF-κB and the production of 
anti-inflammatory cytokine IL-10, and simultaneously inhibits IRAK2-induced p38 to suppress NF-
κB and cytokines IL-8 and RANTES (Maloney et al., 2005; Stack et al., 2013). However, none of 
these interactions are known to occur via the classical p38 activation pathway, involving MKK3 or 
MKK6. The identification of MKK3 as a proviral host factor in the 2014 high-throughput screening 
(Beard et al.) is the first time that VACV has been linked to the p38 pathway via one of the classical, 
and most significant MAP2Ks, MKK3. The initial results in this chapter, replicated the effects of 
MKK3 loss seen in the high-throughput screen, as the validation of the MKK3 knockdown was also 
performed using the fluorescent virus, rather than titre (Beard et al., 2014). However, further 
investigation showed that the direct growth of VACV was not affected, either in vitro or in vivo, by 
MKK3 knockdown or MKK3 null mutation.  
The discrepancy between the two methods of viral growth measurement identified in this work 
highlights the importance of careful analysis of results seen in high throughput screens. During high-
throughput screens large numbers of samples must be examined therefore a fast, cheap and relatively 
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easy method of measuring virus growth is required such as the use of fluorescently labelled VACV. 
However, this chapter demonstrates that fluorescent assays are not necessarily equivalent to viral titre, 
as fluorescence measures levels of expression of a viral protein, not production of infectious virion. It 
is important that any positive results obtained from these screens are validated using direct methods of 
viral growth measurement. 
Loss of MKK3 in vivo did not have any significant effects of disease course, body weight, or viral 
load. Histopathology of the lungs of infected mice also showed no difference in MKK3-/- compared to 
knockout. However, a cytokine panel array performed on the lung tissue of infected mice showed 
significant differences in the expression of ten cytokines: I-309, eoxtaxin, IL-1b, IP-10 (CXCL10), 
MCP-5 (CCL12), MIG (CXCL9), MIP-1a (CCL3), MIP-1b (CCL4), TIMP-1 and TREM-1. All 10 of 
these cytokines have previously been linked to the p38 pathway (Srivastiava et al., 2015; Tibbles  et 
al., 2002; Tong et al., 2004; Murakami et al., 2007; Wang et al., 2006; Kanda et al., 2007; Huang et 
al., 2010).  The reduction in expression of these cytokines indicates that the p38 pathway is inhibited 
by the loss of MKK3 in mice. However, several other cytokines/chemokines that are suggested to rely 
on MKK3 signalling, such as IFN-γ, GM-CSF and IL-17 did not exhibit any significant changes in 
expression in the MKK3-/- samples, which may be due to the ability of MKK6 to compensate for 
MKK3 loss, but only for certain pathways, triggers or downstream activators. (Raingeaud et al., 1996; 
Brancho at al., 2003; Ma et al.,2007).  
Of these ten cytokines/chemokines, IL-1b, IP-10, I-309, eotaxin, MCP-5, MIG and MIP-1a are 
known to be part of the innate immune response to successfully clear a VACV infection (Perera et al., 
2001; Reading et al., 2003; Haga & Bowie, 2005;  Krathwohl et al., 2006; Delaloye et al., 2009; Ryan 
et al., 2009; Hickman et al., 2015). No evidence exists in the literature of VACV interacting with, or 
triggering the expression of TIMP-1 or TREM-1. However, as the reduction of these cytokines did not 
affect disease progression in the MKK3-/- mice, this suggests that they may not essential for the 
VACV-specific immune response, or can be compensated for by other immune components. 
Alternatively, the suppression of cytokine response in MKK3-/- mice was not of a great enough 
magnitude to an effect on the overall disease. For example, IL-1b expression was inhibited only by 
19% in the MKK3-/- mice. Aside from IL-1b, few of the cytokines which are considered key to an 
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anti-VACV immune response such as IFNs or TNF-a, were affected by MKK3 loss, which may 
explain why no overall change was seen in disease progression in vivo (Haga & Bowie, 2005; Ryan et 
al., 2009). Furthermore, cytokine levels were only examined in lung tissue, and it is possible that 
other organs or tissues expressed different levels of cytokines, and showed different effects to MKK3 
loss. 
When VACV infects a cell, it shuts down translation of host proteins, in order to prioritise the 
expression of its own genes. The virus then specifically removes the translational repressor, eIF4E 
binding protein (4E-BP) of the key eukaryotic translation initiation factor 4F (eIF4F), and promotes 
activation of this initiation factor, thereby increasing viral replication and gene expression (Walsh et 
al., 2008). This critical component of translation is rapidly activated by the MAP kinase-interacting 
kinase 1 (Mnk1), which in turn is activated by the MAPKs p38, and ERK. It has been shown that 
stimulation of Mnk1 further increases viral replication and protein expression (Waskiewicz et al., 
1997; Walsh et al., 2008). MKK3 loss may alter p38 phosphorylation, leading to lower levels of 
Mnk1 activation, and subsequently reduced activation of eIF4F and viral protein production. 
However, as discussed previously, further examination of the levels of Pp38 in MKK3 knockdown 
cells would be required to confirm this hypothesis. Examination of eIF4F and Mnk1 levels would also 
help to determine if the role of MKK3 in VACV protein production is as a part of the p38 cascade, or 
if it is a secondary, p38 independent role, as well as determining if VACV utilises the p38 pathway 
only through non-classical routes such as TAK1 and IRAK2.  
Levels of phosphorylated, and therefore activated p38 did not appear to be reduced as expected in 
MKK3 cells, potentially due to the ability of MKK6 to compensate to a certain extent for its fellow 
MAP2K (Raingeaud et al., 1996; Brancho at al., 2003; Ma et al.,2007). Titres of VACV both in vivo 
and in vitro are unaffected by MKK3 loss, as is clinical disease, despite the clear effect on viral 
protein production. This indicates that although viral protein production is significantly impaired, this 
inhibition is not sufficient to effect viral replication as a whole, and therefore suggests that during 
infection VACV produces an excess of capsid proteins. VACV is not currently known to produce any 
excesses of early or late proteins, though this phenomenon has been observed in other viruses, such as 
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hepatitis B (HBV). Excess proteins produced by HBV multimerise in the ER and are released as non-
infectious subviral particles (Churin et al., 2015). 
Despite the evidence presented here, further investigation would be required to fully elucidate the role 
of MKK3 in VACV infection. The first and foremost task for extended investigation of this topic 
would be the repetition of the total p38 and Pp38 western blots, as well as the VACV protein 
production western blots, in order to generate statistics and be able to make reliable conclusions. Viral 
titrations could be performed with VACV-EGFP, to allow direct comparison between fluorescence 
assays and plaque assays, by using the same virus. Aside from these current weaknesses, there are 
multiple areas that could be further characterised. For example, another avenue of investigation would 
be to examine the effects of MKK6 loss, as MKK3 and MKK6 are closely related and share 79% of 
their genetic identity (Moriguchi et al., 1996). Effects of MKK6 loss on fluorescence assays and titre 
would be examined both alone, and as a double knockdown with MKK3, to determine the presence of 
any synergistic effects. There also exist blanket p38 inhibitors such as SB203580, which has been 
shown to reduce EGFP expression in monocytes infected with VACV-EGFP (Hu et al., 2007), and 
SB202190, which inhibits growth of an EGFP-tagged strain of monkeypox virus (Kindrachuk et al., 
2011). Both these studies used EGFP as a measure of viral growth, so the next step would be to treat 
cells with these p38 inhibitors, then directly examine formation of infectious virions by a plaque-assay 
based growth, as well as examining viral protein levels. This would determine if it is still only protein 
production that is affected during complete p38 inhibition, or if the effect is great enough that virion 
formation is also affected. p38 exists as multiple isoforms – p38α, p38β, p38γ and p38δ, and MKK3 
activates only p38α, p38γ and p38δ, and MKK6 is able to activate all 4 isoforms (Enslen  et al., 1997; 
Brancho et al., 2000; Remy et al., 2010). Therefore, even when MKK3 is knocked down by siRNA or 
the gene mutated, MKK6 is still able to activate p38, and compensate for the loss of the closely 
related MKK3. Use of p38 inhibitors to block the kinase cascade would therefore ensure a more 
universal effect, by blocking all p38 isoforms, and potentially amplify the effects of p38 inhibition 
compared to just targeting MKK3.  
The link between VACV and cellular translation could be further examined by measuring the levels of 
phosphorylated Mnk1, or activated eIF4F during VACV infection and MKK3 deficiency. 
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Additionally, it is always good scientific practice to examine the effects of gene loss knockdown in 
more than one cell line, especially when established lab strains such as HeLa cells have been used, as 
they are no longer comparable to primary cell-derived lines, and so the loss of MKK3 may elicit a 
different response in different cells.  
Overall, this chapter shows that removing a key activator of the p38 pathway, MKK3, does alter 
susceptibility of mice to VACV disease. Neither does it affect virion production, however it does 
impair viral protein expression. Further studies are required to determine if this is via a p38-dependent 
or independent mechanism. Additionally, while this chapter successfully shows that MKK3 can be 
successfully knocked down by siRNA targeting, and that MKK3 has a highly specific effect on the 
VACV life cycle, it also highlights the pitfalls of using high-throughput screens. 
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4 Blocking cellular retrograde transport by destabilising the 
GARP complex inhibits VACV morphogenesis 
4.1. Introduction 
Retrograde transport refers to the recycling of proteins from endosomes back to the TGN, in order to 
maintain homeostasis in the cell. The general mechanism of retrograde transport is the same as 
anterograde transport. Selected donor compartment proteins are sorted into a budding vesicle for 
release. Vesicle coat proteins such as clathrin initiate budding and sorting by the formation of 
curvature-inducing scaffolding on the donor surface (McMahon & Mills, 2004). V-SNAREs on 
vesicle membranes and t-SNAREs on acceptor compartments then target transport vesicles to the 
correct acceptor compartment, where tethering factors and Rab GTPases facilitate membrane binding 
and fusion, completing cargo delivery (Bonifacino & Glick, 2004). Although retrograde transport can 
occur via a number of different pathways, some of these pathways overlap, and it is possible for cargo 
to utilise more than one pathway. For example, CI-MPR can travel both by retromer-dependent 
transport in HeLaM cells via the recycling endosomes, and by GARP-dependent transport in HeLa 
cells, via early and late endosomes (Carlton et al., 2004; Pérez-Victoria et al., 2008). The retrograde 
transport system can be hijacked by microbial invaders such as the recruitment of EGRTP 
components by L. pneumophila to the Legionella- containing vacuole in order to promote bacterial 
growth (Finsel et al., 2013). The enterohaemorrhagic E. coli (EHEC) shiga toxin (STx) B subunit uses 
clathrin mediated endocytosis to enter cells then is able to travel via retrograde transport pathways 
from endosomes to TGN and eventually to the endoplasmic reticulum where it inhibits protein 
synthesis. Like CI-MPR, STxB is able to interact with both early and recycling endosomes, and 
therefore utilises more than one retrograde transport pathway (Mallard et al., 1998). 
The GARP complex is a tethering factor of the quatrefoil family that is specific to retrograde transport 
cargo, and is comprised of four large proteins, Vps51, Vps52, Vps53 and Vps54 (Conibear et al., 
2003; Vasan et al., 2010). In both yeast and human cells, Vps51 was discovered significantly later 
than the other three components due to its smaller size and milder mutation phenotype (Siniossoglou 
& Pelham, 2002; Pérez-Victoria et al., 2010b). GARP localises predominantly to the TGN, but is also 
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recruited to early and late endosomal transport vesicles (Liewen et al., 2005; Quenneville et al., 
2006). At the TGN, GARP binds the components of the retrograde transport SNARE, consisting of t-
SNAREs syntaxin 6, syntaxin 16 and Vti1a, and v-SNARE VAMP4 (Pérez-Victoria et al., 2009).  
The GARP complex and the effects of its loss are difficult to study in mammalian cells, as null 
mutation of the components results in embryonic lethality at around E12 (Schmitt-John et al., 2005; 
Karlsson et al., 2013). An alternative to null mutations of GARP components is a hypomorphic 
mutation of Vps54 known as Wobbler (Wob), which reduces the stability of Vps54, in turn increasing 
the rate of degradation of the entire complex (Schmitt-John et al., 2005). Wob was originally observed 
when it arose spontaneously in C57 BL/Fa mice, leaving homozygous individuals with neuronal 
symptoms such as poor growth, infertility, progressive weakness, ataxia and muscle wasting (Duchen 
et al., 1968). The source of the mutation was later identified as a leucine to glutamine substitution at 
position 967 in Vps54, a domain critical for stability and maintaining folding and GARP interaction, 
but not functionality. Therefore, this substitution decreases the stability and half-life of both Vps54 
and the whole of GARP, without affecting the pre-degradation functional activity (Schmitt-John et al., 
2005; Pérez-Victoria et al., 2010a). A reduction in trafficking and resultant mislocalisation for both 
StxB and CI-MPR in Wob mouse embryonic fibroblasts (MEFs) show that this mutation can be used 
as a method to examine the effects of GARP loss on retrograde trafficking (Karlsson et al., 2013) 
It has been suggested in previous research that VACV is able to utilise the retrograde transport 
pathway to aid morphogenesis. The IEV proteins B5, F13, A33 and A36 are recycled under 
permissible conditions from the plasma membrane to the TGN, and accumulate at the cell membrane 
when endocytosis is inhibited (Husain & Moss, 2005). F13 has been shown to colocalise with markers 
for clathrin-mediated endocytosis (Husain & Moss, 2003). Additionally, both F13 and B5 have been 
shown to contain potential motifs for internalisation, interaction with clathrin coated vesicles and 
retrograde transport. A tyrosine residue at position 310, and two leucine residues at 315 and 316 are 
characteristic of this motif, and it is hypothesised that A33 and A36 may contain similar sequences 
(Ward & Moss 2000; Huasin & Moss, 2005). Another route of investigation showed that VACV 
infection in RK13 cells increases the rate of endocytosis, as shown by a rapid increase in transport of 
endocytosis marker horseradish peroxidase (HRP) (Schmelz et al., 1994). Taken together, this 
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evidence supports a hypothesis that VACV stimulates retrograde transport in order to recycle key IEV 
proteins. However, the evidence is not conclusive, and mechanistic details are lacking.  
Two recent high-throughput, siRNA based screens designed to highlight cellular proteins involved in 
VACV replication and spread identified both Vps52 and Vps54 as proviral host factors, further 
supporting a role for retrograde transport in VACV infection (Sivan et al., 2013; Beard et al., 2014) 
This chapter focuses on using various methods of GARP inhibition, in particular Vps52 and Vps54 
depletion to study the effects of GARP loss on VACV replication. Over the course of the chapter, the 




The main aims of the present chapter are as follows: 
1. To characterise the impact of Vps52-targeting siRNA on cellular retrograde transport 
pathways and VACV replication. 
2. To investigate the effects of the Wobbler mutation on VACV replication. 





4.3.1.  siRNA targeting Vps52 reduces the levels of Vps52 in HeLa cells 
In order to investigate the impact of Vps52-loss on VACV growth and retrograde transport, Vps52 
was knocked down by transfection of specific siRNA. GARP is a complex which relies on the 
presence of all four components, Vps51, Vps52, Vps53 and Vps54 for stability and complete function. 
Knockdown of any of the four components destabilises the complex and increases the rate of its 
degradation (Conibear & Stevens, 2000; Pérez-Victoria et al., 2010a). Vps52 was identified as a 
strong pro-viral host factor, and previous findings show that depletion of Vps52 by siRNA gene 
silencing resulted in a five-fold reduction in VACV fluorescence (Beard et al., 2014). To replicate this 
finding, HeLa cells were transfected with either a non-targeting control siRNA targeting herpes 
simplex virus 1 protein VP16, or with a SMARTpool consisting of four distinct siRNAs all targeting 
Vps52. The SMARTpool rather than one individual Vps52-targeting siRNA was used in order to 
enhance the magnitude and specificity of gene knockdown, and reduce the possibility of off-target 
effects. 48h post transfection, cells were harvested and the level of Vps52 expression was assessed 
using western blotting. Cells transfected with the Vps52 targeting siRNA SMARTpool exhibited 40% 
less Vps52 protein than those transfected with the non-targeting control (Figure 4.1A & B). This 
indicates that the SMARTpool was effective at reducing the level of Vps52.  
The levels of autophagosome protein LC3-II (microtubule-associated protein 1A/1B-light chain 3)-II 
were determined in order to verify that Vps52 was functionally inhibited by the siRNA treatment. The 
LC3 protein associates with the autophagosome once autophagy is induced. Increased levels in LC3 in 
a non-autophagic cell can indicate a block in autophagosomal degradation or lysosome function, and 
has previously been linked to loss of GARP function (Renna et al., 2010; Pérez-Victoria et al., 
2010b). Again, HeLa cells were transfected with the non-targeting siRNA, or the Vps52 targeting 
SMARTpool. After 48 hours of transfection, cells were fixed and labelled with DAPI and fluorescent 
antibodies targeting the LC3B isoform of LC3 (Figure 4.1C). Vps52 cells transfected with siRNA 
transfected with siRNA targeting Vps52 displayed elevated levels of bright LC3B puncta compared to 




Figure 4.1 Vps52 Targeting siRNA reduces levels of Vps52 in HeLa cells. (A) HeLa cells were 
transfected with either a non-targeting siRNA (NT), or a SMARTpool composed of 4 siRNAs 
targeting Vps52. After 48h, cells were collected and lysates separated by SDS-PAGE, transferred to 
nitrocellulose and then probed using anti-Vps52 and anti-actin antibodies and visualised using 
fluorescent secondary antibodies and direct infra-red fluorescence (Li-Cor) on an Odyssey scanner. 
Molecular mass markers are shown on the left, and polypeptide species of interest are indicated and 
labelled with arrows. (B) Levels of Vps52 compared to actin were quantified in Vps52 knockdown 
cells and the NT control in Image Studio Lite. Data collated from three biological repeats, SEM 
calculated and displayed as error bars. ***, p < 0.001. (C) HeLa cells were seeded onto coverslips 
and were transfected with either a NT siRNA or the Vps52 SMARTpool. After 48h, cells were fixed 
and labelled using an antibody targeting GARP depletion marker, LC3B, and DAPI. Cells were 
visualised on a Zeiss confocal microscope, and single optical sections taken. 
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4.3.2.  Vps52 knockdown affects retrograde transport, but not Golgi morphology 
The impact of Vps52 knockdown on cellular function was further investigated using markers for the 
TGN and Golgi network. The Golgi network protein TGN46 is recycled between endosomes and the 
trans-Golgi network, and previous studies have shown it to be mislocalised when components of the 
retrograde transport pathway are knocked down (Pérez-Victoria et al., 2008; Nonnenmacher et al., 
2015). Therefore, it was used here as a marker of retrograde transport function in Vps52 knockdown 
cells. HeLa cells were transfected with either the non-targeting VP16 negative control, or the Vps52-
targeting siRNA SMARTpool, or were mock-transfected with the siRNA buffer alone. After 48h of 
transfection, cells were fixed and labelled with anti-TGN46 antibodies. In addition, DNA was stained 
with DAPI, and actin was stained with phalloidin (Figure 4.2A). In mock-transfected, or VP16 
transfected cells, TGN46 consistently labelled a distinct, peri-nuclear location with a speckled pattern, 
consistent with the expected location of the TGN. However, in Vps52 knockdown HeLa cells, the 
TGN46 exhibited a far more focal, juxta-nuclear staining,often of lower intensity, consistent with 
previous studies (Perez-Victoria et al., 2008). The number of cells exhibiting unaffected, or “diffuse” 
staining and cells containing mislocalised or “focal” labelling was quantified (Figure 4.2B). There 
were significantly more cells exhibiting mislocalised TGN46 when Vps52 was depleted, compared to 
the control cells, showing that Vps52 knockdown elicited a disruption of retrograde transport. In order 
to ensure that the mislocalisation of TGN46 was indeed in response to Vps52 depletion and not due to 
Golgi disruption, the Golgi marker giantin was also examined (Figure 4.2C). HeLa cells were 
transfected with the non-targeting VP16 siRNA negative control, the Vps52-targeting siRNA 
SMARTpool, or a siRNA targeting Rab1A. Rab1A is an isoform of the small GTPase Rab1 which 
localises to the ER-Golgi membrane and is involved in Golgi stability (Liu et al., 2016) characteristics 
making Rab1A knockdown an ideal positive control for Golgi structure changes. Giantin distribution 
in both the non-targeting siRNA transfected negative control and the Vps52 knockdown cells 
appeared as focal, peri-nuclear accumulations consistent with the location of the Golgi body. In 
comparison, in the Rab1A depleted positive control, giantin staining appeared to be disorganised and 
covered a greater area than seen in the negative control. Taken together, the results of both the TGN46 
and giantin staining suggest that loss of Vps52 impairs the retrograde transport pathway, but that these 







Figure 4.2 (facing page) Vps52 knockdown affects retrograde transport but not Golgi 
morphology. (A) HeLa cells were seeded onto coverslips and were either mock transfected, or 
transfected with a NT siRNA or an siRNA SMARTpool targeting Vps52. After 48, cells were fixed 
and labelled using an antibody targeting retrograde transport marker TGN46, phalloidin, and DAPI. 
Cells were visualised on a Zeiss confocal microscope and cross section images taken. (B) 
Approximately 100 cells were selected at random from each of the mock, NT and Vps52 knockdown 
slides, and the distribution of TGN46 was visually qualified as diffuse or focal. This analysis was 
then quantified as a percentage of the total number of cells. Data representative of 3 collated 
biological repeats. ***, p<0.001. (C) HeLa CELLs were seeded onto coverslips were transfected 
with either a NT siRNA, an siRNA SMARTpool targeting Vps52 or an siRNA targeting known 
Golgi stabiliser, Rab1A. After 48, cells were fixed and labelled using an antibody targeting the Golgi 





4.3.3. Knockdown of Vps52 inhibits VACV infection 
Given that Vps52 depletion detrimentally affects the endosome to Golgi retrograde transport pathway 
(EGRTP), the impact of this loss on VACV replication and spread was examined. A strain of VACV 
containing EGFP tagged to the viral A5 capsid protein (VACV-A5-EGFP) was used which allowed 
fluorescence readings to be used as an indicator of viral growth (Carter et al., 2003). For negative 
controls, HeLa cells were either mock transfected with siRNA buffer alone, or transfected with the 
nontargeting siRNA. Rab1A-targeting siRNA was used as a positive control, as this small GTPase has 
previously been shown to be essential for optimal growth of VACV (Pechenick-Jowers et al., 2015). 
The Vps52 targeting siRNA was transfected into cells both as a SMARTpool and as the four 
deconvoluted component siRNAs. At 48h, cells were infected with VACV-A5-EGFP at an MOI of 
0.05 plaque forming units (pfu) per cell. A low MOI was used so that not all cells were infected at 
time point 0, and virus was able to spread through the cell monolayer via a series of replication cycles. 
Fluorescence was used as a surrogate of viral growth, and readings were taken every 12hpi from 0 to 
48hpi (Figure 4.3A). As expected, levels of fluorescence in the two negative controls increased 
exponentially over time. However, fluorescence in cells transfected with the Vps52 SMARTpool, as 
well as all four of the deconvoluted siRNAs increased only slightly, in line with the Rab1A 
transfected positive control. By the 48hpi end point of the experiment, all the Vps52 knockdown cells, 
both SMARTpool and deconvoluted, and the Rab1A depleted cells exhibited significantly less EGFP 
signal than the negative controls.  
In order to assess the level of toxicity associated with the siRNA, cells remaining at the final 48h time  
 
point were fixed and stained with Hoechst 33342 to identify live cells (data not shown). Fluorescence 
per cell was then calculated; to ensure that reduction in fluorescence seen in Figure 4.3A did indeed 
represent a reduction in viral replication and spread, rather than off target cytotoxicity (Figure 4.3B). 
This data showed that two out of the four deconvoluted Vps52 siRNAs significantly reduced virus-
linked fluorescence per cell compared to both the negative controls, and a third one reduced 
fluorescence per cell compared to the mock transfected negative control. In addition, both the Vps52 
SMARTpool and the Rab1A positive control showed significant reduction in viral growth per cell 
compared to both the non-targeting and the mock transfected negative controls. These results indicate 
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that the reduction in EGFP fluorescence seen in Figure 4.3A was due to on-target effects, and not cell 
loss.  
To more directly assess the effect of Vps52 loss on viral replication, the experiment described above 
was repeated, with VACV replication measured by viral titration (Figure 4.3C) HeLa cells were 
transfected as described above, with non-targeting, Vps52 or Rab1A targeting siRNA, or mock 
transfected. 48h after transfection, cells were infected with VACV-WR at a low MOI of 0.05. Viral 
samples were collected and titrated from 0 to 48 hpi at 12h intervals. At 48 hpi, there was a significant 
mean reduction of 1-log10 in viral growth in the positive control Rab1A knockdown cells, compared to 
Figure 4.3 Vps52 knockdown inhibits VACV replication. (A) HeLa cells were transfected with 
either a SMARTpool targeting Vps52, or one of four individual deconvoluted components of the 
Vps52 SMARTpool (DC 1-4). Mock transfection, or NT siRNA were used as negative controls, and 
Rab1A siRNA was the positive control. After 48h, cells were infected with VACV-A5-EGFP at an 
MOI of 0.05, and fluorescence was measured every 12h for 48h. Results show the means and SEMs 
of six technical repeats and are representative of 3 biological repeats. (B) Cells from (A) were fixed 
using formalin, and stained with ice-cold Hoechst 33342 solution. Images were taken using a Zeiss 
Cell observer microscope and counted using Image J. GFP fluorescence per cell was then calculated 
to normalise for cell loss. Data represents the means and SEMs of 6 technical repeats. Statistical 
analysis for (A) and (B) were performed using a one-way ANOVAs, comparing test samples to the 
Mock and NT negative controls. *, p<0.05; ***, p<0.001. (C) HeLa cells were transfected as 
described in (A). 48 hours, transfected cells were infected with VACV-WR at an MOI of 0.05. Cells 
were collected and titrated for plaque assay at 12h intervals for 48hpi. Data represents a collation of 2 
biological repeats, error bars are SEMs. (D) Viral titres of the data produced in (C) were statistically 
analysed at 48hpi, using a one-way ANOVA with multiple comparisons. *, p<0.05; ***, p<0.001. 
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the negative controls, which is consistent with results seen previously (Pechenick-Jowers et al., 2015). 
In Vps52 knockdown cells, the reduction in viral growth compared to the negative controls was 
smaller, at approximately 0.5 log10 plaque forming units, but still significant. This was seen more 
clearly when just the 48 hour time points were examined, in Figure 4.3D. Therefore, both fluorescent 
measurements and viral titre support the results of the previous study (Beard et al., 2014), that Vps52 
is required for optimal and effective growth and replication of VACV.  
4.3.4.  Knockdown of any GARP component inhibits replication of VACV 
The effect of the knockdown of each individual GARP component on VACV replication was 
examined, in order to determine if only Vps52 or the whole GARP complex is required by VACV. 
GARP is a heteromeric complex also consisting of three other components in addition to Vps52: 
Vps51, Vps53 and Vps54. All four components are required for full stability of the complex 
(Conibear et al., 2003; Siniossoglou & Pelham 2002, and Vps54 loss was also seen to affect VACV 
growth in a high-throughput siRNA based screen (Sivan et al., 2013). Firstly, the stability of GARP 
was examined during the loss of individual components. HeLa cells were transfected with the non-
targeting siRNA control, or with siRNAs targeting one of the GARP components – Vps51, Vps52, 
Vps53 or Vps54. 48h post transfection, cells were collected, lysed and a Western blot was performed 
to examine the levels of Vps52 in each sample (Figure 4.4A). Targeting of the four Vps GARP 
components resulted in 40-50% reduction of Vps52 expression (Figure 4.4B). This indicates that the 
whole complex is required for stability, and that loss of any one component also decreases expression 
of the other proteins, and is in agreement with previous investigations into GARP stability (Conibear 
et al., 2003; Siniossoglou & Pelham 2002). Ideally, expression of Vps51, Vps53 and Vps54 would 
have also been examined during component knockdown, however, numerous attempts to detect 
Vps51, Vps53 and Vp54 using antibodies targeting these three proteins were not successful (data not 
shown). In order to determine if siRNA depletion of any GARP component affected VACV growth, a 
fluorescence-based multi-step growth curve was performed on siRNA knockdown cells. HeLa cells 
were mock transfected, or transfected with non-targeting, VP16 siRNA as a negative control, as 
previously described. Again, siRNA targeting known pro-viral cellular factor Rab1A was used as a 
positive control. Remaining cells were transfected with either the Vps52-targeting siRNA 
SMARTpool, or single siRNAs targeting Vps51, Vps53 or Vps54. A final set of cells was transfected  
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Figure 4.4 Knockdown of any GARP component inhibits replication of VACV. (A) HeLa cells 
were transfected with either a SMARTpool targeting Vps52, an siRNA targeting Vps51, Vps53, Vps54 
or negative control NT siRNA. After 48 hours, cells were collected and run on an SDS-PAGE gel, then 
probed using anti-Vps52 and anti-actin antibodies and visualised using fluorescent secondary 
antibodies and direct infra-red fluorescence (Li-Cor) on an Odyssey scanner. (B) Levels of Vps52 
compared to actin were quantified in GARP component knockdown cells and the NT control in Image 
Studio Lite. (C) HeLa cells were transfected as described in (A), along with an extra mock transfected 
negative control, Rab1A as a positive control and a combination of all the GARP components. After 
48h, transfected cells were infected with VACV-A5-EGFP at an MOI of 0.05, and fluorescence 
measured every 12h for 48h. Results show the means and SEMs of six technical repeats and are 
representative of 2 biological repeats. Statistical analysis was performed using a one-way ANOVA 
with multiple comparisons at the 48hpi time point. ***, p<0.001. (D) Normalisation for cell death was 
performed as described in Figure 4.3D *, p<0.05; **,p<0.01. (E) HeLa cells were transfected and 
infected with VACV-WR as described in Figure 4.4C. Cells were collected and titrated for plaque 
assay every 12h, up to 48hpi. Data represents a collation of 2 biological repeats, error bars are SEMs. 
(F) Viral titres of the data produced in (E) were statistically analysed at 48hpi, using a one-way 
ANOVA with multiple comparisons. *, p<0.05; **, p<0.01 ***, p<0.001. 
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with siRNA targeting all four of the GARP components. After 48h, cells were infected with VACV-
A5-EGFP at a low MOI of 0.05, and fluorescence was measured as an indicator of viral growth over 
48hpi (Figure 4.4C). Very little or no increase in fluorescence was seen in the Rab1A knockdown, 
positive control cells, Vps52 depleted cells or the GARP depleted cells. The levels of fluorescence in 
the Vps53 knockdown cells showed less of a decrease in fluorescence than the  the positive control. 
Vps51 and Vps54 knockdown showed similar levels of EGFP inhibition, but had the least impact. 
Depletion of any GARP component, as well as depletion of the complete complex resulted in a 
significant reduction in viral growth when compared to both negative controls. The greatest impact on 
virus-induced fluorescence was seen in Vps52 knockdown and would suggest that Vps52 is the most 
important member of GARP in terms of VACV interaction. However, this could be due to the fact 
that only Vps52 was knocked down with a SMARTpool of four distinct siRNAs, rather than just one 
individual siRNA, and so received a more efficient knockdown than the other components.  
At the final 48hpi time point, cells were fixed and DNA stained in order to perform a cell count. 
Fluorescence per cell was then calculated for each sample, in order to confirm that reduction in 
fluorescence was not due to off target, cytotoxic siRNA effects (Figure 4.4D). All GARP components 
displayed significant reduction in viral fluorescence per cell compared to both the mock transfected 
and non-targeting negative controls, confirming that the effects of all transfected siRNAs were not 
through cytotoxic effects.  
Further to using fluorescence as a measure of viral growth, the effects of GARP component depletion 
was examined by measuring infectious virion production by plaque assay. HeLa cells were transfected 
with the controls or GARP components as described above, and after 48h, were infected with VACV-
WR at a low MOI of 0.05, for multi-cycle growth. Viral titrations were then performed over 48hpi. As 
seen in previous results (Figure 4.3 C&D) and Pechenick Jowers et al., 2015), Rab1A knockdown 
reduced the level of VACV plaque forming units by approximately 1 log10 (Figure 4.4E). All the 
GARP components, when knocked down individually, showed a significant reduction, varying from 
0.5 to 0.75 log10 pfu/ml, in infectious virions, compared to the mock transfected control at 48hpi. This 
was seen more clearly when looking at the 48hpi time point alone (Figure 4.4F). 
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4.3.5.  Vps52 loss affects extracellular enveloped virion production 
In order to determine which stage of the VACV life cycle Vps52 affects, the titres of the supernatant- 
and cell-associated virus (CAV) were calculated in a single step growth curve. In a single step growth 
curve the supernatants from infected cell cultures contain EEVs, and are separated from the cell 
associated fraction which contains all other forms of virion, but are predominantly IMVs. As before, 
HeLa cells were transfected with non-targeting, Vps52 or Rab1A siRNA. Rab1A was once again used 
as a control as it has previously been shown to specifically affect the production of EEVs in VACV 
replication, but not CAV (Pechenick Jowers et al., 2015). 48h after transfection, cells were infected at 
a high MOI of 5 with VACV-WR, and viral titres were calculated over the course of 24h. 
Supernatants were separated from the CAV, and any contaminating IMVs in the supernatant were 
neutralised prior to titration with an antibody targeting IMV protein L1, to ensure that only EEVs 
released from cells were titred. When the EEVs present in the supernatant wwere titred (Figure 4.5A) 
a 1-log10 reduction in live virus was seen in the positive control compared to the non-targeting control, 
and approximately a 1/3 of a log10 reduction of VACV in Vps52 knockdown cells compared to the 
non-targeting control. However, the titre of cell-associated virus (Figure 4.5B) reached over 1x107 
pfu/ml in all three samples, and showed no significant difference between the non-targeting negative 
control and the Rab1A knockdown positive control, or when the Vps52 depleted cell titre was 
Figure 4.5  Vps52 loss affects VACV EEV production. (A and B) HeLa cells were transfected with 
a SMARTpool targeting Vps52, NT siRNA or siRNA targeting Rab1a as a positive control. After 48h, 
transfected cells were infected with VACV-WR at an MOI of 5. At 0, 4, 8, 12 and 24hpi, supernatant 
(A) was removed, neutralised for IMVs using anti-L1 antibody and titrated for a plaque assay. Cell 
monolayers (B) were also collected and titrated. Data represents the means and SEMs of 3 biological 
repeats. Statistical analysis was performed using a one-way ANOVA on the 24h time point data. 
p>0.05. 
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compared to the negative control. The reduction in EEV production was consistent across 3 biological 
replicates in cells deficient in Vps52, however, a high degree of inter-experimental variance resulted 
in p>0.05, and therefore no formal statistical significance. This suggests that loss of Vps52 may not 
affect production of IMVs, but suggests that Vps52 does affect VACV morphogenesis after the IMV 
stage of the life cycle, impairing IEV production or EEV release.  
 Overall, these results show that Vps52 is required for optimal function of the EGRTP, and the 
optimal replication of VACV. In addition, the presence of all four GARP components is required for 
complex stability, since knockdown of any one component significantly reduces viral growth, and 
knockdown of any component inhibits the expression of Vps52. Finally, the results of the single step 
growth curve indicate that Vps52 knockdown specifically affects the production of EEVs, but not 
IMVs. However, these results have also highlighted two drawbacks of using siRNA to inhibit cellular 
gene expression. The quantification of retrograde transport disruption in Figure 4.2A shows that 25% 
of the population of cells transfected with Vps52 targeting siRNA retained normal TGN46 
distribution, indicating that transfection was not a completely efficient method of impairing EGRT. In 
addition, Hoechst staining revealed moderate cytotoxic effects of the Vps52 targeting siRNA. While 
this could be controlled by measuring fluorescence per cell, it restricted the use of this model. Another 
method of protein depletion was therefore employed to validate the findings obtained by siRNA 
transfection.  
4.3.6.  Expression of GARP complex is reduced in Wobbler MEFs 
As another method of protein depletion was required to investigate GARP loss, the growth of VACV 
in Wobbler MEF cells was characterised. The Wobbler (Wob) mutation is a hypomorphic missense 
mutation, converting leucine to glutamine at codon 967 in the Vps54 subunit of GARP, and was 
originally characterised in C57BL/6J mice (Schmitt-John et al., 2005). The mutation occurs in an area 
of the protein required for complex assembly, so although the Vps54 is still produced, it is unstable, 
with a shortened half-life.  Consequently, as the presence of the entire complex is required for full 
function and stability, overall GARP levels in Wob cells are reduced, and a partial loss of function is 
seen, including missorting of proteins involved in the EGRTP such as CI-MPR (Perez-Victoria et al., 
2010a; Karlsson et al.,  2013). This makes the Wob mutation a useful tool for studying GARP 
 106 
depletion, and more suitable than homozygous null mutants of any GARP subunit, which are 
embryonic lethal, and exceptionally difficult to work with (Karlsson et al., 2013). 
Primary wild type (WT) and Wobbler (MU) mouse embryonic fibroblasts (MEF) cells were kindly 
donated by Dr Schmitt-John of Aarhus University, Denmark from a parental C57BL/6J  mouse strain. 
Cells were then immortalised through repeated serial passaging, resulting in two independently 
derived WT and two MU cell lines. Immortalisation was achieved by splitting primary cells into as 
many 25cm2 flasks as possible before the crisis stage occurred at approximately passage 10, and cells 
began to die, due to not being adapted to growth in the tissue culture environment. During the crisis 
stage, flasks were passaged at a ratio of 1:1 every three days, until a small proportion of cells 
underwent presumed survival mutations and began to grow to confluence again. The immortalisation 
process took approximately six months. Two independently derived lines of WT and two 
independently derived lines of MU were immortalised and included in future experiments order to 
rule out the possibility that spontaneous mutations acquired during immortalisation caused the 
phenotypes seen. The two WT cell lines both required 38 passages before immortalisation and 
confluency was achieved, and the two MU cell lines, MU1 and MU2 required 54 and 37 passages 
respectively.  
In order to confirm that the Wob mutation destabilises the GARP complex, levels of Vps52 were 
examined in cell lysates. Vps51, Vps53 and Vps54 levels were investigated, but the available 
Figure 4.6. Expression of GARP complex is reduced in Wobbler MEFs, as is VACV replication. 
(A) Reduction in Vps52 expression in WT and Wobbler (Wob) cells. Cell lysates from two 
independently immortalised strains of wild type (WT) MEF cells, and two strains of mutant (MU) 
Wob MEF cells were analysed by SDS-PAGE and Western blotting. The membrane was probed with 
anti-Vps52 and anti-actin antibodies and visualised using fluorescent secondary antibodies and direct 
infra-red fluorescence (Li-Cor) on an Odyssey scanner. (B) Levels of Vps52 compared to actin were 
quantified in WT and MU cells in Image Studio Lite. Results are means and SEMs of three collated 
biological repeats, normalised to actin levels. Statistical analysis was performed using a one-way 
ANOVA, comparing means of MU strains to means of WT cell lines. **, p<0.01. 
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antibodies did not work, and could not be optimised (data not shown). Immortalised WT and MU 
MEFs were collected, and protein levels in cell lysates determined by western blotting. Figure 4.6A 
shows a reduction in Vps52 expression in both of the MU MEF cell lines compared to WT. The 
amount of Vps52 was quantified (Figure 4.6B), and revealed that the Wob mutation significantly 
reduced Vps52 expression by an average of 52%: therefore showing a greater impact than siRNA 
transfection.  
4.3.7.  The Wob MEF mutation reduces VACV replication through inhibition of EEV 
production 
Following confirmation that the Wob mutation reduced levels of GARP, specifically Vps52, multi-
cycle growth curves were performed in order to determine the effect of this depletion on VACV 
replication and spread. WT and MU MEFs were infected with VACV-A5-EGFP at a low MOI of 
0.05, and fluorescence readings were taken as an indicator of viral growth up to 48hpi. Differences in 
viral fluorescence between WT and MU cells were seen as early as 24hpi (Figure 4.7A), while EGFP 
levels in both MU cell lines retained background levels until after 36hpi. Virus-induced fluorescence 
levels were highly similar in both MU cell lines, and both MU cell lines showed a 69% reduction in 
EGFP compared to the WT1 cell line, and a 50% reduction compared to WT2 cells, both of which 
differences were highly significant.  
Levels of infectious virions in MU and WT cells were then compared by plaque assay. WT and MU 
MEF cells were infected with VACV-WR at a low MOI of 0.05 to investigate multicycle growth. 
Cells and supernatants were collected together and titrated up to 48hpi. Figure 4.7B shows that a 
difference of 1 log10 in infectious virions in MU cells compared to WT was seen as early as 12 hpi. 
This reduction of viral growth in MU cells was maintained throughout the experiment, but decreased 
to 0.5 log10 at 48hpi, as virus production plateaued. Again, this results shows that GARP is required 
for optimal VACV replication. 
Following this, a single-cycle growth curve was performed, to determine if the reduction EEV in 
production seen in Vps52-targeting siRNA knockdown cells was also present in the MEFs. WT and 
MU cells were infected with VACV-WR at a high MOI of 5 pfu/cell, and viral titrations performed 
over 24h. At each time point, supernatant was separated from cells and any extracellular IMVs present 
 108 
in the supernatant fraction were neutralised with an antibody targeting IMV protein L1. Supernatant 
and cell-associated virus levels were then assessed independently. A reduction of up to 1 log10 
infectious virions was seen in the supernatant at 8, 12 and 24 hpi (Figure 4.7C), indicating that GARP 
loss impacts the production or release of EEVs from cells. In comparison, no significant differences in 
titre were seen at any time point in the cell-associated fraction (Figure 4.7D) indicating that the early 
stages of VACV replication, namely IMV formation, were not affected by GARP loss. This result also 
confirms, by independent method and cell type, that GARP is required specifically for optimal EEV 
production and/or release. The results of this experiment concur with the results seen in Figure 4.5, 
and show that, by two independent methods of protein depletion GARP is required for IEV 
Figure 4.7 Wob MEF mutation inhibits VACV replication. (A) Two strains each of immortalised 
WT and MU MEF cells were infected with VACV-A5-EGFP, MOI 0.05. Fluorescence was measured 
at 12h intervals up to 48hpi. Results represent the means and SEMs of three collated biological 
repeats. Statistical analysis was performed using a one-way ANOVA, with multiple comparisons at 
48hpi. **, p<0.01; ***, p<0.001. (B) Two strains each of WT and MU  MEF cells were VACV-WR, 
MOI 0.05. At 12h intervals, up to 48hpi, cells were collected and titred for plaque assay. Results 
represent the means and SEMs of three collated biological repeats. Statistical analysis was performed 
using a one-way ANOVA, with multiple comparisons. *, p<0.05. (C and D) Two strains each of WT 
and MU  MEF cells were infected with VACV-WR at an MOI of 5. At 0, 4, 8, 12 and 24hpi, 
supernatant (C) was removed and titrated for a plaque assay. Cell monolayers (D) were also collected 
and titrated. Data representative of 4 biological repeats. Statistical analysis was performed using a 
one-way ANOVA, with multiple comparisons. *, p<0.05. 
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morphogenesis, but not IMV production. The results seen in the  MEFs were far more consistent than 
those seen in siRNA transfected cells, therefore the  MEFs were used for all following work. 
 
4.3.8.  Loss of GARP Affects IEV production and produces aberrant B5-containing vesicles 
In order to identify more specifically the point of EEV production at which GARP is involved, the 
levels and distribution of IEVs in WT and MU  MEFs were compared and examined using 
immunofluorescent microscopy. WT and MU MEFs were infected with VACV-A5-EGFP at a high 
MOI of 5 pfu/cell. After 8h, cells were fixed, permeabilised and labelled with an antibody targeting 
the VACV IEV/EEV membrane protein B5. Maximum intensity projections taken through WT cells 
showed that the EGFP-labelled VACV IMVs were distributed as expected, in large, perinuclear viral 
factories, as well as small punctate labelling throughout the cytoplasm, representing individual virions 
(Figure 4.8A, left panel). B5 labelling in WT cells revealed accumulations close to the viral factories, 
known as wrapping stations. The majority of the EGFP puncta also showed labelling for B5, 
indicating that they were either IEVs in the cytoplasm of the cell, or CEVs on the cell surface. A small 
number of the dispersed, cytoplasmic EGFP puncta did not co-localise with B5, representing 
unwrapped IMVs. The distribution of the EGFP-labelled VACV cores were not altered in MU cells, 
as large EGFP-labelled perinuclear viral factories and dispersed cytoplasmic puncta were still seen 
(Figure 4.8A, right panel). However, B5 staining showed a different pattern. In the GARP depleted 
cells, the wrapping station was still evident, but there were fewer B5-labelled puncta in the cell 
periphery and cytoplasm (Figure 4.8A right panel), indicating that GARP depletion resulted in fewer 
IEVs/CEVs. In addition, higher magnification image Z-stacks (Figure 4.8B) showed that fewer B5 
puncta colocalised with the VACV-EGFP that would identify them as IEVs/CEVs, but that there 
werealso accumulations of B5, that were not associated with EGFP signal at all, suggestive of 
“empty” IEVs lacking a central virion core. For further investigation and quantification, multiple 
infected Wob MEFs were imaged and analysed. Z-stacks were taken of 25 WT cells and 24 MU cells 
randomly selected from three independent experiments. IMARIS software was then used to quantify 
B5-positive puncta. IMARIS is an image analysis software that creates 3D images of cells from 
confocal microscopy data. The nucleus, cytoskeleton, and various structures such as vesicles are 
segmented, labelled and measured. The software allows associations between labelled objects to be  
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Figure 4.8 Loss of GARP Affects IEV production and produces aberrant B5-containing vesicles. 
(A) WT and MU  MEFs were infected with VACV-A5-EGFP, MOI 5. At 8hpi, cells were fixed and 
labelled using an antibody targeting VACV EEV protein B5. Phalloidin actin staining and DAPI were 
also used. Cells were visualised on a Zeiss confocal microscope, and maximum intensity projections 
taken. (B) Serial optical sections were taken at ~6µm intervals throughout the depth of the cell, and 
then processed by Zeiss Zen Black software and visualised as a Z stack. 
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determined. Firstly, the number of IEV/CEVs in the cytoplasm of each of the cells was calculated 
(Figure 4.9A) by quantifying the number of B5-labelled puncta. MU cells showed a highly significant 
(p<0.001), 2-fold reduction in the overall number of IEV/CEVs, compared to WT cells. The next step 
was to calculate the proportion of B5 puncta co-localising with EGFP-labelling, which would 
determine the number of “empty”, i.e. not associating with an EGFP-labelled capsid, IEVs. The 
amount of B5-positive puncta associating with EGFP-labelled virions also showed a statistically 
significant reduction; from over 90% association in WT cells to approximately 60% in MU cells 
(Figure 4.9B). However, the diameter of these B5 puncta were also significantly larger in MU cells 
than WT (Figure 4.9C), increasing from 0.96 µm in WT cells to 1.08 µm in MU cells. Further 
differences were seen when comparing the IEVs/CEV population present in MU cells with the B5 
puncta lacking a VACV capsid. These “free” B5-positive puncta were significantly larger in terms of 
Figure 4.9 Depletion of GARP through mutation disrupts IEV wrapping and results in aberrant 
B5 accumulations. Imaris image analysis software (Bitplane) was used to create 3D images and 
analyse images of WT and MU MEF cells labelled for B5 and infected with VACV-A5-EGFP. (A) 
The total number of B5 puncta per cell. (B) The percentage of B5-containing vesicles per cell that 
were also associated with an EGFP tagged viral capsid. (C) The diameter of B5 puncta in WT cells 
compared to those in MU cells. Data represents the means and SEMs of 49 individual cells (24 WT 
and 25 MU) from 3 independent repeats. Data were statistically analysed using a Student T-test, *, 
p<0.05; ***, p<0.001.  (D) The diameters of B5 puncta in MU MEF cells associated with EGFP 
labelled capsids compared to those vesicles independent of capsids. Data represents means and SEMs 
of 25 individual MU cells from 3 independent repeats. Data were statistically analysed using a 
Student T-test, ***, p<0.001. 
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diameter (Figure 4.9D) than their VACV-capsid associated counterparts. Consequently, these results 
suggest that GARP deficiency disrupts the process of wrapping IMVs to become IEVs, resulting in 






The primary aim of this chapter was to determine the role of EGRTP on VACV replication and 
spread. The work focused on the GARP complex because of the results of the previously performed 
high-throughput siRNA-based screens which identified Vps52 (Beard et al., 2014), and Vps54 (Sivan 
et al., 2013) as pro-viral host factors during VACV infection. Vps52 and Vps54 are components of 
the GARP complex, along with Vps53 and Vps51. GARP acts as a tethering factor at the TGN in the 
EGRTP, interacting with Rab GTPases such as Rab6, and SNAREs such as syntaxin 6 to ensure 
tethering, and later attachment of transport vesicles to specific acceptor compartments in the TGN 
(Liewen et al., 2005; Pérez-Victoria et al., 2010b).  
In this chapter, GARP expression was reduced by two methods. The first method, transfection of a 
Vps52-targeting SMARTpool of siRNAs, reduced Vps52 protein expression by approximately 40%, 
which was sufficient to impair the function of the GARP complex, as shown by the increase in levels 
of autophagy marker LC3, and altered distribution of TGN46. The knockdown of Vps52, and indeed 
knockdown of any GARP component resulted in an average of 2-fold reduction in VACV-associated 
fluorescence, and a 0.5 log10 reduction in infectious virions. A single step growth curve was then 
performed in order to determine which part of the VACV life cycle GARP loss was affecting. 
Separate titration of cell-associated virions and extracellular virions showed no change in IMV 
production in the Vps52 knockdown cells compared to the NT and mock transfected controls, but a 
0.2 log10 reduction in EEV titre. Wobbler MEF cells, containing a hypomorphic mutation in the Vps54 
protein which decreases overall GARP levels, were also used to examine the effects of GARP loss on 
VACV infection. An average reduction of 60% VACV growth was seen in MU MEFs, compared to 
the WT cells in terms of titration. Reductions in viral growth of up to 1 log10 were also seen in EEV 
replication in MU cells over a single replication cycle, while IMV levels were unaffected, confirming 
the results obtained using Vps52-targeting siRNA. Overall, these findings revealed that GARP is 
required for optimal VACV growth. The next aim in this chapter was to further identify the roles that 
GARP and retrograde transport play in IEV production.  Immunofluorescent labelling of VACV and 
the IEV protein B5 in WT and MU MEF cells and the use of image analysis software revealed a 
reduction in IEV/CEV production as well as large aberrant accumulations of B5, which were 
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independent of VACV capsids in the MU MEFs, suggesting that GARP is required for the wrapping 
of IEVs.  
Vps52 knockdown using an siRNA SMARTpool resulted in an average 2-fold reduction in VACV 
growth as measured by fluorescence. However, depletion of the positive control, Rab1A also showed 
an approximate 2-fold reduction in VACV fluorescence. In the initial siRNA screen which highlighted 
Vps52 as a pro-viral factor, siRNA transfection saw a greater reduction in Vps52 expression, and 
induced a five-fold reduction in VACV replication (Beard et al., 2014), while the level of 
fluorescence reduction in Rab1A knockdown cells was consistent with previous studies (Pechenick-
Jowers et al., 2015). The differences between the VACV inhibition by Vps52 depletion seen in the 
fluorescent growth curve compared to the titration highlight the importance of confirming results seen 
in fluorescence assays with live virus counts, as discussed in the previous chapter. 
VACV infection has been previously been linked to retrograde transport in several different ways, 
including recycling of IEV proteins B5, F13, A36 and A33 remaining at the cell surface after EEV 
egress back to the TGN by endocytosis (Husain & Moss, 2005). It was also independently shown that 
VACV infection resulted in increased rates of endocytosis (Schmelz et al., 1994). However, no 
previous study has characterised the exact route that VACV utilises, or why IEV proteins are retrieved 
from the cell surface after EEV/CEV release. Based on the increase in endocytosis in VACV infected 
cells, and evidence of the retrieval of IEV proteins from the cell surface, along with identification of 
Vps52 and Vps54 as pro-viral cellular factors, we hypothesised that GARP is involved in the 
recycling of peripheral IEV proteins from endosomes back to the TGN. Given that IEV production 
peaks earlier in infection than IMV production, suggesting a limited number of IEV wrapping proteins 
(Tsutsui, 1983; Ulaeto et al., 1996) it is possible that GARP facilitates the recycling of these IEV 
proteins, to allow the production of further IEVs. This model supports the hypothesis that the TGN is 
the most likely site for the IEV wrapping station (Ichihashi et al., 1971; Hiller & Weber, 1985; 
Schmelz et al., 1994), 
With the effect of GARP deficiency confirmed by two separate methods, and IEV/EEV production 
highlighted as the life cycle stage requiring retrograde transport, next aim of this chapter was to 
further elucidate the role EGRTP in IEV/EEV production. Several IEV proteins including B5 and 
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F13, remain on the cell surface after EEV egress, and are then recycled back to a juxta-nuclear area in 
a retrograde transport dependent manner (Ward & Moss, 2000; Husain & Moss, 2005) This, along 
with the drop in EEV production during GARP depletion suggests a model in which GARP tethers 
vesicles containing IEV proteins traveling from the cell surface back to the TGN for wrapping of new 
IEVs. The presence of B5 accumulations seen not associated with the green fluorescent viral cores in 
MU cells suggest that in the absence of GARP, these accumulations have not been correctly tethered 
to the wrapping station. However, the results shown here do not rule out the possibility that GARP is 
not involved directly in IEV protein transport, but is responsible for the trafficking of an unknown 
host protein which is required for wrapping. In this model, it is likely that the aberrant B5 puncta 
would be empty IEV membranes which were unable to wrap IMVs. This hypothesis is supported by a 
study performed by Van Eijl et al. (2002) which showed that IEV proteins B5 and F12 are transported 
to the cell periphery even in the event of a morphogenesis block after IMV formation.  
Despite the results obtained so far, deeper investigation is required to completely define the role of 
GARP and EGRTP in VACV infection. For example, the localisation of other IEV proteins could be 
examined in the event of GARP deficiency. F13 would be of particular interest here as, like B5, it is 
deposited on the cell surface during EEV/CEV egress, and is thought to contain a motif for 
internalisation and recycling (Ward & Moss 2000; Huasin & Moss, 2005). Whether or not B5 and F13 
co-localise in GARP deficient cells would shed further light on the identity of the aberrant B5 puncta 
seen in the MU Wob MEFs. A different avenue of investigation would be to examine the effects of the 
loss of other EGRTP components, such as retromer, on VACV infection. This would determine if 
VACV requires only GARP for morphogenesis, or utilises a complete retrograde pathway. siRNA 
could again be used to knockdown other EGRTP components, or a third method of EGRTP block 
could be investigated, such as pharmacological agent, again to further clarify the role of retrograde 
transport in IEV/EEV production.  
In conclusion, the data in this chapter not only validates the results of the previous high-throughput 
screens, but are also the first to confirm a link between a specific component of the retrograde 
transport pathway, GARP, and EEV production. The nature of this link, and whether VACV interacts 
with any other EGRTP components requires further experimentation and will be investigated in the 
next chapter.  
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5 VACV uses retromer-independent, Retro-2 susceptible 
retrograde transport to facilitate IEV wrapping 
5.1. Introduction 
Many infectious agents and toxins utilise the retrograde transport system in order to enter cells, such 
as the bacterial toxin StxB (Spooner et al., 2006).  Most of these cases show the endosome to Golgi 
transport pathway being used as a method to reach the Golgi and ER. It is far less common to see the 
retrograde transport system used to facilitate viral morphogenesis and release, as has been show in 
Chapter 4. This chapter focuses on the nature of GARP’s role in VACV morphogenesis, and other 
potential components of the VACV retrograde pathway, in order to further elucidate the method by 
which VACV engages the EGRTP. 
The IEV/EEV membrane protein F13 typically composes 5-7% of the total EEV protein levels, and is 
required for VACV spread and plaque formation (Hirt et al., 1986; Vliegen et al., 2012). F13 is 
located on the inside of the IEV membrane, in the space between the IEV double membranes. 
Consequently, once the EEV exits the cell, F13 is found on the cytosolic face of the host plasma 
membrane (Schmutz et al., 1995). F13 is often seen to associate with B5, and both proteins are still 
correctly trafficked to the Golgi even when expressed in absence of virions (Payne, 1992; Lorenzo et 
al., 2000). F13 contains a motif which conveys phospholipase activity, and it is thought that this 
domain is responsible for preventing F13 accumulation at the Golgi, and potentially for triggering 
trafficking of IEVs from the wrapping station to the cell surface (Sung et al., 1997). Additionally, F13 
may be the trigger for VACV associated retrograde transportation, as the formation of endocytic 
vesicles required for recycling of IEV proteins is reliant on phospholipase activity (Husain & Moss, 
2003).   
One of the major components of retrograde transport is retromer, a coat complex localised to early and 
recycling endosomes.  Coat protein complexes are recruited to the donor compartment during vesicle 
transport, and form a scaffold on the outside of the donor compartment which induces membrane 
curvature, initiating vesicle formation (McMahon & Mills, 2004). Once budded from the donor 
compartment, vesicles are targeted by SNARE complexes on the vesicle and acceptor compartment to 
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the correct location, where tethering factors such as GARP initiate interaction and binding between 
the SNARE complexes and vesicles, allowing delivery of the cargo (McMahon & Mills, 2004; Chia & 
Gleeson, 2011). Much like GARP, retromer was initially discovered in S. cerevisiae, as two 
subcomplexes: one consisting of Vps26, Vps29, Vps35, and the other of Vps5 and Vps17, which 
associate through the interaction of Vps35 and Vps5. Disruption of Vps29 or Vps35 expression was 
shown to result in mislocalisation of CPY and Vps10, two yeast proteins known to be reliant on 
retrograde trafficking for proper sorting. This indicated a role for retromer in endosome to Golgi 
transport (Seaman et al., 1998). Highly conserved orthologues of the yeast retromer were later 
discovered in mammalian cells. Vps35 was shown to form the core of the complex, binding Vps26 at 
its N-terminus, and Vps29 at its C-terminus, as well as exhibiting multiple binding sites for the other 
retromer subcomplex, composed of  sorting nexin 1/2 (SNX1/SNX2) and SNX5/SNX6, the 
mammalian orthologues of Vps5 and Vps17 respectively.  (Haft et al., 2000; Trousdale & Kim, 2015).  
Formation of the retromer complex is facilitated by Vps26, but it is the SNX subcomplex that targets 
Figure 5.1 The retromer complex. Adapted from Bonifacino & Rojas, 2006. Retromer is a coat 
complex that is recruited to, and forms a scaffold on the outside of transport vesicles. The SNX 
subunits of retromer form dimers and bind endosomes. This SNX subcomplex is also bound to 
Vps35, the core of the Vps subcomplex. The Vps subcomplex, consisting of Vps26, Vps29 and Vps35 
is responsible for binding the cargo and including it in the transport vesicle.   
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retromer to the endosomal membrane, via the interaction of a Phox homology domain in SNX with 
specific lipids on the endosomal surface (Arighi et al., 2004; Carlton et al., 2004). The SNX 
subcomplex is also responsible for the formation of tubular organelles at the surface of endosomes for 
cargo sorting, though it is the Vps subcomplex that binds the necessary cargo for inclusion in 
transport vesicles (Carlton et al., 2004; Trousdale & Kim, 2015). 
Retromer is required not only for the correct sorting of endogenous cargo such as CI-MPR, but is also 
appropriated by several pathogens and toxins (Arighi et al., 2004; Trousdale & Kim, 2015). Most of 
these utilise the retrograde transport pathway, and therefore retromer, as a method of entry into cells, 
and a route to the endoplasmic reticulum. For example, both Shiga toxin and human papillomavirus 
(HPV) 16 rely on direct binding with retromer for exit from the early endosomal compartment before 
further trafficking to the TGN (McKenzie et al., 2013; Popa et al.,2015). However, HIV-1 was shown 
by Groppelli et al., (2014) to exploit retromer and the EGRTP for correct targeting of its envelope 
glycoprotein (Env), in the first instance of retromer facilitating pathogen morphogenesis rather than 
entry. HIV-1 is assembled at the cell surface, and Env, a key protein for infectivity, is transported out 
to the site of virion formation by the anterograde transport pathway. Once there, it is either 
incorporated into virions, or is retrieved back to the Golgi, for recycling. Loss of retromer results in 
increased levels of Env incorporation into virions, and mis-targeting of the protein that is still 
endocytosed (Groppelli et al., 2014).  
The retrograde transport system is a highly conserved system and is utilised by a number of different 
pathogens and toxins. Both of these factors make the EGRTP an attractive potential target for 
pharmacological intervention during disease. One such EGRTP inhibitor is Retro-2, a small molecule 
dihydroquinazolinone which was discovered during a high-throughput screen to identify compounds 
pharmacologically active against ricin and shiga toxin (STx) (Stechmann et al., 2010). Ricin is 
derived from the seeds of the castor oil plant, and is not only highly toxic, but is also considered a 
bioterror risk. STx is produced by Shigella dysenteriae and enterohemorrhagic Escherichia coli, and 
causes severe disease, including kidney failure. Ricin and STx have similar mechanisms, as they are 
both composed of a catalytic A chain, bound non-covalently to receptor-binding B chain, though the 
structures differ  (Johannes & Römer, 2010; Spooner & Lord, 2015). The B-chains bind glycolipids 
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on cell surfaces, then enter by endocytosis, and are trafficked via EGRTPs to the Golgi, and then on to 
the ER. STx binds only to the Gb3 glycosphingolipid, whereas ricin is far more promiscuous, though 
both toxins can enter in clathrin-dependent, and –independent manners (Sandvig et al., 2013). Once at 
the ER, the toxins’ A-subunits inhibit protein biosynthesis by inactivating ribosomes. (Johannes & 
Römer, 2010; Spooner & Lord, 2015). The ability of Retro-2 to inhibit the action of both ricin and 
STx both in vivo and in vitro in multiple cell lines indicates that these toxins share use of at least one 
part of the retrograde transport pathway, or that Retro-2 inhibits more than one part of EGRTP 
(Stechmann et al., 2010; Secher et al., 2015), although the mechanism of Retro-2 is not yet fully 
understood.  
Retro-2 and related compound Retro-1, which was also discovered in the initial high-throughput 
screen performed by Stechmann et al., (2010) spontaneously convert from an achiral to a cyclical state 
for stability. The two compounds have no additional or synergistic effects when administered 
together, indicating that they have the same target (Stechmann et al., 2010; Park et al., 2012.) A 
Retro-2 derived compound, Retro-2.1 was later discovered as another pharmacologically active agent 
against toxins, but with a 500-fold higher inhibitory effect on Stx, and a 1000-fold higher inhibitory 
effect against ricin than Retro-2 (Gupta et al., 2013).  
Investigations into the mechanism of Retro-2 action have shown that it is extremely specific in its 
effect. Treatment of cells with the compound does not affect endocytosis, protein degradation, the late 
endosomal pathway, transport from early or recycling endosomes or anterograde transport 
(Stechmann et al., 2010). However, syntaxin 5, a t-SNARE found in SNARE complexes associated 
with endosome to Golgi transport, is strongly displaced, but not degraded or inhibited on Retro-2 
treatment. This finding was further supported by the discovery that Retro-2, and Retro-2.1 pre-
treatment of cells inhibits the transduction of adeno-associated virus 2 (AAV2). AAV2 utilises a non-
classical route to the TGN of which syntaxin 5 is an essential component, but which bypasses many of 
the classical retrograde pathway markers, such as retromer, Rab7 and Rab9. However, the mechanism 
of syntaxin 5 has not yet been discovered (Stechmann et al., 2010; Nonnenmacher et al., 2015). In 
addition to ricin and Stx, Retro-2 has been shown to inhibit the progress of several viral and 
 120 
parasitical diseases, including Leishmaniasis amazonesis (Canton & Kima, 2012), polyomaviruses 
and papillomaviruses (Nelson et al., 2013; Carney et al., 2014).  
The fact that Retro-2 targets a cellular pathway rather than pathogens, and in EHEC infections inhibits 
toxin action rather than bacterial growth, makes it less likely that resistance to the compound will 
develop as quickly as resistance to conventional antimicrobials (Secher et al., 2015). This, along with 
its low level of toxicity and effect on a wide range of pathogens, makes Retro-2 an attractive potential 
pharmaceutical for further development. 
The previous chapter showed that disruption of EGRTP by both siRNA knockdown and genetic 
mutation of the GARP complex, resulted in a reduction in VACV growth, specifically by the 
inhibition of EEV production, and the failure to correctly wrap IEVs. This chapter aims to further 
elucidate the role of retrograde transport in VACV infection, and determine the identity of the 
aberrant B5 vesicles seen in MU Wob MEF cells. As F13 is, like B5, an IEV/EEV protein which is 
deposited at the cell surface on EEV release (Smith et al., 2002), defining the localisation of this 
protein in MU Wob MEFs may aid the identification of the aberrant B5 vesicles also seen in these 
cells. Retromer is a key component of classical retrograde transport from early and recycling 
endosomes to the TGN (Carlton et al., 2004). Like the GARP complex, it is essential for the correct 
trafficking of EGRTP marker CI-MPR, and knockdown of either complex results in severe 
mislocalisation and disrupted downstream events of this protein (McKenzie et al., 2013; Pérez-
Victoria et al., 2008). As GARP is directly involved in VACV growth, it may be possible that 
retromer is also involved, as EGRTP is not just one route, but a complex set of overlapping pathways.  
A recent RNAi screen to investigate the genetic requirements for ricin intoxication implicated GARP 
components Vps53 and Vps54 as essential factors, not only for ricin effect, but also as essential for 
the function of Pseudomonas exotoxin (PEx), the toxin secreted by Pseudomonas aeruginosa. 
Retromer was also highlighted in this study as a required cellular factor for ricin and PEx intoxication 
(Moreau et al., 2011). Taken together, this evidence suggests that Retro-2 may be a potential third 
way of inhibiting VACV growth by EGRTP disruption, as well as a potential anti-viral treatment for 
in vivo VACV infection. 
 121 
5.2.    Aims 
The main aims of this chapter are as follows: 
1. To characterise the aberrant B5 vesicles seen MU Wob MEFs 
2. To detail the cellular components of the EGRTP that are required for VACV morphogenesis 
a. Investigate the impact of retromer knockdown 




5.3.  Results 
5.3.1.  B5 and F13 colocalise independently of VACV capsids in GARP deficient cells 
In order to determine further the identity of the aberrant B5 vesicles seen in VACV-infected MU Wob 
MEF cells (Figure 4.8), B5 and F13 were simultaneously labelled to examine levels of colocalisation 
in Wob MEF cells. WT and MU cells were infected with VACV-WR at a high MOI of 5 pfu/cell. 
After an 8h infection, cells were fixed, permeabilsed and labelled with antibodies targeting the VACV 
IEV/EEV membrane proteins B5 and F13.  Maximum intensity projections were taken of 10 WT and 
10 MU cells for visual examination, along with Z-stacks for IMARIS image analysis. IMARIS 
software created 3D images of these cells, which were then segmented and analysed. IMARIS 
analysis confirmed that there were three-fold fewer B5 labelled vesicles in the MU MEF cells than in 
the WT cells, confirming the results seen in Figure 4.8 (data not shown). Vesicles where B5 
colocalised with F13 were also counted, and their diameter measured. B5 and F13 labelling in both 
WT and MU MEF cells showed overlapping red B5 and green F13 puncta (Figure 5.2A). 
Approximately 90% of these B5-labelled vesicles in both WT and MU MEF cells were also 
associated with F13 puncta (Figure 5.2B). The vesicles labelled with both B5 and F13 were 
significantly larger in the MU MEFS (Figure 5.2C & D) compared to the WT MEFs. As the VACV 
capsids were not labelled, these puncta could not be differentiated into true IEV/CEVs or the aberrant 
vesicles seen in Figure 4.8. Five colour fluorescence, including VACV-A3-YFP was trialled (results 
not shown), but there was too much overlap between the green and yellow channels meaning a virus 
with a fluorescently labelled capsid could not be incorporated into these experiments. However, these 
results suggest that a considerable percentage of B5/F13 labelled-puncta – most likely the 
corresponding 30% seen in Figure 4.9 - were not associated with a capsid, as both figures 4.8 and 4.9 
in the previous chapter show that B5 puncta not associating with a VACV capsid were also 
significantly larger. Negative controls labelled anti-B5 antibody only, anti-F13 antibody only or no 
primary antibodies were performed and showed no background fluorescence (data not shown). 
Taken together, these results suggest that the aberrant B5 vesicles seen in MU Wob MEFs also contain 
F13. The identity of these vesicles is still unknown, but the evidence here gives rise to two theories. 
Either the vesicles seen may be complete, “empty” IEV membranes which have not been correctly  
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Figure 5.2 B5 and F13 colocalise independently of VACV capsids in GARP deficient cells. (A) 
Wob MEF cells were infected with VACV-WR at MOI 5. After an 8h infection, cells were fixed and 
labelled with antibodies targeting EEV proteins B5 and F13, as well as staining with DAPI and 
phalloidin. Cells were visualised using fluorescent secondary antibodies and an LSM 710 Zeiss 
confocal microscope, and single optical sections were taken. Imaris software was used to quantify 
these images, examining the total number of B5 puncta per cell in WT compared to MU cells (B); the 
percentage of B5 puncta colocalising with F13 labelled puncta (C); and the surface area of these 
B5/F13 containing vesicles in WT and MU cells (D). Data represents means and SEM from 10 
individual cells from 1 biological repeat, and a student t-test was used for statistical analysis. ***,  
p<0.001. 
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wrapped around an IMV, or they are vesicles containing CEV/EEV proteins deposited at the plasma 
membrane during virus egress which cannot be recycled back to the TGN and wrapping station.  
5.3.2.   Retromer knockdown does not affect VACV growth 
GARP functions at the end of the retrograde transport pathway, tethering vesicles to acceptor 
compartments at the TGN. In order to determine if VACV also utilises the donor compartment end of 
EGRTP, the role of the coat complex retromer in VACV infection was examined, by siRNA 
knockdown of retromer components. Retromer is composed of two sub-complexes, the SNX1/2-
SNX5/6 targeting complex, and the Vps26-Vps35-Vps29 cargo binding complex (Trousdale & Kim, 
2015). Previous studies have shown that siRNA knockdown of Vps26 or Vps35 can successfully 
inhibit the function of the whole complex and impair retrograde transport of retromer dependent cargo 
(Gokool  et al., 2007; Popoff  et al., 2007; Groppelli et al., 2014). Therefore, siRNAs targeting these 
genes were used. HeLa cells were transfected with siRNA SMARTpools targeting Vps26 or Vps35. 
SMARTpools of four individual siRNAs were used to knockdown Vps26 and Vps35 rather than one 
single siRNA for each gene in order to enhance the magnitude of reduction and reduce the effect of 
any off-target effects. Cells were infected with a non-targeting siRNA to HSV1 protein VP16 or mock 
transfected as negative controls. After 48h of transfection, cells were lysed and the levels of Vps26 
and Vps35 were assessed using western blotting. Cells transfected with the Vps26 siRNA 
SMARTpool exhibited a 50% reduction in Vps26 expression compared to the negative controls 
(Figure 5.3A, B). Vps35 protein was reduced by 60% compared to the non-targeting and mock-
transfected controls (Figure 5.3C, D).   
The function of the EGRTP in cells with reduced levels of Vps26 or Vps35 was then examined by 
TGN46 staining. TGN46 is a TGN marker known to display mislocalisation and reduced expression 
when retrograde transport is inhibited (Perez-Victoria et al., 2008). HeLa cells were mock transfected, 
or transfected with NT siRNA, or SMARTpools targeting Vps26 or Vps35. After 48h of transfection, 
cells were fixed and labelled with an anti-TGN46 antibody. In the negative control cells, TGN46 
appeared as intense peri-nuclear accumulations, consistent with the expected site of the TGN (Figure 
5.3E). In both Vps26 and Vps35 knockdown cells, less juxta nuclear staining was seen, with very little 
TGN46 visible at all in the Vps26 cells, and dispersed, weak staining of Vps35 seen throughout the 
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cells in addition to the juxta-nuclear location seen in the positive control. These results indicated that 
the Vps26 and Vps35 targeting SMARTpools reduce protein expression sufficiently to impair 
retrograde transport.  
With this confirmation, the next step was to examine the effect of Vps26 or Vps35 depletion on 
VACV infection in vitro. HeLa cells were transfected with the VP16 non-targeting siRNA, or mock-
Figure 5.3. Retromer knockdown inhibits retrograde transport. (A) HeLa cells were transfected 
with an siRNA SMARTpool targeting Vps26. Negative controls were either mock transfected or 
transfected NT siRNA. After 48h cells were collected and lysed for protein separation on an SDS-
PAGE gel, before transfer to a PVDF membrane by western blotting. Antibodies targeting Vps26 and 
loading control actin, and proteins were visualised using fluorescent secondary antibodies and a Li-
Cor Odyssey. (B) Protein levels from (A) were quantified using Image Studio Lite, and normalised to 
each lane’s actin control. The yellow band seen is an off-target background band at the same size of 
the actin band. (C) HeLa cells were transfected with an siRNA SMARTpool targeting Vps35. 
Controls and western blotting was performed as described in (A). Antibodies targeting Vps35 and 
loading control actin, and proteins were visualised using fluorescent secondary antibodies and a Li-
Cor Odyssey. (D) Protein levels from (E) were quantified using Image Studio Lite. (E) Retromer 
depletion alters trafficking of retrograde transport marker TGN46. HeLa cells were transfected with 
siRNA targeting a retromer component, Vps26 or Vps35. Mock transfection or transfection with an 
NT siRNA were used for negative controls. After 48h cells were fixed and labelled with antibodies 
targeting retrograde transport marker TGN46, and labelled with DAPI, then visualised on a Zeiss 
LSM 710 confocal microscope.    
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transfected with siRNA buffer as negative controls. A siRNA targeting 5’-AMP-activated protein 
kinase subunit beta-1 (PRK-AB1) was used as a positive control, as this is the human orthologue of 
Drosophila gene AMPKβ, which is a known pro-VACV cellular gene (Moser et al., 2010). The 
SMARTpools targeting Vps26 and Vps35 were also transfected into cells, and all wells were 
incubated for 48h. After this transfection period, cells were infected with VACV-A5-EGFP at an MOI 
of 0.05 and fluorescence measured as an indicator of viral growth and spread up to 48hpi (Carter et 
al., 2003). Over the course of 48hpi, the virus-induced fluorescence in Mock and the NT negative 
controls increased by around two-fold from the initial background levels. The positive control PRK-
AB1 knockdown cells exhibited significantly reduced EGFP fluorescence in comparison to these 
negative controls. However, VACV-linked fluorescence was not affected in the retromer knockdown 
cells (Figure 5.4A). Very little difference was seen in the Vps26 or Vps35 knockdown HeLa cells 
compared to the negative control, any changes seen were not significant (p>0.05). In order to ensure 
that the transfected siRNAs were not inducing cytoxicity, a cell death assay was performed using the 
CellTiter Blue cell viability assay at the final 48hpi time point. The assay consists of redox dye 
resazurin, which live, viable cells are able to convert to the fluorescent resorufin, while non-viable 
cells produce no fluorescence. Cells were incubated for 1-4 hours, and then the fluorescent signal was 
Figure 5.4. Retromer knockdown does not affect VACV growth. (A) HeLa cells were transfected 
with siRNA targeting retromer components Vps26 or Vps35. Controls were transfected either with 
siRNA buffer alone (mock), NT siRNA, or, as a positive control, the siRNA targeting PRK-AB1. 
After 48h, cells were infected with VACV-A5-EGFP at an MOI of 0.05, and fluorescence was 
measured at 12h intervals up to 48hpi. Data represents the means and SEMs of 6 technical repeats 
collated from 2 biological repeats. Statistical analysis was performed using a one-way ANOVA at 
48hpi, with multiple comparisons. ***, p<0.001. (B) At the final time point in the multi-step growth 
curve described in (A), cells were fixed and stained with Celltiter Blue and read at 590nm. Data 
represents the means and SEMs of 6 technical repeats collated from 2 biological repeats. Statistical 
analysis was performed using a one-way ANOVA at 48hpi, with multiple comparisons. p>0.05 
 
 127 
read as a measure of cell viability. No differences in cytotoxicity were seen when comparing any of 
the transfected cells to the mock transfected cells (Figure 5.4B). The results of these two experiments 
show that although retromer was successfully knocked down by transfection of siRNAs targeting 
Vps26 and Vps35, and retrograde transport was subsequently inhibited, this did not affect VACV 
production. Therefore, VACV does not require retromer for optimal growth and spread. 
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5.3.3.  Retro-2 inhibits VACV growth 
5.3.3.1 Retro-2 treatment protects against shiga toxin-2 by blocking retrograde transport 
In order to further characterise the retrograde transport pathway used by VACV, chemical inhibition 
of EGRT was used. Retro-2 and the related Retro-1 are dihydroquinazolines that were originally 
discovered in a high throughput screen for pharmacological inhibitors of ricin and STx, two toxins 
known to hijack the EGRTP for successful intoxication (Stechmann et al., 2010; Park et al., 2012). 
Retro-2 treatment results in the extremely specific displacement of retrograde transport-associated t-
SNARE syntaxin 5, without affecting other processes such as anterograde transport, endocytosis or 
protein degradation. However, the exact mechanism of action is unknown (Stechmann et al., 2010). 
Retro-2 and its derivatives were an attractive method for inhibiting retrograde transport in VACV and 
examining the impact of this compound on growth of the virus. Retro-2 and the related compounds: 
Retro-1, VP184, and Retro-2.1 were kindly donated by Dr. Daniel Gillet at CEA Saclay, France. 
To test the activity of Retro-2, a cell death assay was performed using Shiga toxin 2 (STx-2). Vero 
cells were pre-treated with concentrations of Retro-2, ranging from 25µM to 200µM. As DMSO had 
been used to resuspend and dilute the Retro-2, this was used as a negative control. STx2 from EHEC 
was serially diluted in media from 100ng/ml to 32pg/ml and used to intoxicate the cells after 2h of 
Retro-2 pre-treatment. Retro-2 was not removed, and was present throughout the intoxication. At 48h 
post intoxication, cells were fixed and stained with CellTiter Blue in order to measure cell viability. 
Cells treated with STx-2, but not Retro-2 (dark blue bars) exhibited a dose-dependent decrease in cell 
viability, with approximately 50% of cells dead at the highest Stx2 concentration, compared to cells 
treated with media alone (Figure 5.5). Even at the lowest concentration of STx2, 32pg/ml, an average 
4 fold reduction in cell survival was seen between the intoxicated and the media only cells, indicating 
that even at extremely low concentrations, this batch of Stx2 (lot #111108V2, Toxin Technology, Inc) 
was still extremely toxic.  
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Figure 5.5. Retro-2 treatment protects against STx by blocking retrograde transport. (A) Vero 
cells were treated with varying concentrations of Retro-2 resuspended in DMSO, from 200µM-25µM, 
or DMSO alone as a negative control. After a 2h incubation, cells were treated with STx2 of 
concentrations ranging from 100ng/ml to 32pg/ml, or media alone as a negative control. Retro-2 
concentrations were reapplied, so as to be present throughout. At 48hpi, cells were fixed with 
CellTiter Blue and fluorescence was read to assay cell viability represented by arbitrary fluorescent 
units. Representative of 5 biological repeats. (B) HeLa cells were treated with Retro-2 at a working 
concentration of 30µM. After an 8h incubation, cells were fixed and labelled with an anti-TGN46 
antibody, and stained with DAPI.  Cells were then visualised using a Zeiss LSM 710 confocal 
microscope. (C) Approximately 250 cells were selected at random from each of the mock and Retro-2 
knockdown slides, and the distribution of TGN46 was visually qualified as diffuse or focal. This 
analysis was then quantified as a percentage of the total number of cells. Data representative of one 
biological repeat.  
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Despite the strong effect of STtx2, pre-treatment with 200µM Retro-2 was still able to partially inhibit 
STx2 action and increase cell viability, again in a dose-dependent manner. Even at the highest 
concentrations of STx2, treatment with 200µM Retro-2 increased cell survival by 25% compared to 
the cells treated with the DMSO control. 
 The ability of Retro-2 to inhibit retrograde transport was also examined using the retrograde transport 
marker TGN46. HeLa cells were mock-treated with DMSO, or treated with Retro-2 at the 30µM 
working concentration of Retro-2, as used by Stechmann et al., (2010). After an 8h incubation, cells 
were fixed and labelled with an anti-TGN46 antibody and a fluorescent secondary antibody for 
visualisation with confocal microscopy. In mock treated cells, TGN46 was seen as expected, in 
intense, perinuclear accumulations consistent with the expected location of the TGN (Figure 5.5B, 
top). In comparison, Retro-2 treatment resulted in more dispersed and less intense staining (Figure 
5.5B, bottom). Quantification of these results (Figure 5.5C) exhibited a clear decrease in the number 
of cells with focal TGN46 after Retro-2 treatment compared to the mock treated control, indicating 
that a concentration of 30µM was sufficient to disrupt the retrograde transport pathway, even though 
higher concentrations were required to make an impact on STx2 intoxication.  
5.3.3.2 Retro-2 treatment inhibits VACV growth 
In order to determine whether Retro-2 inhibits VACV growth, a multi-cycle growth curve was 
performed. HeLa cells were treated with a range of Retro-2 concentrations from 1nM to 100µM. 
Although the working concentration of Retro-2 is 30µM, a full range of concentrations were used to 
ensure that VACV inhibition did not require a different concentration of the compound, as it had not 
been previously tested on this virus. Control cells were mock treated with DMSO, or received only 
media. After a 2h pre-treatment, cells were infected with VACV-A5-EGFP at an MOI of 0.05, in the 
continued presence of Retro-2, and fluorescence was measured as an indicator of viral growth and 
spread up to 48 hpi. The cells treated only with DMSO, and those cells treated with the lower 
concentrations of Retro-2: (1µM, 100nM, 10nM and 1nM), showed at least 100% increase in EGFP 
expression over background fluorescence levels by 48hpi In comparison, fluorescence in 100µM and 
10µM treated cells increased by only 25% and 40% respectively from infection to 48hpi (Figure 
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5.6A), indicating inhibition of viral replication.  The effect of Retro-2 treatment was apparent from 
24hpi, and by 48hpi, cells treated with 100µM or 10µM Retro-2 exhibited highly significant inhibition 
of VACV growth (p<0.001) compared to both the negative controls. The IC50 Retro-2 was calculated 
as 6.10µM. At 48hpi, all cells were fixed and stained with CellTiter Blue to ensure that Retro-2 had 
not had a cytotoxic effect at the higher concentrations of treatment. Figure 5.6B shows that not only 
were 100µM and 10µM concentrations non-toxic, but they appeared to slightly increase cell survival 
compared to the DMSO control. This was most likely due to the reduced viral growth in these cells 
resulting in less virus-induced cell lysis, rather than any direct protective effect on the cell itself. The 
result verifies that the reduction in viral fluorescence seen in 100µM and 10µM Retro-2 treated cells 
in Figure 5.6A was not due to Retro-2-induced cell death.  
5.3.3.3 Retro-2 related compounds also inhibit VACV growth 
In addition to Retro-2, three related compounds were also available: Retro-1, VP184 and the far more 
efficient derivative of Retro-2, Retro-2.1 (Gupta et al., 2013). These compounds were also tested for 
their effect on VACV infection. As described above, HeLa cells were pre-treated for 2 hours with a 
range of concentrations, from 1nM to 10µM for each compound, then infected with VACV-A5-EGFP 
at an MOI of0.05. 100µM was not used for any of the three compounds, as unlike Retro-2, Retro-1, 
Figure 5.6 Retro-2 treatment inhibits VACV growth. (A) HeLa cells were incubated for 2h with 
Retro-2 at concentrations ranging from 100µM to 1nM, or DMSO or media alone for negative 
controls. Cells were infected with VACV-A5-EGFP at an MOI of 0.05 in the continued presence of 
Retro-2, and fluorescence was measured every 12h up to 48hpi. Data represents means and SEMs of 
six technical repeats, and is representative of five independent biological repeats. Statistical analysis 
was performed using a one-way ANOVA at 48hpi with multiple comparisons   ***, p<0.001. (B) 
After the 48h infection, cells pretreated with Retro-2 were fixed and stained with CellTiter Blue to 
assess cell viability. Data shows the mean and SEM of six technical repeats, representative of 5 
biological repeats. p>0.05. 
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VP184 and Retro-2.1 all showed significant cytotoxic effects at the highest concentration (data not 
shown). Over the course of 48h, fluorescence was measured at regular intervals, and at the conclusion 
of the experiment cells were stained with CellTiter Blue to determine cell viability. Retro-1 treatment 
resulted in a significant reduction of VACV–linked fluorescence at 10µM and 100nM (Figure 5.7A), 
exhibiting a 44% and 18% reduction in final fluorescence levels respectively. Despite seeing an 
inhibitory effect at 100nM, no effect was seen at 1µM Retro-1. However, the Retro-1 IC50 was 
calculated at 7.59µM.   The cell viability assay showed minimal cytotoxicity at all concentrations of 
compound used in the growth assay, once again confirming that the highly significant reduction seen 
at 10µM Retro-1 was due to loss of viral EGFP expression as opposed to increased cell death. 
In VP184 treated cells, only treatments of 10µM and 1µM exerted significant inhibitory effects on 
EGFP expression compared to the negative controls (Figure 5.7B), resulting in a 49% and 24% 
respective reduction in final fluorescence levels. All other concentrations of the compound showed 
levels of virus-linkedfluoresence very similar to those seen in the controls, indicating that these 
concentrations were too low to have any effect. The IC50 of VP184 was calculated at 1.75µM, 
indicating a higher efficacy than Retro-2 and Retro-1. Once again, no significant cytotoxic effects 
were recorded in cells treated even with the highest concentrations of VP184 (Figure 5.7B). 
Of the four compounds tested, Retro-2.1 was by far the most effective, as concentrations of 10µM, 
1µM and 100nM were all extremely inhibitory, preventing almost all fluorescence increase in the 
treated cells (Figure 5.7C). In keeping with this, the IC50 calculated at 27.6nM, a far lower 
concentration than the other three compounds. This is consistent with previous studies that showed 
that Retro-2.1 was 500-fold more effective than Retro-2 in STx intoxication, and 1000-fold more 
effective during ricin intoxication (Gupta et al., 2013). In VACV infection, Retro-2.1 is 100-fold more 
effective than Retro-2, as 10µM is the lowest concentration at which Retro-2 is effective, and the IC50 -
of Retro-2.1 is 100-fold lower than that of Retro-2. However, this increased efficiency is coupled with 
slight cytoxicity (Figure 5.7C) at 10µM and 1µM compared to lower concentrations, though the 
decrease in cell survival is still not a significant effect when compared to the survival of the control 
treated cells. 100nM appears to be the optimum working concentration for Retro-2.1, as it exerts a 
similar level of inhibition as the higher concentrations, but has no cytotoxic effects.  
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Figure 5.7 Retro-2 related compounds also inhibit VACV growth. HeLa cells were incubated for 
2h with either Retro-1 (A),VP184 (B), or Retro-2.1(C) at concentrations ranging from 10µM to 1nM, 
or DMSO or media alone for negative controls. Cells were infected with VACV-A5-EGFP at and 
MOI of 0.05 in the continued presence of the small molecule compounds, and fluorescence was 
measured every 12h up to 48hpi . Data represent means and SEMs of six technical repeats. Statistical 
analysis was performed using a one-way ANOVA, at 48hpi with multiple comparisons *, p<0.05; 
***, p<0.001. After the 48h infection, cells pretreated with the small molecule compounds were fixed 
and stained with CellTiter Blue to assess cell viability. Data shows the mean and SEM of six technical 
repeats. 
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5.3.3.4 Retro-2 and related compounds inhibit EEV production 
As all four of the tested compounds significantly inhibited VACV growth, the next step was to 
determine at which stage of the VACV life cycle the compounds exerted their effects. To this end, a 
single-step growth curve was performed to allow the separate calculation of CAVs and EEVs in the 
supernatant. HeLa cells were pre-treated with one of the four compounds at the final working 
concentrations, which were derived from Figure 5.6 and Figure 5.7. After 2h of treatment, cells were 
infected with VACV-WR at a high MOI of 5 pfu per cell, in the continued presence of the 
compounds, and viral titres were examined at 0 and 24hpi. Supernatants were separated from the cell 
associated virus, and IMVs in the supernatant were neutralised prior to titration with an antibody 
targeting IMV protein L1, to ensure that only EEVs released from cells were titred.  
At 24h, levels of EEV increased by 1.6 log10 pfu/ml in the mock and DMSO samples, but by only 0.3-
0.7 log10 in the compound treated cells. Therefore, treatment of cells with any of the compounds 
resulted in highly significant (p<0.001) reductions in EEV titre by the final 24hpi time point, 
compared to the DMSO mock-treated and media only treated cells (Figure 5.8A). The inhibition of 
EEV release was greatest in Retro-2.1 treated cells, which again confirmed that Retro-2.1 was a more 
Figure 5.8 Retro-2 and related compounds inhibit EEV production. (A and B) HeLa cells were 
treated with Retro-2 or a related small molecule compound at the appropriate working concentration. 
After a 2h incubation, cells were infected with VACV-WR at MOI of 5, in the continued presence of 
the compounds. At 0 (to measure residual inoculum) and 24hpi, supernatant (A) was removed, 
neutralised for IMVs using anti-L1 antibody and titrated for a plaque assay. Cell monolayers (B) 
were also collected and titrated. Data represents the means and SEMs of 2 individual biological 
repeats. Statistical analysis was performed using a one-way ANOVA with multiple comparisons. 
***, p<0.001 
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efficient than Retro-2. In comparison, levels of cell associated virus in all cells, both treated and mock 
treated, exhibited a 2 log10 increase over the residual inoculum by 24hpi. This increase in viral titre 
indicated normal IMV production, and revealed that none of the compounds exerted any effect on the 
levels of cell associated virus when compared to the negative controls (Figure 5.8B). These data show 
that as with siRNA knockdown of VPS52 and the Wob mutation, the production and release of EEVs 
is affected by Retro-2 induced EGRT inhibition. 
5.3.3.5 Retro-2 treatment displays additional effects on VACV to the Wob mutation 
A growth curve involving both Retro-2 and the Wob mutation was used in order to determine if the 
combination of EGRTP inhibition methods resulted in any additional or synergistic effects. Retro-2 
treatment results in the dispersal of Golgi SNARE syntaxin-5 (Stechmann et al., 2010), though the 
exact mechanism is still unknown. A yeast 2-hybrid screen of Caenorhabditis elegans cells by Luo et 
al. (2011) showed an interaction between the syntaxin 5 and GARP component Vps54. However, this 
interaction has not been further investigated, or seen in mammalian cells. WT and MU MEF cells 
were incubated for 2h with 30µM of Retro-2, after which cells were infected with VACV-A5-EGFP at 
a low MOI of 0.05 pfu per cell, in the continued presence of Retro-2. Virus-linked Fluorescence was 
measured over 48h, before end point cell viability was determined using the CellTiter Blue assay. By 
48hpi, both WT MEF cells pretreated with media alone, and those pretreated with the DMSO carrier 
exhibited a 24000 unit increase in fluorescence, showing that the DMSO carrier had no effect on  
EGFP expression (Figure 5.9A). Pre-treatment of WT cells with Retro-2 resulted in a significant, 33% 
reduction in EGFP expression to 13000 fluorescence units, compared to the mock and DMSO treated 
WT cells. This inhibition mirrors the result seen in HeLa cells pretreated with Retro-2, and confirmed 
the effects of Retro-2 on viral EGFP expression in different cell lines (Figure 5.6). VACV-linked 
fluorescence in MU MEFs mock treated with media or treated with the DMSO carrier alone exhibited 
lower levels of EGFP expression than the WT control cells, as expected. Finally, treatment of MU 
Wob MEF cells with Retro-2 further inhibited VACV growth, with a 48hpi reading of just 6000 
fluorescent units. This was a 62% reduction in VACV fluorescence compared to the MU control cells, 
and a 64% reduction compared to the WT, Retro-2 treated cells, indicating that combining the Wob 
mutation and Retro-2 treatment had an additive effect on VACV growth, as measured  by 
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fluorescence. The inhibition of viral growth in all cells was confirmed as not due to cell death by a 
cell viability assay (Figure 5.9B). As seen in previous assays, Retro-2 treatment actually increased cell 
survival in infected cells compared to the corresponding control treated cell, though again this is most 
likely due to reduced virus-induced cell lysis due to lower levels of virus in the Retro-2 treated cells. 
This additional reduction in viral growth in Retro-2 treated Wob MEF cells indicates these two 
methods of inhibiting VACV growth are non-redundant. It also suggests that VACV is dependent on 
both the GARP complex and syntaxin 5 function for optimal growth, but potentially uses these 
cellular factors in separate pathways.  
5.3.3.6 Retro-2 treatment affects IEV production and causes formation of aberrant B5 vesicles 
One of the key findings of VACV infection in GARP deficient Wob MEFs was the appearance of 
aberrant B5 puncta in the MU MEFs, which were independent of a VACV capsid (Figure 4.8). An 
immunofluorescence assay to show the distribution of IEV/EEV protein B5 in Retro-2 treated cells 
was therefore performed in order to determine if pharmacological inhibition of EGRTP also resulted 
in capsid-independent accumulations of B5. HeLa cells were pre-treated with Retro-2, or mock treated 
with DMSO for 2h before cells were infected at a high MOI of 5 pfu per cell, using VACV-A5-EGFP   
Figure 5.9 Retro-2 treatment displays additional effects on VACV to the Wob mutation. (A) WT 
and MU Wob MEF cells were treated with 30µM Retro-2, DMSO alone or media for 2h before 
infection with VACV-A5-EGFP.  Presence of Retro-2 was maintained throughout the course of the 
growth curve. Fluorescence was measured every 12h up to 48hpi. Data shows the means and SEMs of 
three technical repeats, representative of four biological repeats. Statistical analysis was performed 
using a one-way ANOVA with multiple comparisons, to allow comparison of treated cells compared 
to non-treated cells, as well as WT to MU. ***, p<0.001. (B) After the 48h infection, cells were fixed 
and stained with CellTiter Blue to assess cell viability. Data shows the mean and SEM of three 
technical repeats, representative of 5 biological repeats. 
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Figure 5.10 Retro-2 treatment affects IEV production and causes formation of aberrant B5 
vesicles (A) HeLa cells were treated with Retro-2 at 30µM for 2h, then infected with VACV-A5-
EGFP, MOI 5 in the continued presence of Retro-2. At 8hpi, cells were fixed and labelled using an 
anti-B5 antibody, and phalloidin, and DAPI were stained. Cells were visualised on a Zeiss confocal 
microscope, and single optical sections taken. (B-D) Z-stacks were taken and used to create 3D 
images of the cells on IMARIS software. The total number of B5 puncta per cell in mock compared to 
Retro-2 treated cells (B); diameter of these puncta (C); the percentage of B5 puncta colocalising with 
VACV-EGFP capsids (D). Data represents means and SEM from 13 individual cells from 1 biological 
repeat, and a student t-test was used for statistical analysis. **, p<0.01, ***, p<0.001. 
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in the continued presence of Retro-2. At 8hpi, cells were fixed, permeabilised and labelled with an 
antibody targeting the IEV/EEV membrane protein B5, and a fluorescent secondary antibody.  
Maximum intensity projections taken through the mock-treated cells showed a juxta-nuclear viral 
factory, indicated by the presence of VACV-EGFP accumulation, and DAPI DNA staining (Figure 
5.10A, left panel). Further examination showed high numbers of yellow colocalised staining of green 
VACV and red B5 puncta in the periphery of mock-treated cells, indicating the presence of 
IEVs/CEVs. Retro-2 treatment did not alter the distribution of VACV-EGFP; however it did result in 
the appearance of fewer B5 puncta in the HeLa cells. Additionally, there was a reduction in the levels 
of B5-labelled puncta colocalising with VACV-EGFP, indicating fewer IEVs/CEVs in Retro-2 treated 
cells (Figure 5.10A, right panel). These observations were quantified by taking Z stacks of randomly 
selected mock- and Retro-2-treated cells, which were recreated into 3D images using Bitplane 
IMARIS software. B5-labelled puncta were identified and counted, and numbers in control treated 
cells were compared to those in the treated cells. Retro-2 treatment resulted in a highly significant, 2-
fold reduction in B5-positive puncta in the cell cytoplasm (Figure 5.10B), compared to the cells 
treated only with DMSO. The percentage of these B5-labelled vesicles associating with a VACV 
capsid was also significantly reduced (Figure 5.10D), from 95% association in the mock treated cells, 
to 66% in the Retro-2 treated cells. This indicated not only a reduction in IEV production, but also 
matches the presence of the same capsid-independent, aberrant B5 puncta seen in the Wob MEFs 
(Figures 4.8, 4.9). In further support of this, measurement of the diameters of the B5 puncta showed a 
significant, 20% increase in vesicle size in the Retro-2 treated cells (Figure 5.10D).  Taken together, 
these results indicate that impairment of EGRTP through Retro-2 treatment inhibits the correct 
wrapping of IMVs to form IEVs/EEVs, in a similar mechanism to the inhibition seen in the Wob 
MEFs.  
5.3.4. Retro-2 treatment prior to infection inhibits VACV growth, and alleviates systemic 
disease symptoms in vivo 
Retro-2 has been shown in previous studies to protect against ricin, EHEC and Leishmania species in 
vivo (Stechmann et al., 2010; Secher et al., 2015; Canton et al., 2012).  In animal models of VACV 
infection, EEVs are responsible for the long-range spread of VACV around the body, and the 
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initiation of systemic disease (Payne, 1980), and as Retro-2 pre-treatment strongly inhibited EEV 
formation and release in vitro (Figure 5.8, Figure 5.10) suggesting that it might protect against 
systemic VACV disease. In order to investigate this hypothesis, the effect of Retro-2 in an in vivo 
model of VACV was investigated. Retro-2 was resuspended in a DMSO carrier at a concentration of 
210mM [67.3mg/ml]. Although Retro-2.1 proved more effective in vitro, there were solubility issues 
which rendered this compound unsuitable for  in vivo use. On two separate occasions, mice were 
injected intraperitoneally with 100mg Retro-2 per kg body weight. One group received treatment 24h 
before and 24h after infection with VACV-WR, and a second group were treated 24h and 48h post 
infection. For the infection, mice were lightly anaesthetised with isofluorane, then VACV was 
delivered by intranasal injection at a dose of 1x104 pfu , diluted in a PBS vehicle. Control groups were 
either treated but not infected, infected and treated only with the DMSO vehicle, or both mock treated 
and mock infected. Uninfected mice, both Retro-2 treated and mock-treated, maintained their body 
weight throughout the course of the experiment, with no difference seen between mice receiving 
injection of Retro-2, and those receiving only the vehicle (Figure 5.11A, groups 1, 5 and 6). These 
results are consistent with previous in vivo assays showing no toxicity or side effects in Retro-2 
treatment (Stechmann et al., 2010; Secher et al., 2015; Canton & Kima, 2012). In comparison, mice 
infected with VACV, and mock-treated (group 2) rapidly lost weight from day 3 post infection 
onwards, and displayed all the expected symptoms of systemic VACV infection, including ruffled fur, 
a hunched posture, and reduced activity. Of the six mice in this group, 3 reached the humane 
endpoint, and were euthanized before the conclusion of the experiment. Similar results were seen in 
those mice receiving Retro-2 treatment only after VACV infection (group 4), at 24 and 48hpi; rapid 
weight loss and increasing signs of disease, and one instance of euthanasia (Figure 5.11B).  However, 
the mice that received pre-treatment of Retro-2 24h before and 24h after VACV infection lost less 
weight than their group 2 and group 4 counterparts, and showed less severe disease symptoms. 
Although the difference in weight loss did not reach overall significance, a significant reduction in 
weight loss was seen at day 5 in the mice pretreated with Retro-2 compared to the sham treated 
animals. By 7dpi, the mice pretreated with Retro-2 showed a significant reduction in clinical 
symptoms compared to the group 2 and group 4 animals (Figure 5.11B), and none of the mice in this 
group reached the humane end point.  
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Figure 5.11. Retro-2 treatment 
prior to infection inhibits VACV 
growth in vivo. BALB/c female mice 
were randomly assigned into 6 groups 
of 6 mice each. Group 1 were 
untreated, uninfected controls. Group 
2 were inoculated intranasally (i.n.) 
with 1x104 PFU of purified VACV-
WR on day 0, and sham treated with 
300µl 10% DMSO in PBS on day 1 
and 2 post infection. Group 3 were 
infected on day 0 as described and 
treated with 100mg/kg Retro-2 in 
PBS on day -1 and +1. Group 4 were 
infected on day 0 as described and 
treated with 100mg/kg Retro-2 in 
PBS on day +1 and +2 post infection. 
Group 5 were uninfected and treated 
with 100mg/kg Retro-2 in PBS on 
day -1 and +1. Group 6 were 
uninfected and treated with 100mg/kg 
Retro-2 in PBS on day +1 and +2 post 
infection. All mice were examined 
daily for weight loss (A), and clinical 
symptoms (B) Crucifixes represent 
the number of animals that reached 
the human end point before the 
conclusion of the experiment. At 7 
days post infection, the experiment 
was terminated and viral loads were 
assessed in all infected mice – groups 
2, 3 and 4 by collection and lysing of 
lung tissue and standard plaque assay 
(C). Error bars represent SEMs of six 
individual animals. Statistical 
analysis was performed using a one-
way ANOVA with multiple 
comparisons, and student T-tests. *, 
p<0.05; ***, p<0.001 
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These results indicate that Retro-2 can significantly alleviate systemic disease, but only when given 
prior to infection.  
After the infection course, lungs were collected from the mice and the titre of VACV in infected 
groups (groups 2, 3 and 4) was determined by plaque assay (Figure 5.11C). This revealed that pre-
treatment of mice with Retro-2 24h before infection (group 3) on average reduced the titre of VACV 
in the lungs compared to groups 2 and 4 – sham treated and treated only post infection, though this 
result did not quite reach significance (p=0.07). Overall however, these results indicate that Retro-2 






5.4.1.  F13 and B5 
The focus of this chapter was to characterise the interaction between the EGRTP and VACV. The 
localisation of B5vesicles in Wob MEFs was compared with that of another IEV/EEV protein, F13. 
Almost all the B5 seen colocalised with F13 in vesicles which although fewer in number were, on 
average, significantly larger in the MU MEFs than those seen in the WT cells. Although a proportion 
of the puncta in MU MEF cells are likely to be IEVs/CEVs, the mean increase in diameter is 
consistent with the aberrant B5-labelled vesicles seen in Figure 4.8 and 4.9, and suggests that these 
same capsid-independent vesicles were present, and also contain F13.  
Both B5 and F13 are essential for VACV growth, and key components of the IEV/EEV membrane, as 
deletion of B5 results in a small plaque phenotype and a loss of comet formation (Wolffe et al., 1993), 
and loss of F13 results in an inability to form plaques at all (Blasco & Moss, 1991). As VACV IEVs 
exit from the cell, several envelope proteins, including F13 and B5 are deposited on the cell surface 
after fusion of the plasma and virus membranes (Smith et al., 2002). Previous studies have shown that 
B5 left at the plasma membrane is recycled back to the TGN, due to a motif in the protein’s 
cytoplasmic tail which has been implicated as a regulator for endocytosis (Ward & Moss (2000) and 
Husain and Moss (2005). Additionally, F13 has been implicated in clathrin-mediated endocytosis, as 
VACV-infected cells treated with the endocytosis inhibiting drug chlorpromazine exhibit 
accumulations of F13, and TR-tfn, a marker of clathrin–dependent internalisation, under the plasma 
membrane (Husain & Moss, 2003). Together, these results showing colocalisation of B5 and F12 
support a model whereby IEV/CEV proteins deposited at the plasma membrane on viral egress cannot 
be retrieved and recycled back to the wrapping station for further IEV membrane production in the 
absence of GARP. However, there is also the possibility of an alternative model in which GARP is 
required for the correct sorting of an as-yet-unidentified cellular protein required for wrapping and 
IEV formation. In this model, the B5/F13-labelled puncta would represent IEV membranes which 
could not be correctly tethered to the wrapping station, or enveloped round the IMVs. This model is 
supported by the evidence that B5 and another IEV protein, F12, are still transported to the cell 
periphery, even when morphogenesis is inhibited after IMV formation (Van Eijl et al., 2002), and 
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both B5 and F13 are correctly targeted to the Golgi area, even when expressed in the absence of 
VACV infection or other IEV proteins (Lorenzo et al., 2000). A similar situation is seen in HSV-1, 
with the production of non-infectious L particles (Szilágyi & Cunningham, 1991).  
In comparison, Sivan et al, (2016), showed that when retrograde transport is blocked by the small, 
pharmacologically active molecule Retro-2, IEV/EEV formation is blocked, and F13 accumulates in 
vesicles in the cell periphery. However, no colocalisation was seen between F13 and B5. Sivan et al., 
suggested that F13 localises in early endosomes before being trafficked through the retrograde 
transport pathway to associate with B5 in IEV membrane precursors at the TGN. However, as a 
different method of EGRTP impairment was used, targeting a different component of the retrograde 
transport pathway, it is likely that the effects seen on F13 transport in Retro-2 treated cells are due to 
these differences. It may be that Retro-2 interferes with the initial trafficking of F13 to the wrapping 
station, while GARP affects the recycling of IEV proteins back to the wrapping station after an initial 
incorporation into a VACV enveloped virion membrane.  
In order to determine whether the B5/F13 puncta in the MU Wob MEFs are whole membranes unable 
to correctly wrap IMVs, or are membranes deposited at the cell surface which cannot be recycled back 
to the wrapping station due to the block in retrograde transport, a number of experiments could be 
performed. Initially, localisation of other IEV/EEV proteins in Wob MEFs could be examined, such as 
A36 and F12, and their level of association with B5, F13 and each other in the absence of optimal 
GARP levels. Should all the IEV/EEV proteins associate with each other, this would support the 
model that IEV membranes are assembled in GARP deficient cells, but cannot be correctly wrapped 
around IMVs. The nature of the puncta themselves could also be examined. The B5 and F12 
structures seen when these proteins are expressed alone co-stain with the fluid phase endocytosis 
marker HRP, indicating that they are contained in endosomes (Van Eijl et al., 2002). Similar staining 
could be performed in Wob MEFs to examine if the B5/F13 labelled puncta seen in the mutant cells 
are contained in endosomes, and if so, which kind of endosomes: early, late or recycling. If these 
experiments showed positive results it, would support the model that GARP loss prevents recycling of 
plasma membrane-deposited IEV/EEV proteins.  
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5.4.2.  Retromer 
Another focus of this chapter was investigation into other components of EGRTP that are involved in 
optimal VACV growth. This focused firstly on the siRNA knockdown of retromer components Vps26 
and Vps35. Retromer is a coat complex which associates with early and recycling endosomes, and is 
required for the correct retrograde transport of both endogenous cargo, and several pathogens and 
toxins (Trousdale & Kim, 2015). The hydrolase chaperone CI-MPR is a well characterised cargo of 
EGRTP, and relies on both retromer and GARP for its correct sorting and trafficking in HeLa cells 
(Arighi et al., 2004; Pérez-Victoria, et al., 2008). As GARP is required for optimal VACV growth, we 
hypothesised that retromer is also involved in EEV production. Transfection of siRNA SMARTpools 
targeting retromer complex components Vps26 and Vps35 successfully reduced expression of these 
proteins and disrupted EGRTP as demonstrated by TGN46 trafficking. However, despite this 
successful reduction in protein levels, VACV growth was not affected, disproving the hypothesis and 
indicating the presence of a non-classical, retromer-independent retrograde transport pathway. This 
finding highlights the complexity of these cellular pathways. There are two main retrograde transport 
routes which have been characterised, one from early endosomes to the TGN, often via recycling 
endosomes, and one from late endosomes to the TGN. Despite requiring different GTPases, tethering 
factors and SNARE proteins for their function, both routes have been shown to be reliant on retromer 
for initial cargo sorting (Ganley et al., 2008; McKenzie et al., 2013), and revealing the role of 
retromer as a key component in EGRTP. Retromer is required for the correct localisation of multiple 
endogenous genes, such as CI-MPR (McKenzie et al., 2013), as well as successful trafficking of 
several toxins and pathogens, including exit from the early endosomal compartment of the STxB 
subunit, and HPV16 (Mallard et al., 1998; Popa et al., 2015), and sorting of HIV-1 protein Env 
(Groppelli et al., 2014). However, examples of non-classical, retromer-independent retrograde 
transport have been observed. One such endogenous example is the retromer-independent, Rab9-
dependent recycling of the endopeptidase furin from late endosomes to the TGN (Chia et al., 2011). 
Non-classical, retromer-independent retrograde transport has also been exhibited by adeno-associated 
virus 2 (AAV2), for transduction of its genome to the nucleus. AAV2 utilises a retrograde pathway 
independent of retromer, as well as late and recycling endosomes, and the syntaxins 6 and 16, key 
components of the retrograde transport SNARE complex. This evidence, along with the results 
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achieved here, support the presence of a non-classical retrograde pathway, used by endogenous and 
exogenous cargo. (Nonnenmacher et al., 2015) Further steps in this line of investigation would be to 
examine the effects of the loss of other suspected components in this non-classical, retromer-
independent pathway on VACV infection. 
5.4.3.  Retro-2 
As syntaxin 5 had been implicated in the non-classical EGRTP, as an essential requirement for AAV2 
transduction (Nonnenmacher et al., 2015), this SNARE was knocked down using siRNA transfection. 
Here however, the siRNA proved highly cytotoxic, hampering interpretation of the experiment 
(results not shown). Another method of syntaxin 5 disruption was therefore used, in the form of Retro-
2, a small molecule inhibitor of the retrograde transport pathway (Stechmann et al., 2010). Retro-2 
impairs retrograde transport by causing displacement of t-SNARE syntaxin 5, though the exact 
mechanism is unknown (Stechmann et al., 2010). Initially, TGN46 trafficking assay and an STxB cell 
death assay showed that Retro-2 successfully inhibited retrograde transport. Following this, single and 
multi-cycle VACV growth curves examined the effect of Retro-2 and related compounds Retro-1, 
VP184 and Retro-2.1 on VACV growth. All the compounds tested showed significant inhibition of 
VACV growth, specifically EEV production, indicating that VACV also requires syntaxin 5 as well as 
GARP for IEV wrapping. Treatment with Retro-2 also resulted in the aberrant, large, capsid-
independent B5-labelled vesicles as seen in the mutant Wob MEF cells. This model of VACV 
inhibition also translated to an in vivo mouse model, as Retro-2 pre-treatment of mice infected with 
VACV-WR reduced viral titres and clinical signs of disease.  
There are two well-characterised anti-poxvirus drugs already in circulation which, like Retro-2, also 
target the IEV wrapping process. The first of these, IMCBH was initially discovered to inhibit VACV 
growth and release in 1968, and was later found to selectively target the IEV/EEV protein F13. 
However, this drug is ineffective both in vivo, and against any other poxvirus, and so is not a target for 
further development as a therapeutic agent (Kato et al., 1968; Schmutz et al. 1991). The more recently 
characterised anti-poxvirus drug, ST-246 is a small molecule compound active against multiple 
poxviruses, which again targets the F13 IEV/EEV protein (Yang et al., 2005). Retro-2 and ST-246 
show similar effects, in they both reduce EEV production 5-10 fold in single-step growth curves, 
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which is enough to almost completely block VACV multi-cycle growth. Additionally, neither drug 
affects IMV production (Yang et al., 2005, this work). However, each drug holds advantages over the 
other. ST-246 is susceptible to resistance by substitution or insertion mutations in the F13 gene, 
rendering it ineffective (Duraffour et al., 2015). In this aspect, Retro-2 is the superior choice for 
therapeutic development, as targets not only a cellular factor which is a far lower mutation/resistance 
risk than a viral protein, but is extremely specific, and inhibits only one component of EGRTP. 
Despite this, while ST-246 successfully protects against VACV inoculation in vivo when administered 
post infection (Yang et al., 2005), Retro-2 only protects against VACV when administered as a pre-
treatment, when administered at days -1 and +1 either side of infection, and does not have an effect 
when administered only as a post-infection treatment, and so requires further development in this area. 
In comparison, when used as a treatment for Leishmaniasis amazonesis and EHEC, Retro-2 exerted a 
protective effect when administered up to 3 weeks or 26 hours post infection respectively (Canton & 
Kima, 2012; Secher et al.,2015). Taken along with the results seen here, this evidence indicates that 
Retro-2, with development, could eventually have potential not only as an anti-poxvirus drug, but to 
supplement poxvirus vaccination in the event of an outbreak or bioterror incident.  
As the difference in viral titres seen here from the in vivo experiment did not quite reach significance, 
additional work in this area would begin with a biological repeat of the infection time course and lung 
titre, administering Retro-2 several hours before the VACV infection was performed, rather than one 
day, as seen in the Stechmann et al. protocol (2010). Retro-2.1 could also be tested against VACV in 
vivo, as it is known to have a far higher efficiency than Retro-2; including 1000-fold greater inhibition 
of ricin intoxication (Gupta et al., 2013), and 100-fold greater inhibitory affect against VACV. With 
regards to further elucidating the mechanism of Retro-2 action on VACV growth, several more in 
vitro studies could be performed. Other researchers have shown that when Retro-2 is used as the 
method of retrograde transport inhibition, B5 fails to associate with VACV capsids, which is 
consistent with the results obtained here, but B5 and F13 do not colocalise, as discussed earlier (Sivan 
et al., 2016). Further development of this project would certainly require the re-examination of B5 and 
F13 colocalisation, as these two proteins have high levels of association in retrograde-deficient Wob 
MEF cells. Should the results of the Sivan et al paper be confirmed, this may suggest that VACV uses 
at least two separate, non-classical retrograde pathways. 
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Overall, the results of this chapter show that VACV utilises a retromer-independent, non-classical 
retrograde transport pathway to correctly wrap IEVs. This pathway involves GARP and syntaxin 5, 
and loss of these components results in one of two possible models: either retrograde transport is 
required to recycle EEV/CEV proteins deposited on the cell surface after virus egress, or this pathway 
is required for the correct trafficking of an as-yet-unknown cellular factor which is required for IEV 
membrane envelopment of the IMV at the wrapping station. Additionally, Retro-2 has been shown to 
be a potential candidate as an anti-poxvirus prophylactic.   
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6. General Discussion 
6.1. Thesis aims and overview.  
The aim of this thesis was to investigate the role of two cellular proteins during VACV infection: 
MKK3 and Vps52. siRNA knockdown, genetic mutation and pharmaceutical agents were used to 
inhibit expression of the proteins of interest both in vitro and in vivo in order to determine the effects 
of MKK3 and Vps52 on VACV infection. In addition to its role as the prototypic poxvirus, VACV 
has many applications as a vaccine vector and as a tool to investigate cellular mechanisms. However, 
the replication cycle of VACV is complex and poorly understood. By examining the interactions of 
VACV with cellular proteins and pathways, the mechanisms of VACV replication and growth can be 
further elucidated. 
6.2. Conclusions and implications 
A high-throughput, siRNA based screen performed by Beard et al. (2014) identified multiple novel 
pro-viral cellular factors required for optimum VACV growth and replication, two of which are the 
proteins of interest here: MKK3 and Vps52. Both proteins exhibited significant pro-viral effects in the 
original screen, and validation with a fluorescence-based growth assay showed that knockdown of 
these proteins significantly affected viral-linked fluorescence. As the two proteins were unrelated, 
they were investigated separately, but using similar techniques. 
6.2.1.  MKK3 
 Transfection of HeLa cells with an siRNA SMARTpool targeting MKK3 was able to not only 
substantially knock down MKK3 expression, but also significantly inhibit the expression of viral 
linkedEGFP in both multi-and single-cycle growth assays. However, this inhibition did not translate 
to viral titre in cell culture or disease severity in a murine model of VACV disease. While virion 
production was not altered by loss of MKK3, production of VACV early and late proteins was 
substantially inhibited by 50% compared to the negative control. This result, along with the reduction 
in A5-tagged fluorescence indicates that MKK3 is required for optimal viral protein production.  
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One of the key roles of the p38 pathway is the production of cytokines during the inflammatory 
response, with expression of appropriate cytokines occurring by differential activation of the pathway. 
As a consequence of this, p38 has been linked to both the pathology of a number of infectious 
diseases, including influenza A and dengue fever (Börgeling et al., 2014; Fu et al., 2014). Use of 
SB203580 during dengue virus infection suppresses the dengue-induced over-production of pro-
inflammatory cytokines such as TNF-α and IL-8 which can lead to severe dengue fever (Fu et al., 
2014). Highly pathogenic avian influenza is also able to over-induce p38 activation, leading to 
increased pro-inflammatory cytokine expression and viral pathogenicity (Börgeling et al., 2014). In 
comparison, VACV both activates and inhibits the p38 pathway, and subsequently, the expression of 
downstream genes; upregulating the production of anti-inflammatory cytokines, and down-regulating 
inflammatory mediators in order to promote its own survival (Myskiw et al., 2009; Maloney et al., 
2005).  
Although previous studies have shown that the MKK3 and the p38 pathway are required for optimal 
EGFP expression in cells infected with fluorescently tagged VACV (Hu et al., 2007; Beard et al., 
2014), the direct effect of MKK3 inhibition on viral titre had not been examined. Investigation here 
showed that loss of MKK3 had no discernible effect on viral titre in vivo or in vitro, despite a 
reduction in the production of early, late and IMV proteins in HeLa cells. The lack of effect on direct 
measurements of growth such as viral titre suggests a model in which VACV produces an excess of 
proteins, meaning that inhibiting protein expression by MKK3 loss is not enough of an effect to also 
inhibit virion formation or morphogenesis. This occurrence of protein levels exceeding the amount 
required for virion production has been seen in other viruses, such as Hepatitis B virus (Churin et al., 
2015),  where overproduced proteins are multimerised and formed into non-infectious sub-viral 
particles. However, this protein excess has never been seen before in VACV, and the model outlined 
here also suggests a role for MKK3 in regulating viral protein production. Although MKK3 
specifically has not been previously linked to viral protein production, the p38 and ERK-activated 
kinase Mnk1 has been shown to activate cellular translation initiation factor eIF4F, at the control of 
VACV. As VACV shuts down translation of cellular genes in favour of its own, this activation of 
eIF4F substantially increases viral gene expression and replication (Waskiewicz et al., 1997; Walsh et 
al., 2008)  In the Walsh et al. study, cells deficient in Mnk1 exhibited not only a reduction in VACV 
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protein expression, but also a reduction in production of plaque forming units a result which was not 
seen here. This is likely due to the fact that Mnk1 is activated by the ERK pathway as well as the p38 
cascade (Waskiewicz et al., 1997), and so direct loss of Mnk1 has a greater effect on VACV 
translation than only inhibiting one part of the p38 pathway by MKK3 knockdown. Therefore, the 
results of this thesis suggest that in this signalling cascade, p38 may be activated specifically by 
MKK3 in order to promote the production of viral proteins. However, while p38 may be important in 
VACV pathogenesis, the role of MKK3 specifically is not essential, as although viral protein 
production was effected by loss of MKK3, the impact was not sufficient to affect replication.  
6.2.2. Vps52 
The host protein Vps52 was knocked down using siRNA SMARTpool transfection, as well as using 
the Wobbler genetic mutation in MEFs. Both methods significantly reduced expression of the Vps52 
protein, and resulted in a significant inhibition of VACV-A5-EGFP growth. Direct measurement of 
infectious virions produced during Vps52 loss showed significant reductions in viral titre compared to 
the corresponding controls in both siRNA transfected cells and Wob mutated cells. Separate 
examination of the cellular and supernatant fractions of single step growth curves showed that both 
Vps52-targeting siRNA transfection and the Wob mutation had the same effect: a reduction 
specifically in EEV production, but no difference in IMV production compared to the corresponding 
controls. This indicated that Vps52 and the GARP complex affect wrapping of IMVs to form IEVs, or 
a later process in virion morphogenesis such as EEV release. Immunofluorescent labelling of VACV 
and IEV proteins in Wob MEF cells confirmed the IEV/EEV reduction shown in the single cycle 
growth curve, and also revealed large, aberrant, accumulations consisting of B5 and F13, but existing 
independently of VACV capsids.  
Having identified the GARP complex as required for IEV production, we expanded our study to 
identify other components of EGRTP involved in infection. The retromer complex, despite being one 
of the key components of many retrograde transport pathways was shown to not be required for 
VACV growth as transfection of siRNA targeting two of the components of the complex, Vps26 and 
Vps35 did not alter VACV growth compared to the negative control. Although retromer is not 
required by VACV, the t-SNARE syntaxin 5 is essential for optimal growth, as pharmacological 
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inhibition of this protein by small molecule compound Retro-2, and several related compounds not 
only successfully disrupted EGRTP, but also inhibited both multi-cycle VACV growth and EEV 
production, as seen in Wob MEFs and siRNA knockdown of Vps52. Again mirroring the results seen 
in Wob MEFs, treatment of cells with Retro-2 also produced large, aberrant accumulations of 
IEV/EEV protein B5, which were seen to exist independently of a VACV capsid. These effects also 
translated into a mouse model, as treatment of mice with Retro-2 prior to VACV infection reduced 
viral titres and inhibited clinical symptoms, weight loss and disease progression, though only 
marginally  
Several studies have previously suggested that retrograde transport may play a role in VACV 
infection, as cells infected with VACV exhibit increased rates of endocytosis, and increased activity 
of the endosome to TGN pathway (Schmelz et al., 1994), and several IEV proteins, such as B5 and 
F13, deposited on the cells surface after EEV egress are thought to be recycled back to the TGN 
(Husain & Moss, 2004). However, this is the first time that the exact retrograde components and 
pathway required for optimal VACV growth have been investigated. Taking into account the increase 
in endocytosis in VACV infected cells, the recycling of IEV proteins from the cell surface and the 
identification of Vps52 and Vps54 of pro-viral cellular factors in two independent screens (Schmelz et 
al., 1994; Husain & Moss, 2005; Sivan et al., 2013; Beard et al., 2014), we hypothesised that GARP 
is involved in retrieving deposited IEV proteins from the cell surface, and recycling them back to the 
TGN-located wrapping station.  
As previously mentioned, several IEV proteins including B5 and F13, remain on the cell surface after 
EV egress, and are then recycled back to a juxta-nuclear area in a retrograde transport dependent 
manner (Ward & Moss, 2000; Husain & Moss, 2005) This, along with the drop in EEV production 
during GARP depletion, suggests a model in which GARP tethers vesicles containing IEV proteins 
traveling from the cell surface back to the TGN for wrapping of new IEVs. The presence of 
accumulations containing B5 and F13 that were not associated with the green fluorescent viral cores 
in MU cells suggest that in the absence of GARP, these accumulations have not been correctly 
tethered to the wrapping station, or as recycled membrane components from the cell surface unable to 
dock to the site of IEV production. However, the results shown here do not rule out the possibility that 
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GARP is not involved directly in IEV protein transport, but is responsible for the trafficking of an 
unknown host protein which is required for wrapping. In this model, it is likely that the aberrant B5 
puncta would be empty IEV membranes which were unable to wrap IMVs. This hypothesis is 
supported by a study performed by Van Eijl et al. (2002) which showed that IEV proteins B5 and F12 
are transported to the cell periphery even in the event of a morphogenesis block after IMV formation. 
In the van Eijl study, treatment of cells with IMCBH, which inhibits IEV wrapping showed 
aggregates of B5 accumulating in vesicles in the cytoplasm, similar to the B5 puncta we observed 
when retrograde transport was impaired by both GARP mutation and Retro-2 treatment. Additionally, 
co-localisation of B5 and F12 in capsid-independent puntca was seen under these conditions, 
supporting the colocalisation of capsid-independent B5 and F13 seen in this thesis, and again 
supporting the theory that loss of GARP results in empty IEV membranes that cannot be correctly 
tethered to the wrapping station.   
VACV infection has been shown to increase the rates of cellular endocytosis (Schmelz et al., 1994), 
and the IEV/EEV protein F13 has been linked to clathrin-mediated endocytosis, as blockage of this 
endocytic pathway with chlorpromazine resulted in F13 accumulation under the plasma membrane 
(Husain & Moss, 2003). However, the reduction in IEV/CEV and EEV production seen in retrograde 
transport inhibition is independent of endocytosis. Examination of fluid phase endocytosis in Wobbler 
MEFs showed no difference in rates of endocytosis between WT and mutant cells, indicating that the 
effect of MEFs is limited to endosome to TGN transport (Karlsson et al., 2013). Nor does Retro-2 
affect endocytosis, as treatment of cells with the compound did not inhibit clathrin-mediated uptake of 
endocytosis marker transferrin (Stechmann et al., 2010). Additionally, inhibition of endocytosis using 
a strain of VACV expressing a dominant negative clathrin-coated endocytosis adaptor protein did not 
affect levels of IEV/CEV production, suggesting that endocytosis is not essential (Husain & Moss, 
2005). However, in this paper, IEV/CEV production was counted using electron microscopy, with 
greatly varying virion numbers between sections, calling into question the accuracy of such a 
technique. Therefore, this work shows that inhibition specifically of the retrograde transport pathway 
reduces IMV wrapping, but we cannot make any conclusions about the impact of inhibition of 
endocytosis, as the first step in the pathway returning viral proteins from cell surface to the TGN.  
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We also hypothesised that GARP was not the only cellular EGRTP component involved in recycling 
of VACV IEV proteins back to the TGN. Retromer is a key component in the correct retrograde 
trafficking of a wide variety of cargo both endogenous, such as CI-MPR (Arighi et al., 2004) and 
invasive, such as the HIV Env protein (Groppelli et al., 2014). Given its involvement in transporting 
pathogen components, and its role in sorting and binding cargo at endosomal compartments (Carlton 
et al., 2004; Kim et al., 2015), we proposed a model in which retromer played a role in recycling IEV 
proteins for further use at the TGN wrapping station. However, this hypothesis was disproved when 
results showed that loss of retromer subunits Vps26 and the complex core Vps35, did not alter VACV 
growth compared to the negative controls. This lack of effect was maintained, despite the fact that 
retromer knockdown was able to disrupt trafficking of retrograde transport marker TGN46, therefore 
showing that siRNA knockdown of Vps35 and Vps26 was successful. Since retromer is a core 
component of EGRTP, this suggested that VACV utilises a non-classical pathway, as the two main 
retrograde transport routes, one originating from early endosomes and one from late endosomes both 
rely on retromer for initial cargo sorting, despite being otherwise largely independent of each other 
(Ganley et al., 2008; McKenzie et al., 2013). Although retromer is involved in trafficking many 
different retrograde cargoes, the evidence presented is not the first instance that retromer-independent, 
non-classical retrograde transport has been observed, and supports the findings of previous studies 
such as Nonnenmacher et al., (2015) which, through siRNA transfection targeting various retrograde 
components, showed that transduction of AAV2 does not require retromer, or the several key 
components of the retrograde SNARE complex such as syntaxin 6 and syntaxin 16. 
The final route of investigation into retrograde transport and VACV infection was the 
pharmacological inhibitor of retrograde transport, Retro-2. In addition, Retro-2 is thought to disrupt 
retrograde transport by altering the distribution of syntaxin 5, a SNARE required for the non-classical, 
retromer-independent transduction of AAV2. This requirement was shown by both siRNA targeting 
of syntaxin, and treatment with Retro-2 (Stechmann et al., 2010; Nonnenmacher et al., 2015). These 
links suggested that Retro-2 treatment may constitute a third method of disrupting EGRTP in order to 
inhibit VACV growth, as well as a potential VACV anti-viral. Retro-2, along with related compounds 
Retro-1, VP184 and Retro-2.1 all significantly impacted overall VACV growth and EEV production, 
a similar effect to the anti-poxvirus drug ST-246. However, while ST-246 directly targets the virus via 
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the F13 IEV protein, Retro-2 targets the cell, and inhibits VACV growth by disrupting syntaxin 5 
distribution, and therefore the retrograde transport pathway, meaning that Retro-2 treatment poses a 
lower risk of resistance mutations (Yang et al., 2005; Stechmann et al., 2010). Although the results 
presented here indicate that only pre-treatment with Retro-2 is protective against VACV infection in 
vivo, investigations with other pathogens have shown that Retro-2 can exert a protective effect several 
hours or days after infection, as systemic treatment with the drug can successfully reduce weight loss 
and improve survival of mice intoxicated with EHEC strain O104:04 (Secher et al., 2015). This, along 
with the fact that cellular factors are far less susceptible to functional mutations than viral proteins, 
indicates that if further development, Retro-2 could have potential as anti-poxvirus prophylactic. 
6.3.  Overall Discussion 
Although the two hits from the original screen, MKK3 and Vps52 appear to play very different roles 
in VACV infection, examining the results from the three chapters together presents some interesting 
perspectives.  Although they only constitute a small percentage of virions production of IEVs/EEVs 
during VACV is a process of much controversy and debate.  The origin of the IEV double membrane, 
and the location of the IEV wrapping station has been proposed as the ER/Golgi network intermediate 
compartment (Sodeik et al., 1993; Van Eijl et al., 2002); the TGN (Ichihashi et al., 1971; Hiller & 
Weber, 1985; Schmelz et al., 1994); or endosomal compartments (Van Eijl et al., 2002). The results 
presented here do not add any new evidence to the arguments for IEV membrane origin, they do 
support the theory that the IEV wrapping station is situated at, or closely associated with, the TGN. 
While GARP acts as a tethering factor at early and late endosomes, it localises predominantly at the 
Golgi, as seen by colocalisation of Vps52, Vps53 and Vps53 with Golgi marker GM130 (Liewen et 
al., 2005). Syntaxin 5 is also found localised to the TGN, and is displaced from this positioning 
following treatment with Retro-2 (Stechmann et al., 2010). Therefore, the two retrograde components 
found here to be essential for IEV production are both localised to the TGN, implying that this is 
where wrapping of IEVs occurs.  
Two potential models are proposed here for the involvement of retrograde transport in VACV 
IEV/EEV production. One model suggests that GARP tethers vesicles containing IEV proteins at the 
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TGN wrapping station as they are recycled back from the cell surface, while the other suggests that 
loss of GARP results in an inability for formed IEV membranes to wrap IMVs. 
Syntaxin 5 has previously been linked to retrograde transport, and as the part of a SNARE complex 
also including GS28, Ykt6 and GS15, is required for the endosome to Golgi transport of STxB and the 
mannose-6-phophate receptor (Tai et al., 2004; Amessou et al., 2007). Specific RNAi knockdown of 
syntaxin 5 resulted in a significant block in StxB transport, an effect similar to that caused by syntaxin 
16 knockdown (Amessou et al., 2007). As syntaxin 5 and syntaxin 16 are known to function in two 
independent SNARE complexes, this suggests the existence of a separate, syntaxin 5 dependent 
retrograde transport route. The main SNARE complex that GARP is thought to interact with is the 
late-Golgi complex containing syntaxin 6 and syntaxin 16 (Pérez-Victoria & Bonifacino, 2009). 
However, not only does the C. elegans GARP complex interact with the syntaxin 5 orthologue, SYX-
5 in a yeast two-hybrid system, but the Vps54 orthologue has been shown to bind directly to C. 
elegans SYX-5 (Luo et al., 2011), indicating that GARP does not interact exclusively with the 
syntaxin 16 containing SNARE complex . The evidence presented here and in previous studies 
indicates that in the context of VACV infection, GARP interacts with the syntaxin 5 SNARE complex 
at the TGN as well as the syntaxin 6 and syntaxin 16 SNARE complex, most likely to ensure correct 
targeting of its cargo.  
While these results shed more light on the specific components of the retrograde pathway that VACV 
utilises for IEV production; they does not support either of the proposed mechanisms over the other. 
Determining which of these models is correct would require more investigation. For example, a yeast 
two-hybrid screen could be conducted for proteins that interact with GARP, and the hits from this 
examined for their effect on VACV growth. Any proteins not directly part of EGRTP may be a 
candidate for the unknown cellular protein that may be responsible for IEV wrapping, which also 
requires GARP for correct targeting.  In another route of investigation, the identity of the aberrant 
accumulations of B5 and F13 in GARP deficient and Retro-2 treated cells could be further 
investigated. If the IEV proteins are seen to colocalise with markers of early, late or recycling 
endosomes, this would support the model that GARP is required for tethering vesicles containing 
recycled proteins from the cell surface. If, however, the proteins were not contained inside an 
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endosome, but the complete repertoire of IEV proteins were present, this would support the ‘empty 
membrane’ model.  
Another method of determining which of the proposed models is correct would be an antibody uptake, 
or ‘antibody gobbling’ experiment. In such an experiment, Wob MEF cells would be infected with 
VACV-EGFP at a high MOI, and infected for 6h, before being chilled on ice with a high 
concentration of anti-B5 antibody, to stall progression of the infection. A cohort of cells would be 
fixed and levels of surface B5 examined after this incubation, while another cohort would 
subsequently be incubated at 37oC for 2h to reactivate morphogenesis, and allow uptake and 
trafficking. Levels of internalised B5 staining could then be examined and compared to the previously 
fixed control, and as well as comparing levels between WT and MU cells. Co-staining with a TGN 
marker such as TGN46, or a Golgi marker such as giantin would also indicate if internalised B5 had 
been recycled back to the TGN/wrapping station. Previous studies have used a similar protocol to 
follow the route of retrograde transported cargo, such as Groppelli et al. (2013), which utilised an 
antibody feeding assay to track the movement of HIV-1 protein Env, and showed that if this protein is 
not incorporated into new virions at the site of morphogenesis near the cell surface, it is recycled back 
to the Golgi, in a retromer-pathway. Seaman et al. (2004) also used this protocol to show that CI-MPR 
cannot be recycled back to the Golgi in absence of retromer, and   later in 2007 to demonstrate that the 
retrograde trafficking of CI-MPR is specifically dependent on a sorting motif in the CI-MPR tail. We 
obtained preliminary data from an antibody gobbling experiment which showed that MU Wob MEF 
cells exhibit lower levels of internalised B5 after a 2h 37oC reactivation incubation. However, lack of 
time meant we were unable to complete colocalisation staining, or quantification of B5 levels on the 
surface post anti-body addition on ice and pre-incubation, meaning that we were unable to draw any 
conclusions from this experiment (data not shown). 
The proteins examined here, MKK3 and Vps52 are involved in very different aspects of the VACV 
life cycle; MKK3 in viral protein production, and Vps52 in IEV wrapping. However, the results show 
that the role of MKK3 in protein production is not significant enough to impact virion formation in 
MKK3 deficient cells, suggesting that IMV and non-structural proteins are produced in excess. 
Conversely, the requirement of Vps52 and EGRTP in recycling IEV/EEV proteins back from the cell 
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surface to the wrapping station suggests that IEV envelope proteins are produced at a deficiency, 
especially as blocking retrograde transport so significantly impacts IEV production. Considering that 
EEVs are key for the long range dissemination and spread of VACV (Appleyard et al, 1971; Payne, 
1980), this difference between levels of IEV proteins and other viral proteins is an interesting 
revelation that warrants further investigation, including the effect of MKK3 loss on IEV protein 
levels, and the subsequent effect on IEV production.  It could also be argued that the effects of MKK3 
and Vps52 knockdown have shown that the overall amount of viral proteins is not important, but the 
location of viral proteins are key for optimal growth. 
Overall, this thesis highlights the pitfalls of carrying out high-throughput genetic screens in 
transformed cell lines, and measuring a representative of viral growth rather than directly examining 
virion formation. However, the work presented here also demonstrates the power of high-throughput 
genetic screens to identify novel features of virus-cell interactions, and aid in the understanding of 
viral infection cycles and the role of the host cell in VACV infection. This is particularly important in 
VACV as it has multiple applications in molecular biology and vaccine development, but a highly 
complex life cycle, many features of which are still poorly understood, such as the process of 
wrapping IEVs. In addition, we have identified a potential druggable target in the retrograde transport 
system, which with future development, may make Retro-2 and its derivatives successful 
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